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ABSTRACT OF THE DISSERTATION 
Mass Spectrometry and Protein Analysis:  
Structure, Oligomerization and Interaction 
by 
Hanliu Wang 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2016 
Professor Michael L. Gross, Chair 
 
 
Protein aggregation is common in biological processes including neurodegenerative diseases, as 
well as artificial development in biopharmaceutical production and protein storage. Therefore, 
understanding proteins involved in aggregation systems is important. It is generally difficult for 
high resolution structural methods, such as X-ray or NMR, to interrogate proteins possessing 
aggregation propensities. On the other hand, techniques that tolerate solution heterogeneities, 
such as circular dichroism, only provide global or low-resolution information. Mass 
spectrometry (MS)-based methods are appropriate and powerful in such applications because 
they can deal with mixtures. Additionally, primary sequence, post-translational modification, and 
structural information can be obtained at low sample consumptions and fast turnover. 
This thesis aims to develop and apply MS-based methods in understanding three proteins 
involved in two aggregation/oligomerization systems. Bacteria biofilm provide protection for 
bacteria from host defense and in severe environments, causing great concerns in human health. 
The major proteinaceous component of biofilm, Curli, is the first system on which we focus. 
Curli family has seven members. We focus on the major curli subunit CsgA and a proposed 
xv 
 
CsgA chaperon, CsgE, in chapter 2 to 4. CsgA is an amyloid protein that shares common 
features with other well-known disease-associated amyloid proteins. CsgE also forms oligomers, 
for which the details were unknown when we started the project. In chapter 5 to 7, we 
concentrate on apolipoprotein E (apoE), which is has strong implications in Alzheimer’s disease. 
ApoE regulates lipid and cholesterol transportation in the blood and central nervous system. 
There is no structure of wild-type apoE as it exists as a mixture of monomer, dimer, and tetramer 
at micromolar concentration in vitro. 
The primary method used in the thesis is hydrogen–deuterium exchange (HDX), which is 
described in detail in chapter 1. Principles of instrumentation and fragmentation are also 
included. In chapter 2, we first applied conventional, continuous HDX to identify the 
oligomerization interface of CsgE. This result guided a mutagenesis study for developing a 
monomeric mutant, whose NMR structure now has been published. We also compared the 
difference between the monomeric mutant and the wild-type protein by continuous HDX. We 
found an interesting structural rearrangement for wild type CsgE by using pulsed HDX. In 
chapter 3, we improved the pulsed HDX platform, adding a reference peptide, to study the 
aggregation behavior of CsgA. The addition of reference peptide allows us to monitor CsgA 
aggregation from another dimension and helps HDX data interpretation. We systematically 
followed CsgA deamidation by collision-induced dissociation (CID) and MS label-free 
quantification as described in chapter 4. We discovered that deamidated CsgA loses its ability to 
form fibrils by using the pulsed HDX platform developed in chapter 2, circular dichroism, and 
the Thiofavin T fluorescence assay. In chapter 5, we characterized the binding between a small 
molecule compound and apoE. A sequential digestion was implemented in HDX for better 
coverage and shorter peptides (higher HDX resolution). We extended our understanding of the 
xvi 
 
same system, using two adapted HDX-based techniques, in chapter 6. Peptide-level binding 
affinities are extracted by using PLIMSTEX, and unfolding properties are monitored by using 
peptide-level SUPREX. In chapter 7, we employed native MS to inspect oligomeric composition 
and study the gas-phase structures. With ion mobility data and additional support from electron-
capture dissociation, we built a coarse-grained model of the tetrameric complex of apoE. 
Conclusions and future directions are discussed in chapter 8. 
The six research chapters demonstrate the power of MS in understanding protein structure, 
protein–protein/ligand interaction and oligomerization/aggregation. These approaches can be 
extended to other biological systems that are difficult to study by conventional analytical 
methods. Every method provides information from a unique perspective. To advance our 
understanding of complicated systems, multiple techniques, including MS, should be used in 
combination to achieve complementary information and the most complete results and 
interpretation.
14 
 
Chapter 1: Introduction 
  
15 
 
1.1 Abstract 
Investigating protein post-translational modification, higher-order structure and protein–
protein/ligand interactions is essential for understanding biological processes. Conventional high 
resolution methods, including X-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy, are difficult to apply to proteins with oligomerization propensities, for example, 
the three disease-related proteins explored in this work. Mass spectrometry-based approaches 
have become powerful tools in protein biophysics applications because they have many 
advantages including high sensitivity, low sample consumption, medium resolution, capabilities 
to sample complex mixture, and fast turnover. Protein and PTM identification is achieved 
through both accurate mass and product-ion scans. In structural proteomics, protein structural 
and binding information can be coupled to mass shift through in-solution labeling prior to MS 
analysis because the labeling extent reflects local conformation and environment. One of the 
most popular structural proteomics techniques is hydrogen–deuterium exchange (HDX). An 
alternative and complementary approach to structural proteomics is native MS coupled with ion 
mobility (IM) or top-down fragmentation. This chapter first introduces the two biological 
systems that we investigated in the thesis, then covers the principles and instrumentation of MS 
that we utilized. In the third part, we focus on HDX as this is primary experimental method 
utilized in this thesis research. 
16 
 
1.2 Two Biological Systems 
1.2.1 Bacteria Biofilm and Curli Biogenesis  
Bacteria coalesce and integrate into communities coated with complex matrices of nucleic acids, 
proteins and polysaccharides, known as biofilm.1, 2 Bacteria within biofilms are protected from 
the host defense and environmental extremes (e.g., disinfectants, antibiotics), allowing many 
infections in humans to re-occur.3 Biofilms also raise concerns in medical and industrial settings 
because of their resistance to cleaning processes.4 The major proteinaceous component, curli, 
adhere to a host’s surface, promote cell–cell contact, and are critical for biofilm formation in 
Escherichia coli, and other enteric bacteria.5-7 Understanding biogenesis of curli is important for 
controlling biofilm formation and for treating persistent bacterial infections.8 
Amyloids are commonly associated with the neurodegenerative diseases, including Alzheimer’s, 
Parkinson’s, and Huntington’s.9 Despite the differences in primary amino acid sequences and 
protein sizes, amyloids from various proteins share common features including a cross β-sheet 
structure, highly resistant to denaturant, and to binding specific dyes such as thioflavin T (ThT) 
and Congo red.7, 10 Curli, the extracellular fibers, are the first identified functional amyloids. 
Biogenesis of curli fibers is highly regulated, which involves two csg (curli-specific gene) 
operons, csgBAC and csgDEFG.1, 5, 11 A model of curli biogenesis is provided in Figure 1.1 
(reused with permission from ref 1). CsgD, whose activity is controlled by the N-terminal 
residue phosphorylation,12 is a transcriptional factor that regulates operon csgBAC.11 All Csg 
proteins except CsgD have a Sec-recognized signal peptide that allows them to be transferred 
from the cytoplasm to the periplasm. Curli are composed of a major subunit CsgA and a minor 
subunit CsgB at an approximate ratio of 20:1 in vivo.13 CsgA and CsgB share 30% sequence 
17 
 
identity. The Sec-signal peptide is cleaved in mature CsgA that is intrinsically disordered. CsgA 
is secreted to the outer membrane surface through a protein pore formed by CsgG, and rapidly 
converted into amyloid fibrils upon interacting with CsgB, the nucleator.14, 15 CsgA migrates 
away from the cell as monomers if CsgB is absent in vivo.7 CsgC prevents CsgA self-association 
within the periplasma. It also completely inhibits CsgA fibrilization at a very low molar ratio in 
vitro.16 Moreover, CsgC is able to inhibit several other aggregation proteins.1 Outer-membrane-
bound CsgG is required for secretion of CsgA, CsgB, and CsgF.17-19 CsgG forms pore-like 
nonameric complexes that are found at sites of curli production, indicating its role of guiding 
curli localization. CsgF serves as a connection between the CsgG complex and the nucleator 
CsgB. Deletion of CsgF gene results in formation of soluble CsgA oligomers in the environment 
instead of curli fibrils,20 presumably because no CsgB is attached at the cell surface. It is shown 
that CsgE forms a nonameric complex and behaves as a capping adaptor to the CsgG secretion 
channel.18 CsgE also prevents CsgA amyloid formation in vitro at equimolar ratio.21 CsgE is 
suggested as a periplasmic chaperon that delivers CsgA to the pore CsgG for secretion.21  
Understanding this highly regulated, amyloid production process is not only important in 
infectious disease management but also in providing a perspective on molecular mechanisms 
underlying disease that are caused by misfolded amyloids. In chapter 2 and 3, we investigated 
conformational changes of CsgE and CsgA accompanying their oligomerization and aggregation 
processes at regional level by hydrogen–deuterium exchange (HDX). In chapter 4, we 
investigated deamidation of CsgA and studied deamidation effect on its aggregation profiles. 
These three chapters provide useful outcomes for better understanding curli biogenesis. For 
example, results from chapter 2 suggest oligomeric interfaces for alanine mutagenesis, resulting 
in a CsgE monomeric mutant whose NMR structure has now been published.22.   
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Figure 11.1: Model  for curli b iogenesis  
Figure 1.1 Model for Curli Biogenesis (reused with permission from ref 1). After entering 
periplasm through SecYEG, CsgA is degraded (left dotted error with scissor) or stabilized by 
CsgC (right dotted error) at state A* before further aggregating into fibrils in the periplasm. 
CsgE forms a nonameric complex capping the nonameric CsgG and recruiting CsgA. CsgF 
bridges CsgB and CsgG. CsgA forms fibrils once it contacts CsgB. 
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1.2.2 Apolipoprotein E and Alzheimer’s Disease 
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly, clinically defined by 
progressive loss of memory and cognitive functions.23 It is a complex neurodegenerative disease 
pathologically characterized by extracellular amyloid-β plaques/fibrils, intracellular tau fibrillary 
tangles, and significant synaptic/neuronal loss.24 Multiple genetic determinant factors have been 
proposed for AD in genome studies, among which APOE is a major predictor for late-onsite AD 
(LOAD).25, 26 LOAD accounts for the majority of AD (> 95%), in which symptoms become 
apparent in patients’ mid-60s.25 The human APOE gene has three major polymorphic alleles: ε2, 
ε3 and ε4 with a frequency of ~ 7%, 80%, and 13%, respectively. The allele ε4 carrier has higher 
risks for developing LOAD compared to ε2 and ε3 carrier.25, 27, 28 Their corresponding proteins, 
apoE2, apoE3 and apoE4 differ at two amino acid residues: apoE2 has Cys at sites 112 and 158; 
apoE3 has one Cys at 112 and one Arg at 158; apoE4 has two Arg at both sites. ApoE is highly 
expressed in the liver and the central nervous system (CNS), regulating lipid and cholesterol 
transportation.28 Three apoE isoforms have significantly different lipoprotein-binding 
preferences. ApoE2 and apoE3 preferentially bind to high-density lipoprotein (HDL), whereas 
apoE4 to low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL).25 The binding 
of apoE to LDL receptors (LDLR), the major apoE receptors, is also isoform-dependent.25 
The role of apoE and the isoform-dependent effect (i.e., apoE4 is detrimental, apoE3 neutral, and 
apoE2 protective) in AD is not well-understood. A brief summary of the potential roles of apoE 
in AD is provided in Figure 1.2 (reused with permission from ref 28). In CNS, apoE is mainly 
produced by astrocytes and activated microglia, conditionally (e.g., stress) by neurons (#1). One 
of the Aβ dependent hypotheses is that apoE contributes to the progress of LOAD by affecting 
Aβ production, in association with amyloid precursor protein (APP) (#2). In the extracellular 
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space, apoE influences Aβ transportation, accumulation, and clearance in an isoform-dependent 
manner.26 Through LDLR, the apoE-lipoprotein particle with Aβ is endocytosed into cells and 
can lead to apoptosis via lysosomal leakage (#4), of which the process is also isoform-dependent. 
There are also several Aβ-independent pathways to AD pathogenesis,25 one of which involves 
the proteolytic fragment of apoE to cause cytoskeletal disruption (#3). 
 
Figure 2 1.2: P roduction of apoE in CNS and its potential roles in AD  
Figure 1.2 Production of apoE in CNS and its potential roles in AD (reused with permission from 
ref 28). See text for discussion. 
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Understanding structure, oligomerization, and conformational differences among the three 
isoforms should help elucidate molecular mechanisms for AD and other apoE-related diseases. 
In chapter 5, we studied binding of a small molecule to apoE as a therapeutic target. Using the 
same system, we integrated a HDX-based platform to characterize further binding affinities and 
binding-induced unfolding changes, as described in chapter 6. In chapter 7, we characterized 
apoE structures by native MS coupled with ion mobility (IM) and electron-capture dissociation 
(ECD).   
1.3 Protein Mass Spectrometry: Instrumentation 
Protein mass spectrometry (MS) refers to the application of MS-based strategies in protein 
analysis, including identification, quantification, and structural characterization. Protein MS has 
become an essential tool in life sciences.29 Analytes are ionized and introduced to the gas phase 
in the source region of the instrument, separated by mass analyzers based on their mass-to-
charge (m/z) ratios, and recorded by detectors. MS was once limited to small molecule analysis 
due to the lack of appropriate ionization methods to introduce fragile large biomolecules into the 
gas phase. The invention of two soft ionization techniques, electrospray ionization (ESI) by John 
Fenn,30 and matrix-assisted laser desorption ionization (MALDI) by Franz Hillenkamp and 
Michael Karas,31 has greatly advanced protein MS since the late 1980s. Its application was 
further extended with the development of modern mass analyzers and hybrid instrumentation 
(i.e., coupling two or more mass analyzers). Several modern hybrid instruments, interfaced with 
ESI, are used in the thesis research. Basic concepts and schematics of each instrument are 
described in the next section 
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1.3.1 Quadrupole/Time-of-flight (Q-TOF) Mass Spectrometer  
 
Figure 3 1.3: Schema tic of a Bruker maXis Q-TOF  
Figure 1.3 Schematic of a Bruker maXis Q-TOF (taken from Maxis user manual). 
 
The instrument schematic of a Bruker maXis Q-TOF is provided in Figure 1.3 (taken from the 
Maxis user manual). The quadrupole and time-of-flight mass analyzers are highlighted in red. 
The ion pathway in the instrument is colored in magenta. The marriage of quadruple and TOF 
provides high sensitivity, resolving power, and mass accuracy of both precursor and product 
ions.32 In the source region, the sample is introduced into the spray chamber and submitted to 
ESI with the aid of nebulizer. A high voltage is applied to the liquid during ESI to generate 
23 
 
multiply charged droplets, which eventually become nearly naked charged ions. A stream of 
heated drying nitrogen gas that flows in the opposite direction of droplets further assists solvent 
evaporation. The multiply charged protein ions, along with drying gas and small amount of 
solvent, enter the transfer region, where a double stage ion funnel (stacked ring ion guide) is used 
to confine the ion beam while neutrals are pumped away. The ion beam is further focused and 
transferred with a subsequent multipole stage located before the quadrupole. 
In the hybrid Q-TOF instrument, the quadrupole analyzer is used as a mass filter to isolate a 
certain mass window. The quadrupole mass analyzer, invented by Wolfgang Paul in the early 
1950s,33 consists of four parallel hyperbolic rods. Each pair of opposite rods is held at the same 
polarity of radio frequency (RF) and direct current (DC) voltage by connecting them to the same 
power supply. As a result, an electrical field is created, the shape of which depends on the 
geometry of the rods and the RF and DC potentials. Ions are “pushed” and “pulled” in the x and 
y directions while traveling along the z direction. The RF frequency is usually constant whereas 
the magnitude of RF and DC voltages are varied to pass through a narrow mass range of ions of 
interest. In the RF only mode (i.e. DC voltage equals zero), the quadruple does not have mass 
selectivity, functioning as an additional ion guide to transmit all ions. After quadrupole selection, 
precursor ions enter a collision cell upon acceleration to collide with neutral gas and produce 
product ions by collision induced dissociation (CID, see next section for more details). The ions 
are then cooled by transferring energy to the background gas and re-focused before exiting the 
collision cell. A cooling region extends the ion cooling and focusing allowing a narrow 
distribution of ions to be injected into the TOF analyzer. 
 The principle of the TOF analyzer is to separate ions based on the time needed for each ion to 
travel in a fixed length of a field-free drift tube. The TOF analyzer is arranged orthogonally to 
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the ion beam because the ion source is continuous, but the TOF is operated in a pulsed mode. 
After exiting the cooling cell, ions first fill the extraction volume, and then are pushed by a high 
voltage into the flight tube. The injection velocity is inverse to the square root of m/z at a given 
injection voltage. The flight time can be calculated knowing the tube length and injection 
velocity. Because ions have both extraction and injection velocities, they enter the flight tube at 
an angle that is independent of the mass. To achieve higher mass resolving power, a modern 
TOF is mostly equipped with a reflector to compensate for kinetic energy dispersion. Depending 
on the starting positions in the acceleration region, ions experience different accelerating 
potentials. The ones close to the repeller gain more energy. In the reflectron region located at the 
top of the flight tube, ions are retarded, stopped, and reaccelerated towards the detector. 
Refocusing ions with different kinetic energies is possible because ions with higher energy travel 
a longer distance before being stopped and turned than the ones with less energy.  
1.3.2 Linear Trap Quadrupole (LTQ)/Orbitrap Mass Spectrometer   
The schematic of the Thermo LTQ Orbitrap XL is provided in figure 1.4 (taken from Thermo 
product specifications brochure). The linear ion trap LTQ and Orbitrap mass analyzers are 
highlighted in red. Since the release of the first commercially available Orbitrap-based mass 
spectrometer by Alexander Makarov and coworkers from Thermo Fisher Scientific in 2005, the 
Orbitrap family has become a mainstream modern instrument for many applications owing to its 
capability of ultra-high resolution, outstanding mass accuracy, and high sensitivity.34  
The quadrupole mass analyzer discussed in the last section transmits ions with stable trajectory. 
LTQ also has two sets of rods to which are applied radio frequencies. In contrast to the 
transmission quadrupole, the LTQ has two additional lenses in the front and back with slightly 
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higher DC voltages to form a three-dimensional potential well that allows storage of all ions or 
of selected mass ranges of ions. Buffer gas, typically helium, is used in the LTQ for ion cooling 
(i.e., damping of the ion motions). In addition to preparing ions for Orbitrap analysis, the isolated 
ions in LTQ can also be directly excited and fragmented for MS/MS or MSn (i.e., stepwise multi-
stage fragmentation analysis).  
The novel idea of an orbital trapping device was introduced in 1923 by Kingdon35. In Kingdon 
trap, ions orbit a charged wire that was stretched along an axis in an enclosed metal “can”. Based 
on the idea and subsequent work, Makarov and coworkers developed orbitrap mass analyzer 
coupled with an external C-trap for ion injection.34 RF-only voltages are applied to the C-trap to 
store and cool ions, followed by application of high voltage across the C-trap to eject the ion 
packets orthogonally into the Orbitrap. A set of optics is used to direct and focus the ion packets 
before they enter the Orbitrap. 
 
 
Figure 4 1.4: Schema tic of the Thermo LTQ Orb itrap  XL 
Figure 1.4 Schematic of the Thermo LTQ Orbitrap XL (taken from the Thermo product 
specifications brochure). 
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In the Orbitrap, a spindle-shaped electrode is placed in the center of two symmetrical outer 
electrodes. Because the ion packets are injected into the Orbitrap offset from the equator of the 
device, the axial electric field accelerates the ion packets while the radial electric field keeps the 
ion packet orbiting around the central electrode via a balance of electrical and outward 
centrifugal forces. The outer electrodes not only provide an electric field for ion trapping, but 
also develop an image current induced by the coherently oscillating ions. The recorded signals in 
the time domain are then converted to mass spectra by Fourier transform (FT). FT is a 
mathematic method to transform a complicated periodic motion to a set of simple frequencies.  
In this instrument, the full MS scan is performed in the Orbitrap analyzer for high mass accuracy. 
The MS/MS experiment, instead, is commonly performed in the ion trap for high speed and 
sensitivity when coupled with liquid chromatography (LC). The fragment ions, because the ion 
trap analyzer is low performance, are of low mass resolving power. 
1.3.3 Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer 
The schematics of Q Exactive Plus, another Orbitrap-based instrument used in the thesis 
research, is provided in Figure 1.5 (borrowed from ref 3434 with permission). This instrument 
provides significantly increased sensitivity and scan speeds compared to the LTQ Orbitrap XL. 
The S-lens, a stacked ring ion guide, enhances ion-transmission efficiency and increases 
sensitivity in the source region. A quadrupole, instead of the LTQ, is placed in front of the 
Orbitrap for isolating precursor ions. MS/MS fragmentation takes place in a higher energy 
collision (HCD) cell that is located after the C-trap in a similar manner as beam-type CID 
fragmentation in a Q-TOF instrument. Ion accumulation in the C-trap and HCD cell is in parallel 
with ion detection from the previous MS/MS scan in the Orbitrap, enabling maximum ion duty 
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cycle for higher sensitivity. This instrument design, along with enhanced FT,36 provides high 
scan rates and high mass accuracy for both MS and MS/MS experiments. 
 
Figure 5 1.5: Schema tic of the Thermo Q  Exactive 
Figure 1.5 Schematic of the Thermo Q Exactive (taken from ref 34 with permission). 
 
1.3.4 Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass 
Spectrometer 
FT-ICR was first introduced by Comisarow and Marshall in 1974.37 Ions travel in a circular 
motion perpendicular to the magnetic field. The cyclotron frequency is proportional to the 
magnetic field strength and inversely proportional to m/z. FT-ICR affords the highest resolution 
among all mass spectrometers so far.38  
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Figure 6 1.6: Schema tic of a Bruker solariX 12 T FT-ICR  
Figure 1.6 Schematic of a Bruker solariX 12 T FT-ICR (adapted from Bruker manual). 
 
The schematics of Bruker solariX 12 T FT-ICR is provided in Figure 1.6 (adapted from Bruker 
user manual). The ESI source, quadrupole, collision cell, and other ion optics are generally 
similar to the Bruker Q-TOF instrument introduced in 1.3.1. The cylindrical ICR cell is placed in 
a homogeneous 12 T superconducting magnetic field (insert in Figure 1.6). Two electrode plates 
are placed at both ends of the cylinder to provide ion trapping in the axial direction. The cylinder 
is composed of two sets of oppositely arranged plates. One set is the excitation plates that are 
used to excite ions to a larger orbit and afford phase coherence. The other set is the detection 
plates for detecting the image current, in a similar way used as the outer electrodes of Orbitrap. 
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The signals recorded in the time domain are then transformed by FT to the frequency domain 
(i.e., mass spectra). 
An Electron Capture Dissociation (ECD) cathode is placed at the back of ICR cell (the green 
rectangle at the far right end in Figure 1.6). A beam of electrons generated from the cathode is 
pulsed into the ICR cell to interact with the protein/peptide ions. The resultant ions from ECD 
(see next section for more details about ECD) are trapped and analyzed in the ICR cell. 
1.3.5 Ion Mobility Spectrometry (IMS) 
Mass analyzers separate ions based on their m/z ratios. In contrast, IMS separates ions of the 
same m/z in the gas phase based on their size and shape. This gas-phase separation is analogous 
to solution-phase electrophoresis.39 The instrument schematic of a Waters Synapt G2 HDMS is 
provided in Figure 1.7 (taken from the Waters instrument manual). The ion mobility section, 
placed between the Quadrupole and TOF, is boxed in red. The TOF analyzer is shown here in the 
“W” mode which provides higher mass resolving power compared to the “V” mode owing to the 
increased flight pathway. The experiment performed in this thesis was done in the “V” mode, as 
described in 1.3.1, to achieve maximum sensitivity. 
The IM module (labeled Triwave in Figure 1.7) consists of three traveling-wave (T-wave) 
stacked ring ion guides: trap, IMS and transfer. In each region, RF voltages of opposite phases 
are applied to adjacent electrodes to constrain ions in the radial axis. Meanwhile, a transient DC 
voltage is applied to each electrode successively from the front to the back, guiding the ions 
along the axial direction. The combination of wave functions generates a travelling waves 
allowing the ions to “surf the waves” while being transmitted. In the trap region (i.e., the first T-
wave ion guide), ions are accumulated after quadrupole selection and released into the IMS when 
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ready. The potential difference between the quadrupole and the trap region can be increased to 
induce unfolding or CID fragmentation. The second ion guide, IMS, is commonly pressurized 
with N2. Because of the large pressure difference between the trap region and the IMS, a helium 
cell is included at the beginning of IMS to reduce fragmentation and increase transfer efficiency. 
Under the guidance of the T-wave, ions possessing identical m/z yet different shapes are 
separated because they experience the same electrical driving forces but undergo different 
collisions with background buffer gas. The mobility of each ion is measured as drift time, which 
can be then converted to collision-cross section (CCS) for structural information. The third T-
wave ion guide is used to transfer ions to the TOF analyzer after mobility separation. 
 
Figure 7 1.7: Schema tic of a W aters Synapt G2 HDMS  
Figure 1.7 Schematic of a Waters Synapt G2 HDMS (taken from the Waters instrument manual). 
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1.4 Fragmentation 
Peptide identification is the most fundamental step in conducting the research in this thesis. In 
addition to accurate mass, fragment or product ions are the other important term to permit 
identification. Several selected fragmentation techniques and their corresponding fragment ions 
are provided in Figure 1.8 (reused with permission from ref 40). The series of a, b, c are 
observed if the charge is retained on the N-terminus, whereas the series of x, y, z are present if 
the charge is on the C-terminus. By comparing the mass difference between successive ions of 
the same series, one can determine the amino acid residue and whether there is a PTM at that 
site. Two of the fragmentation methods, collision-induced dissociation (CID) and electron-
capture dissociation (ECD), were used in this thesis research, and they will be described in the 
following. 
 
Figure 8 1.8: Pep tide backbone fragmentation  
Figure 1.8 Peptide backbone fragmentation induced by selected techniques (adapted from ref 
40). 
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1.4.1 Collision Induced Dissociation (CID) 
Collision-induced dissociation (CID), sometimes referred as collision-activated dissociation 
(CAD), is the most common fragmentation method employed in modern tandem mass 
spectrometers.41 Two steps are involved in CID. The isolated precursor ions are first activated by 
colliding with neutral gas molecules. The activated ions then undergo unimolecular dissociation 
upon conversion of kinetic energy into internal or vibrational energy. Energy redistribution over 
all bonds occurs faster than the unimolecular dissociation. Consequently, a covalent bond, at any 
part of the molecule, breaks if the vibrational energy exceeds its bond energy. This explains why 
fragment ions formed at weaker bonds are predominant. 
 
Figure 9 1.9: CID fragmentation mechanism  
Figure 1.9 CID fragmentation mechanism (bx-yz pathway). 
 
The commonly accepted theory of CID is the mobile proton model (Figure 1.9).42, 43 An ionizing 
proton is mobilized to the vicinity of the cleavage site and fragmentation is initiated in a charge-
directed manner. Whether the charge retains on the N-terminal or the C-terminal fragment to 
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generate b or y ions depends on the thermochemistry of the reactions producing the two species. 
The b ions can loss CO and form a ions. If a peptide is multiply charged, charge separation and 
complementary b/y ion pairs can be produced.  
In an ion trap device, as employed in the LTQ-Orbitrap instrument, the precursor ion not only 
gains energy from the collisions with background gas, but also experiences deactivation due to 
“ion-cooling” effects. Therefore, the activation time in the ion trap is slower than in the collision 
cell of Q-TOF, or the HCD cell in Q Exactive instrument family.41 The amount of energy 
deposited onto precursor ions also varies in different instruments. The energy of beam-type CID 
in Q-TOF or HCD is higher than that in the ion trap, leading to additional fragmentation of b 
ions to give a ions.44  
1.4.2 Electron Capture Dissociation (ECD) 
Labile PTMs are not easily detected by CID because their weak bonds are likely cleaved during 
the slow-heating process of collisional activation. PTM information, thus, is lost in the b/y ions. 
Electron-transfer dissociation (ETD) and electron-capture dissociation (ECD) can preserve the 
labile PTM during fragmentation while cleaving the protein backbone because intramolecular 
vibration energy redistribution is not involved. This is also known as a non-ergodic process45 
although many do not accept the non-ergodic hypothesis. Because ECD or ETD works well with 
multiply, not singly, charged species, they are largely applied in top-down experiments. In 
Chapter 7, we performed an ECD experiment on a tetrameric protein complex in the FT-ICR cell 
(the instrument setup is introduced in section 1.3.4). 
ECD was introduced by McLafferty and coworkers45 in 1998. Multiply charged protein cations 
capture thermal electrons emitted by a cathode in the FT-ICR cell, generating fragments 
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extensively along the backbone. Lys, Arg, and His are favored protonated sites. The ECD 
mechanism, in the example of Lys side chains, is provided in Figure 1.10 (taken from ref 4646). 
The first step is to form neutralized hypervalent species after capturing an electron at a positively 
charged site. Noticeably, the C-terminal fragments, z• ions, are odd-electron products. If 
precursor ions only capture electrons yet do not induce backbone cleavage or the fragment ions 
are not separated, they remain as undecomposed ions and are termed “charge-reduced species”. 
Charge-reduced species are found at higher m/z and are often very abundant in ECD spectra. 
 
Figure 10 1.10: ECD fragmentation mechanism  
Figure 1.10 ECD fragmentation mechanism (taken from ref 46). 
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1.5 Hydrogen–deuterium exchange (HDX) 
Hydrogen–deuterium exchange (HDX) measures the exchange rate of hydrogen atoms of protein 
with deuterium in the solvent. It was enabled by nuclear magnetic resonance (NMR) to afford 
residue-level information in biological applications starting in the late 1980s and 1990s.47, 48 
Since the invention of the soft ionization techniques for large molecules,30, 31 HDX coupled to 
MS (HDX-MS) has become the commonly used tool in investigating protein structure/dynamics 
and protein–protein/ligand interactions.49 Now HDX-MS has been widely adopted by both 
academic and industrial experimentalists.48  
 
Figure 11 1.11: Three types of hydrogens in p rotein s  
Figure 1.11 Three types of hydrogens in proteins (borrowed from ref 50). Backbone amide 
hydrogens are color in black. Fast exchange hydrogens that are attached to heteroatoms are 
colored in white. Very slow or non-exchangeable hydrogens attached to carbon are colored in 
gray. 
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HDX-MS monitors the exchange of protein backbone amide hydrogens with deuterium, colored 
in black in Figure 1.11 (taken from ref 50). This is because the half-lives of backbone amide 
hydrogens are from seconds to hours, which can be readily followed by MS. The exchange rates 
of side-chain hydrogens covalently bonded to heteroatoms (colored in white) are very fast, 
whereas the rates of exchange of hydrogens linked to carbons (colored in gray) are very slow or 
essentially not exchangeable. These two kinds of hydrogen atoms are not measured in a 
conventional HDX-MS experiment. There is no HDX information on the proline residue because 
there is no backbone amide hydrogen. 
1.5.1 HDX Mechanism and pH Effect 
 
 
Figure 12 1.12: HDX mechanism  
Figure 1.12 HDX mechanism through (A) N-protonation acid catalysis, (B) O-protonation acid 
catalysis, and (C) base catalysis.  
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HDX can be catalyzed by acid, base, or water. However, water catalysis is much slower than 
acid or base catalysis, and often disregarded. The mechanisms of acid or base catalysis are 
provided in Figure 1.12.48 Acid catalysis may occur via either N-protonation (Figure 1.12A) or 
O-protonation (Figure 1.12B) process. 
The rates of HDX are dependent on several parameters, the most dominant being pH. The rate of 
base catalysis is several order of magnitude faster than that of acid catalysis in a polypeptide.51 
Therefore, HDX exchange rate versus pH is V-shaped with minimum values at pH 2–3, 
depending on neighboring residues (Figure 1.13, taken from  ref 52). In the pH range of 3–7, 
every pH unit increment roughly leads to 10-fold increase of exchange rate. Following an HDX 
experiment at physiological pH, we normally include a quench step by lowering the pH to ~ 2.7 
to insure that minimal back exchange occurs during sample handling, considering the labeling is 
reversible. 
 
Figure 13 1.13: HDX ra tes depend on pH  
Figure 1.13 HDX rates depend on pH (taken from ref 52). The set of multiple V-shaped curves 
are due to different neighbor residues combination. 
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1.5.2 Temperature, Ionic Strength, and Pressure Effect 
Like many other chemical reactions, HDX is also temperature dependent. It is proposed that the 
major effect of temperature is due to the change of water ionization constant.48 A modified 
Arrhenius equation can be used to predict HDX exchange rates at a certain temperature 
compared to a reference rate.51 The HDX rate is decreased approximately 10-fold when 
temperature is changed from 25 to 0 °C. Therefore, lowering temperature in the quench step 
further decreases exchange rates and helps minimize back exchange. All the following sample 
handling steps prior to MS analysis are performed at 0 °C as well. 
Another factor influencing HDX rate is ionic strength. For uncharged residues in dipeptides, 
higher salt concentration leads to a higher exchange rate of acid catalysis but lower rate of base 
catalysis.51 HDX rate constants of charged residues in dipeptides show smaller change in higher 
salt concentration.51 It is also suggested that the salt effect is residue-dependent as determined by 
local electrostatic fields in polypeptide and proteins.53-55 
Other factors that alter the ionization of water may affect HDX rates. For example, the HDX rate 
is elevated at high pressures because of increased concentration of hydroxide as a result of 
enhanced water ionization.56 In contrast, adding organic solvents into aqueous solvent lowers the 
water ionization constant, and, therefore, reduces HDX rates.57 Although these other factors are 
not as critical as pH and temperature for HDX, it is important to keep solution environment 
consistent when comparing HDX results of multiple protein states to avoid misinterpretation. 
Additionally, protein conformation may be altered upon different solvent conditions, and this can 
be followed by controlling carefully the media effects on HDX. 
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1.6 Two HDX Kinetic Regimes: EX1 and EX2 
The parameters discussed in section 1.5 have effects on the intrinsic exchange rates of HDX. 
Secondary or higher-order structures prevent local hydrogen exchange, which are the other major 
influencers on the HDX rates. In a folded protein, there are two key steps involved for a 
backbone amide hydrogen to exchange with solvent deuterium.58 The first step is to make the 
labile hydrogen accessible to the solvent, either by local fluctuations, unfolding, or other 
molecular motions. Following that is the second step where the labile hydrogen exchange with 
solvent deuterium. The overall process is described at the top of figure 1.14 (adapted from ref 
5959). A labile hydrogen in state UH could either go back to the folded state (FH) at a rate 
constant of k-1, or become deuterated in state UD at a rate constant of k2. 
 
Figure 14 1.14: The overa ll kinetics and two reg imes of p rotein unfolding and HDX  
Figure 1.14 The overall kinetics and two regimes of protein unfolding and HDX (adapted from 
ref 59).   
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The exchange step is considered irreversible because deuterium water is in large excess in the 
HDX experiment. The overall exchange rate constant can be expressed by equation 1.148: 
𝑘𝐻𝐷𝑋 =  
𝑘1𝑘2
𝑘1+𝑘2+𝑘−1
 ≈  
𝑘1𝑘2
𝑘2+𝑘−1
   eq 1.1 
 The opening rate (𝑘1) is typically much smaller than the closing rate (𝑘2), and therefore 
negligible in eq 1.1. 
In one extreme, the refolding event occurs much faster than the intrinsic HDX exchange rate (i.e. 
𝑘−1  ≫  𝑘2). This regime, termed EX2 kinetics, is commonly observed under physiological 
conditions because the proteins are always undergoing many folding–unfolding cycles. Each 
amide hydrogen is independently exchanged with deuterium. Thus, EX2 is also called 
uncorrelated exchange. Now eq 1.1 is simplified to eq 1.2. Thermodynamic information of 
protein opening, ΔGop = -RTlnKop, can be calculated in EX2 kinetics because the opening/closing 
equilibrium constant Kop is defined by (𝑘1/ 𝑘−1) and 𝑘2 is the intrinsic HDX rate. 
𝑘𝐻𝐷𝑋 =  
𝑘1𝑘2
𝑘−1
   eq 1.2 
In another extreme, which is relatively rare under physiological conditions, the refolding rate is 
much smaller than the exchange rate (i.e. 𝑘−1  ≪  𝑘2). In this event, HDX rate equals the 
opening rate (eq 1.3). After unfolding, all exposed amide sites in the local region exchange with 
deuterium before returning back to the folded state. This regime is termed EX1 kinetics or 
correlated exchange. 
𝑘𝐻𝐷𝑋 =  𝑘1   eq 1.3 
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The mass spectra of HDX via EX1 or EX2 kinetics are distinguishable (Figure 1.1459). In EX2, a 
single binomial distribution is shifted to the higher m/z as a result of longer exchange times. In 
EX1, as one increases the incubation time of protein in D2O, multiple populations (commonly 
two) occur. The centroid m/z of each population remains the same whereas the relative intensities 
of the different populations change. If the two extremes, EX1 and EX2, occur concurrently, both 
m/z and relative intensities of multiple populations may change. This mixed regime is called 
EXX.60 
1.7 HDX-MS-based Techniques for Protein Biophysics 
HDX-MS is a general term referring to any experiment using MS to detect the mass shift as a 
result of exchange of protein hydrogen with solvent deuterium. There are different approaches to 
execute HDX-MS, such as bottom-up or top-down HDX performed in either solution or gas 
phase.48 Under each category, there are also various techniques. The next section focuses on 
several techniques utilized in this thesis, which use bottom-up HDX performed in solution.  
1.7.1 Continuous Labeling 
Continuous labeling is the conventional and most applied technique. A typical workflow is 
provided in Figure 1.15 (taken from ref 6161 with permission). A protein at different states, with 
or without ligand, is incubated in D2O for various times at physiological pH. Less HDX occurs 
typically in the presence of ligand compared to the absence. HDX is quenched at lower pH on ice 
to minimize back exchange. Protease that are active at acidic conditions, such as pepsin or fungal 
protease XIII, are used for digestion in peptide-level analysis. The digested peptides are 
separated over a short gradient of HPLC and submitted to MS analysis. 
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Figure 15 1.15: Schematic of  a conventional continuous  HDX workflow 
Figure 1.15 Schematic of a conventional continuous HDX workflow (taken from ref 61 with 
permission).   
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The mass of each isotopic distribution is extracted and compared to that of the non-deuterated 
peptide. The percentage of deuterium uptake is determined by eq 1.4: 
%Deuterium Uptake =  
𝑚𝐻𝐷𝑋−𝑚0
𝑁−2
× 100%   eq 1.4 
N is the residue number (except proline) of any given peptide. The first two residues at the N-
terminus are generally assumed not to retain deuterium owing to their fast back exchange. The 
term 𝑚𝐻𝐷𝑋 is the mass of the deuterated peptide, and 𝑚0 is the mass of the non-deuterated 
peptide.  
For each peptide, the percentage of deuterium uptake is plotted against incubation time to 
construct a differential kinetic plot. The differential deuterium uptake between states can be 
further mapped onto structures for visualization. 
1.7.2 Pulsed Fast Labeling 
Pulsed labeling technique (i.e. HDX coupled with quench-flow mixing), has been developed to 
study protein folding and transient motion at millisecond to subsecond time scales.52, 62, 63 A 
general pulsed labeling setup52 is provided in Figure 1.16. The unfolded sample is first mixed 
with large excess amount of buffer to start folding. HDX is triggered by mixing solution 
containing protein with D2O buffer brought in from another syringe, followed by quenching and 
digestion before MS injection. The time scale of exposure to D2O can be as short as ms. The 
folding or labeling time can be kept constant or varied by adjusting flow rate or the diameters of 
capillaries if needed. 
Gross and coworkers64 developed a pulsed labeling platform to probe the conformational 
changes of amyloid protein aggregation. Aβ protein was subjected to aggregation under different 
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conditions over a period of time (minutes to days). A relatively brief HDX (seconds) pulse was 
applied at certain time points to monitor protein conformation. Both HDX and protein 
perturbation prior to labeling are time dependent. Therefore, it is important to ensure that the 
time scale of HDX is much shorter compared to that of protein perturbation such that protein 
conformational change during HDX is negligible. In other words, it is crucial to maintain the 
protein at steady state during a continuous HDX experiment. 
 
 
Figure 16 1.16: Schematic of  a pulse labeling set up  
Figure 1.16 Schematic of a pulse labeling set up.   
 
1.7.3 PLIMSTEX 
PLIMSTEX (Protein–Ligand Interactions by Mass Spectrometry, Titration, and H/D Exchange), 
developed by Gross and coworkers65, is one of two HDX-based techniques that measure binding 
affinities. Protein samples are incubated with various amounts of ligands before subjecting to 
HDX for a fixed HDX time. PLIMSTEX is a titration platform utilizing HDX instead of 
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fluorescence66 or other conventional spectroscopic methods to detect signal changes as a result of 
ligand binding. A typical PLIMSTEX curve is provided in Figure 1.17A (adapted from ref 6565 
with permission).  To construct a PLIMSTEX curve, it is necessary to obtain the HDX difference 
between apo and holo states as a function of the extent of titration. 
Data analysis of PLIMSTEX involves a fitting process of a 1:n (total binding sites) sequential 
binding model.67 The cumulative binding constant 𝛽𝑖 is defined by eq 1.5, in which 𝐾𝑖 is the 
stepwise binding constant. 
𝛽𝑖 =  𝐾1 × 𝐾2 × … × 𝐾𝑖   eq 1.5 
The experimental overall deuterium uptake change is described as a function of the ligand 
concentration in eq 1.6: 
ΔD =  D0 − ∑ ΔD𝑖(
𝛽𝑖[𝑙𝑖𝑔]
𝑖
1+∑ 𝛽𝑖[𝑙𝑖𝑔]
𝑖𝑛
𝑖=1
𝑛
𝑖=1 )   eq 1.6 
where D0 is the deuterium uptake of the apo state (i.e., without ligand). The term ΔD is the 
overall deuterium uptake change, and ΔD𝑖 is the deuterium uptake decrease caused by each 
ligand binding. The term[𝑙𝑖𝑔] is the free ligand concentration. Detailed descriptions of how to 
solve the equation to accomplish PLIMSTEX data analysis can be referred to in previous 
publications 48, 65, 67.  
If a protein concentration is much larger than the binding constant, one can obtain a “sharp-
break” curve that can be used to determine binding stoichiometry. As shown in Figure 1.17B, a 
sharp break point occurs at a protein/ligand ratio = 1, indicating a 1:1 binding system. This 
“sharp-break” experiment can also be used in testing purity of a known system.65 When coupled 
with enzyme digestion, PLIMSTEX can be used to determine binding orders in a complicated 
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binding system.68 In chapter 5, we obtained site-specific binding constants directly from peptide-
level PLIMSTEX. 
 
Figure 17 1.17: PLIMSTEX resu lts at the g loba l level 
Figure 1.17 PLIMSTEX results at the global level. (A) A typical PLIMSTEX curve (B) A 
“Sharp break” curve when the protein concentration is much higher than the binding affinity. 
Figures are adapted with permission from ref 65. 
1.7.4 SUPREX 
The other HDX-based technique for measuring binding affinities is SUPREX (Stability of 
Unpurified Proteins from Rates of H/D Exchange), developed by Fitzgerald and coworkers69, 70. 
SUPREX is an energetics-based technique that extracts binding affinities from protein unfolding 
properties. Protein samples, in the presence and absence of a fixed amount of ligands, are 
incubated with D2O buffer containing increasing amount of denaturant, such as urea or guanidine 
hydrochloride, for different periods of time. Protein undergoes unfolding as well as HDX. Higher 
deuterium uptake due to unfolding of structured regions. SUPREX curves are typically S-shaped 
(Figure 1.18, taken from ref 7171 with permission). 𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋 of each SUPREX curve is extracted 
by fitting data to a four-parameter sigmoidal eq 1.771: 
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ΔMass[𝑑𝑒𝑛𝑎𝑡𝑢𝑟𝑎𝑛𝑡] = Δ𝑀0 +
𝑎
1+ⅇ
−([𝑑𝑒𝑛𝑎𝑡𝑢𝑟𝑎𝑛𝑡]−𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋)/𝑏
   eq 1.7 
In eq 1.7, ΔMass[𝑑𝑒𝑛𝑎𝑡𝑢𝑟𝑎𝑛𝑡] is the mass shift of a deuterated protein/peptide compared to non-
deuterium exchanged form. The term Δ𝑀0 is the mass change before globally protected protons 
exchange with deuterium. The term[𝑑𝑒𝑛𝑎𝑡𝑢𝑟𝑎𝑛𝑡] is the molar concentration of denaturant. The 
term 𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋 is denaturant concentration at the half-way transition point of a SUPREX curve. 
The terms 𝑎 and 𝑏 are unknown parameters describing amplitude and steepness of the transition 
region of a SUPREX curve. 
Multiple 𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋 values obtained at different D2O incubation times for apo or holo state are 
used to calculate the folding energy by using eq 1.8: 
−𝑅𝑇 ln(
𝑘𝑖𝑛𝑡
0.693
−1
𝑛𝑛
2𝑛−1
[P]𝑛−1
) = 𝑚𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋 + 𝛥𝐺𝑓    eq 1.8 
where 𝑘𝑖𝑛𝑡 is the average HDX intrinsic exchange rate, n is the number of subunits of any given 
protein, 𝑚 is a value measuring the dependence of 𝛥𝐺 on the denaturant concentration change, 
𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋 is from eq 1.7, 𝛥𝐺𝑓 is the free energy of protein folding, R is the gas constant, and T is 
the temperature. 
The dissociation constant can be then calculated from the folding free energy difference between 
holo and apo states (𝛥𝛥𝐺𝑓) using eq 1.9: 
𝐾𝑑 =  
[𝐿𝑖𝑔]
𝑒−𝛥𝛥𝐺/𝑛𝑅𝑇−1
   eq 1.9 
Here, n is the number of binding sites. [𝐿𝑖𝑔] is the concentration of free ligand, which is 
estimated as the total ligand concentration considering ligand is in large excess of protein. 
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SUPREX was initially conducted using MALDI mass spectrometry, providing a high throughput 
capability as one of its advantages.69 However, this setup also restricts the resolution of SUPREX 
to the global or domain/large peptide level because no separation is coupled before MS analysis 
and not all peptides from a digestion would be detected. In chapter 5, we adapted SUPREX with 
ESI and monitored local unfolding of apoE upon ligand binding.  
 
Figure 18 1.18: Representat ive SUPREX curves of two protein  sta tes  
Figure 1.18 Representative SUPREX curves of two protein states (taken from ref 71 with 
permission). ΔMass (mass shift of deuterated sample compared to non-deuterated sample) is 
plotted as a function of guanidinium chloride (GdmCl). 
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1.8 Native MS 
In native MS, protein complexes or protein/ligand complexes are introduced into gas phase and 
interrogated by MS.72, 73 Concerns were raised initially whether gas-phase structures are relevant 
to native solution structures, considering water and salts are not present in vacuum to stabilize 
proteins.72 Over twenty years, evidence has accumulated from molecular dynamics (MD) 
simulations, ECD and IM to show that gas-phase structures are compact and native-like, at least 
on the millisecond time scale.73 Native MS opens a new door to study protein higher-order 
structures by MS. Unlike structural proteomics approaches that utilize enzymes and obtain 
average information of all protein states in solution, the gentle conditions employed in native MS 
preserve non-covalent interactions in a protein complex and allow us to observe or isolate 
directly the species of interest for further studies. 
The first and most critical step in native MS is to control carefully spray conditions so as not to 
disrupt protein structures when introduced into the gas phase. In a regular ESI or denaturing ESI, 
acid/base, organic solvent and high source temperature are employed to assist ionization process. 
The spray voltage is typically higher than 3 kV at microliter flow rates. Protein are denatured, 
and non-covalent interactions are interrupted under such “harsh” conditions. In contrast, native 
MS uses aqueous solutions containing volatile salts, commonly ammonium acetate, at 
physiological pH. The sample is introduced into MS through an emitter with a small inner 
diameter. Because the flow rate, spray voltage (~1.5 kV) and temperature are much lower than in 
denaturing ESI, a “gentle” condition pertains, and protein ions are introduced into the mass 
spectrometer in a native or near-native state. In native MS, proteins carry much less charge than 
in regular ESI, producing ions in a high m/z region. Therefore, special instrumentation that can 
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accommodate ions at high m/z are needed for native MS experiment. In chapter 7, we used native 
MS with ECD and IM to study apoE oligomers. 
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Chapter 2: Continuous and Pulsed 
Hydrogen–Deuterium Exchange and Mass 
Spectrometry Characterize CsgE 
Oligomerization*1 
 
 
 
 
 
 
 
 
                                                 
* This work is based on the following publication: Wang, H., Shu, Q., Rempel, D. L., Frieden, 
C., and Gross, M. L. Continuous and Pulsed Hydrogen–Deuterium Exchange and Mass 
Spectrometry Characterize CsgE Oligomerization, Biochemistry, 2015 54, 6475-6481. Wang, H. 
performed all the MS experiment and analyzed the HDX data. Shu, Q. provided the protein CsgE 
WT/mutant, and performed thermal denaturation and analytical ultracentrifugation experiment. 
Rempel, D. L. wrote the algorithm for HDX multi-species analysis. 
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2.1 Abstract 
We report the use of hydrogen–deuterium amide exchange coupled to mass spectrometry (HDX–
MS) to study the interfaces of and conformational changes accompanying CsgE oligomerization. 
This protein plays an important role in enteric bacteria biofilm formation. Biofilms provide 
protection for enteric bacteria from environmental extremes and raise concerns about controlling 
bacteria and infectious disease. Their proteinaceous components, called curli, are extracellular 
functional amyloids that initiate surface contact and biofilm formation. The highly regulated 
curli biogenesis involves a major subunit, CsgA, a minor subunit CsgB, and a series of other 
accessory proteins. CsgE, possibly functioning as oligomer, is a chaperonin-like protein that 
delivers CsgA to an outer-membrane bound oligomeric CsgG complex. No higher-order 
structure, or interfaces and dynamics of its oligomerization, however, are known. In this work, 
we determined regions involved in CsgE self-association by continuous HDX, and, on the basis 
of that, prepared a double mutant W48A/F79A, derived from interface alanine scan, and verified 
that it exists as monomer. Using pulsed HDX and MS, we suggest there is a structural 
rearrangement occurring during the oligomerization of CsgE. 
2.2 Introduction 
Curli are the first identified functional amyloid fibers produced by Escherichia coli, and other 
enteric bacteria. Curli fibers adhere to a host’s surface and are critical for biofilm formation.1-3 
Bacteria within biofilms are protected from environmental extremes (e.g., disinfectants, 
antibiotics), allowing many infections to reoccur.4 Thus, curli proteins are a target for treatment 
of many persistent and chronic bacterial infections.5 Understanding this highly regulated amyloid 
production process is not only important in infectious disease management but also in providing 
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a perspective on molecular mechanisms underlying Alzheimer’s, Parkinson’s, Huntington’s, and 
other human neurodegenerative diseases that are caused by misfolded amyloids.6  
The highly regulated biogenesis of curli fibers is encoded by two divergently transcribed csg 
(curli-specific gene) operons, csgBAC and csgDEFG.1, 7 Operon csgBAC is regulated by the 
transcriptional factor CsgD.7 CsgA, the major curli subunit, is secreted as an intrinsically 
disordered protein to the outer membrane surface and rapidly forms amyloid aggregates upon 
interacting with CsgB, the nucleator and a minor curli subunit.8, 9 CsgC stabilizes periplasmic 
CsgA and efficiently inhibits CsgA aggregation.10 Membrane-bound CsgG associates into a 
porelike nonamer that is required for curli secretion and localization.11-13 CsgF, a surface-
exposed chaperonin-like protein, assists in directing and tethering curli amyloid to the cell 
surface by interacting with both CsgG and CsgB.14 CsgE is another chaperonin-like protein that 
prevents CsgA amyloid formation within the periplasm and delivers CsgA to the pore CsgG for 
secretion in vivo.15 CsgE inhibits amyloid formation of CsgA in vitro.15, 16 Little else is known 
about the biophysical properties of CsgE except that it may form a nonameric adaptor that binds 
to the membrane-extracted nonameric CsgG complex.12 It is possible that CsgE functions in this 
oligomeric state rather than as monomer. Therefore, the structural characterization of CsgE and 
its oligomerization-induced conformational changes are critical to elucidate the role of CsgE in 
curli biosynthesis.  
Given the tendency of CsgE to aggregate, high resolution methods including X-ray 
crystallography and NMR are difficult, if not impossible, to apply. Here, we utilized continuous 
and pulsed methods of hydrogen–deuterium exchange coupled to mass spectrometry (HDX-MS) 
to study regions of self-association, and we followed the conformational changes during the 
protein’s extensive oligomerization. We chose HDX because it is useful in probing protein 
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conformation and dynamics.17-21 Protein backbone amide hydrogens exchange with deuterium 
based on solvent accessibility and hydrogen bonding. Thus, protein structural information is 
coupled to a mass shift that is easily detected by mass spectrometry. In conventional and widely 
employed continuous HDX, the protein is diluted into D2O buffer for various times prior to 
measurement of deuterium uptake. The increased uptake, as a function of exchange time, reflects 
dynamics of backbone amide hydrogen bonds and solvent accessibility, and, therefore, provides 
insights into protein conformation.17, 18 On the other hand, pulsed HDX examines a short HDX 
time window after perturbing the protein for different periods of time. In this case changes in 
deuterium uptake represent distinct populations of molecules, each of which has different 
exchange profiles. Therefore, protein structural change is probed in a complementary way to 
continuous HDX.22, 23 Here, we performed complementary studies of CsgE oligomerization by 
both continuous and pulsed HDX. 
2.3 Materials and Methods 
2.3.1 Protein Expression and Purification 
Wild type CsgE was expressed with a C-terminal 6xHis-tag and without the signal peptide 1–21 
by using pNH27 in strain NEB 3016 with 100 μg/mL ampicillin, as reported previously.15  The 
substitution, tryptophan 48 to alanine (W48A) was first introduced into the wild type CsgE by 
using the QuikChange, site-directed mutagenesis kit (Stratagene, La Jolla, CA). A substitution of 
phenylanaline 79 to alanine (F79A) was further introduced into W48A to produce the double 
mutant W48A/F79A. All constructs were sequenced with BigDye Terminator v3.1 cycle 
sequencing kit and the 3730 DNA Sequencers (Applied Biosystems, Foster City, CA) to ensure 
their integrity and accuracy. 
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Both WT and mutant CsgE were expressed as previously described.15, 24 The proteins were 
purified by using two steps of FPLC. Any precipitate that formed during purification was 
removed by centrifugation, and the supernatant was filtered through a 0.22 μM membrane before 
loading on to the column. The lysis of cell pellets was done in 20 mM imidazole, 0.5 M NaCl, 50 
mM potassium phosphate, pH 8.0. After centrifugation and filtration, the supernatant was applied 
to affinity FPLC using a nickel affinity column, HisTrap FF Crude (GE Healthcare, 
Buckinghamshire, UK). The protein was washed with lysis buffer and eluted with a solution of 
500 mM imidazole, 500 mM NaCl, 50 mM potassium phosphate (pH 7.4). The protein in the 
eluate was further purified by size-exclusion FPLC by using a HiPrep 26/60 Sephacryl S-100 HR 
column (GE Healthcare) and 50 mM potassium phosphate (pH 7.4), 150 mM NaCl, 500 mM 
arginine. Purified CsgE was stored at 4 °C before concentrating and exchanging the buffer for 
further analysis. Trace amounts of arginine possibly exists in solution after buffer exchange. The 
protein concentration was determined by absorbance at 280 nm on a Varian Cary 50 Bio UV/vis 
spectrophotometer (Palo Alto, CA) by using 1 mL volume and molar absorptivities of 19460 and 
13980 M–1 cm–1 for wild type and mutant, respectively. 
2.3.2 Materials 
All chemicals unless otherwise stated were purchased from Sigma-Aldrich (St. Louis, MO). D2O 
was purchased from Cambridge Isotope Laboratories Inc. (Andover, MA). 
2.3.3 HDX Protocol 
Continuous HDX was initiated by diluting CsgE stock solution in phosphate buffer saline (PBS), 
pH 7.4, 1:3 into D2O buffer (PBS, pD 7.4) at 4 °C. The 1:3 dilution factor was chosen so that a 
relatively high protein concentration could still be maintained after D2O dilution without 
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concentrating the stock solution and causing aggregation during preparation or sample storage. 
At various incubation times (10 s, 30 s, 1 min, 5 min, 15 min, 1 h, 4 h), HDX was quenched by 
adding 3 M urea/1% (v/v) trifluoroacetic acid (TFA) at 2:3 volume ratio. For establishing a back 
exchange correction, 0.75 μM WT CsgE with 5 mM Arg or the CsgE W48A/F79A mutant was 
incubated in D2O buffer at 4 °C for 72 h.  
For pulsed HDX, 10 μM CsgE (PBS, pH 7.4) was incubated at 25 °C with continuous stirring to 
promote CsgE oligomerization. Pulsed HDX was performed by mixing the incubated sample 1:5 
into D2O buffer (PBS, pD 7.4) at 4 °C for 30 s, and then quenched the same way as for 
continuous HDX. 
2.3.4 LC–ESI/MS Analysis 
The quenched solution was immediately injected into a custom-built, online sample-handling 
device that was immersed in a water-ice (0 °C) bath to minimize back exchange, as previously 
described.25 Briefly, the protein solution was digested by passing it through an immobilized 
pepsin column (2 mm × 2 cm) at 200 μL/min in 0.1% TFA via an Agilent 1100 HPLC (Santa 
Clara, CA), and the resulting peptic peptides were trapped and desalted on a C8 trap column (2.1 
mm × 1.5 cm, Agilent, Santa Clara, CA) for 3 min. The peptic peptides were then eluted from 
the trap column and separated on a C18 analytical column (1.9 μm Hypersil Gold, Thermo 
Fisher, Waltham, MA) with a linear gradient (4–40% CH3CN, 0.1% (v/v) formic acid) at 50 
μL/min delivered by a Waters nanoACQUITY UPLC (Milford, MA) for 5 min. All 
measurements were done in triplicate.  
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2.3.5 HDX Data Analysis 
Preliminary to HDX, peptides from pepsin digestion were identified in a data-dependent mode 
on a Thermo LTQ XL Orbitrap (San Jose, CA). The six most abundant ions were submitted to 
collision-induced dissociation (CID) fragmentation. Product-ion spectra were then submitted to 
MassMatrix (version 2.4.2) for identification,26 and manually inspected. Only verifiable peptides 
were used for the HDX analysis. HDX data were collected on a MaXis quadrupole time-of-flight 
(Bruker, Bremen, Germany) mass spectrometer in the positive-ion electrospray ionization mode. 
The settings were as follows:  capillary voltage, 3.8 kV; nebulizer gas, 0.8 bar; drying gas flow 
rate and temperature, 6 L/min and 180 °C, respectively. Data analysis of continuous HDX was 
carried out with HDExaminer (version 1.1.0, Sierra Analytics, Inc., Modesto, CA). EX1-like or 
EXX-like kinetics were fit by a customized program implemented in MathCAD (v14, Parametric 
Technology Corp., MA).  
2.3.6 Thermal Denaturation by Circular Dichroism 
The far-UV circular dichroism (CD) spectra were measured on a Jasco-715 spectropolarimeter 
(Tokyo, Japan) equipped with thermoelectric temperature control. The CD melting curves were 
recorded as a function of temperature at 222 nm to report structural unfolding. The temperature 
change was from 20 to 80 °C at a rate of 1 °C/min. The protein concentration was 10 μM in 10 
mM potassium phosphate buffer, pH 7.4.  
2.3.7 Analytical Ultracentrifugation 
A Beckman Optima model XL-A analytical ultracentrifuge (Brea, CA) was used for the 
sedimentation velocity experiments. Samples were loaded into a conventional double-sector 
filled Epon centerpiece (path length 1.2 cm).  Data were collected in continuous mode at 290 nm. 
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Experimental conditions: 50 mM potassium phosphate, pH 7.4, 150 mM NaCl at 25 C at 20 μM 
CsgE. Data were analyzed using Sedfit.27 
2.4 Results and Discussion  
Self-assembly of proteins into different oligomeric states is a complex process that remains 
difficult to understand.28, 29 Therefore, it is necessary to start this section with the design of the 
oligomerization study reported here. First, we studied CsgE at different concentrations by 
continuous HDX and identified regions involved in self-association. Considering that CsgE is 
prone to aggregate at 25 °C, we conducted our HDX experiments at 4 °C to maintain the protein 
oligomeric state the same within the experimental window. The protein is likely restricted to 
mainly monomer and a fraction of oligomers at this low temperature. It is also known that 
quaternary structural rearrangement derived from oligomerization significantly affect protein 
function and play a vital role in biochemical processes.30 Curli are expressed in a stationary 
phase at temperatures below 30 °C.31 Thus, we are also interested in investigating the 
oligomerization-induced conformational changes at biologically relevant conditions (i.e., 25 °C), 
to improve our understanding of the role of CsgE in curli biogenesis. Continuous HDX is not 
applicable here, however, as both oligomerization and HDX are time-dependent processes, and 
the results are a convolution of both. Thus, we applied pulsed HDX, a platform implemented by 
us previously for Aβ4223, to study CsgE conformational changes accompanying extensive 
oligomerization. 
2.4.1 Structural and Interface Information from Continuous HDX 
We conducted comprehensive differential HDX analysis of CsgE at different concentrations and 
at 4 °C to determine the oligomerization interfaces of the protein.  We do not know, however, the 
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concentration that CsgE exists as monomer. Arginine can suppress protein aggregation.32 We 
found that adding arginine at mM concentration results in a monomer-predominant CsgE 
solution possibly by interrupting various hydrophobic interactions. Therefore, we performed 
HDX on 0.75 μM CsgE WT in the presence of 5 mM arginine (WTArg) to help identify the self-
association regions. We corrected for back exchange to ensure a more accurate interpretation of 
the results.  In our study, 99% of the CsgE could be covered with multiple overlapping peptides 
formed by online pepsin digestion. We selected 12 peptides to represent the HDX kinetics over 
the full protein (Figure 2.1). The complete set of kinetic curves is provided in Figure 2.2 for 
additional support.
 
Figure 19 2.1: Con tinous HDX o f selected peptides of wild-type CsgE  
Figure 2.1 Continuous HDX kinetic plots of selected peptic peptides of CsgE at concentration 
(after dilution) of 0.75 μM with 5 mM Arginine (red), 0.75 μM (green), 5 μM (cyan), 33 μM 
(purple), 67 μM (black) at 4 °C. 
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Figure 2.2 Continuous HDX kinetic plots of all peptic peptides of CsgE at concentration (after 
dilution) of 0.75 μM with 5 mM Arginine (red), 0.75 μM (green), 5 μM (cyan), 33 μM (purple), 
67 μM (black) at 4 °C. 
 
Figure 20.2 2.2: Continuous HDX of al l peptides of wild-type CsgE 
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Considering there is currently no report of a CsgE structure, we first studied deuterium uptake of 
0.75 μM CsgE WT (green, Figure 2.1) to obtain broad structural information. HDX provides 
insights into structure because regions with secondary structure undergo slower HDX than do 
loops or unstructured regions.17, 18 Deuterium uptake of peptides 4–9, 89–97 and 98–114 reached 
maximal exchange rapidly, suggesting that those regions located at the N- and C- termini are 
highly dynamic and unstructured. In contrast, less than 5% HDX occurred for peptides 59–62 
and 80–88 over the entire time course. This extraordinarily slow exchange behavior indicates 
that either these two regions contain rigid secondary structural elements or the regions are 
located at a central core of the structure. HDX extents at regions represented by peptides 11–22, 
23–38, 39–51, 63–66, and 67–79 were between these two extremes, indicating some locally 
defined secondary structures. Deuterium uptake of peptide 52–58 remained constant at about 
40%, and this is likely a result of composite behavior caused by partially unstructured and 
partially rigid structures in this region of the protein, given that back exchange has already been 
corrected.  
We next compared the time-dependent HDX of each peptide under the following conditions: 
0.75 μM WTArg (red), 0.75 μM WT (green), 5 μM (cyan), 33 μM (purple), and 66 μM (black) 
(Figure 2.1). There are regions that are unaffected by oligomerization occurring under these 
conditions.  We view those regions, 4–9, 52–58, 59–62 and 98–114, as a negative control; HDX 
in those regions was not affected by protein concentration or the presence of arginine. To 
identify the critical regions in self-association, we made two comparisons:  one is the HDX 
difference between 0.75 μM WTArg (red) and 0.75 μM WT (green), and the other is the difference 
between WT at 0.75 μM (green) and at 5 μM (cyan), 33 μM (purple) and 66 μM (black) (Figure 
2.1). In the first comparison, differential information is obtained between monomer and 
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oligomers. Major differences for peptides 26–33, 39–51 and 67–79 occurred at short HDX times 
but diminished at longer times. We interpret this to be due to equilibrium dissociation of 
oligomers and faster HDX in their monomeric forms. A small but statistically significant 
difference (student’s t-test at 95% confidence interval) for peptide 23–38 was observed over the 
entire time course, further supporting that 26–33 is an important interface. Apparent differences 
in HDX also occurred for peptides 11–22 and 80–88 at longer time points (after 1 h), but not at 
shorter time points. This phenomenon indicates that long-term dynamics and protein breathing, 
instead of solvent exposure of these regions, are mostly affected.  
In the second comparison no arginine was involved. Here, the HDX profiles give an integrated 
picture of equilibrium between monomers and different oligomers in solution. Presumably, 
higher protein concentrations increase the average size of oligomers present in solution. More 
extensive HDX of peptides 26–33, 39–51 and 67–79 was again observed at 0.75 μM than at 
higher concentration for most time points, while the HDX difference for peptide 63–66 became 
significant only after 1 h incubation. The results from the two comparisons suggest that regions 
26–33, 39–51 and 67–79 are important oligomerization interfaces. There is a possibility, 
however, that other critical regions in self-association were not clearly revealed by our data. It is 
difficult to tell whether small differences of deuterium uptake are directly from oligomerization 
interfaces or the result of an allosteric effect where conformational changes occur remote from 
the oligomer interfaces. Nevertheless, continuous HDX provides useful information on CsgE 
structure and strongly suggests the self-association regions.  
70 
 
2.4.2 A Monomeric Mutant 
To confirm further that regions identified above contain critical residues involved in self-
association, we substituted alanine for certain amino acids located at the putative interfaces. 
Among all the substituted proteins, we found that the W48A/F79A double mutation is 
significantly more stable than the WT in vitro, as measured by thermal denaturation (Figure 2.3). 
Using analytical ultracentrifuge experiments of this mutant, we found a single species with a 
calculated molecular weight of 12–13 kDa essentially the same as the theoretical molecular 
weight of 12.3 kDa for the monomer (Figure 2.4). We monitored circular dichroism signals at 
 
Figure 2.21 2.3: therma l denaturation of W T and W48A/F 79A CsgE  
Figure 2.3 Comparison of thermal denaturation of WT CsgE (blue) and the doubly substituted 
W48A/F79A (red) monitored by CD at 222 nm. The signal change was fit to a two-state (folded 
and unfolded) unfolding transition of each form. The TM values of WT and W48A/F79A are 36.7 
± 0.2 and 45.6 ± 0.1 °C, respectively. 
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222 nm, indicative of α-helices, as a function of temperature for both WT (blue) and 
W48A/F79A (red). The denaturation curve for W48A/F79A was shifted to higher temperature 
relative to that of WT. The TM values, midpoint of the unfolding transition, of WT and 
W48A/F79A are 36.7 ± 0.2 and 45.6 ± 0.1 °C, respectively, determined by fitting the signal 
change to a two-state (folded and unfolded) unfolding transition.33 The increased TM value 
indicates that W48A/F79A is more stable than the WT. Protein stability should correlate 
inversely with oligomerization propensity.34, 35 This offers a means to interpret the continuous 
HDX on W48A/F79A at 0.75 μM in comparison with the HDX of 0.75 μM CsgE WT and 0.75 
μM WTArg to test whether HDX of W48A/F79A is consistent with the protein being monomeric. 
Overall, the HDX extents for peptides that are not involved in self-association are the same for 
W48A/F79A, WT, and WTArg (Figure 2.1), strongly suggesting that substitution of W48A/F79A 
does not affect overall protein structure and dynamics. 
 
Figure 2.22 2.4: Sedimenta tion veloci ty analys is of W 48A/F79A  
Figure 2.4 Sedimentation velocity analysis of CsgE double mutant W48A/F79A. 
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The deuterium uptake plots for critical self-association regions (26–33, 39–51 and 67–79) 
(Figure 2.5), however, show that for all three regions, HDX of W48A/F79A mutant (blue) is 
greater when compared to that of WT (green), indicating more exposure or weaker H-bonding at 
self-association interfaces. This is consistent with the results of our HDX experiments discussed 
above. Interestingly, significantly higher HDX of W48A/F79A (blue) than that of WTArg (red) 
occurs for peptides 39–51 and 67–79, but not for peptide 26-33. Noticeably, two mutation sites 
are located within peptides 39–51 and 67–79.  One explanation is that there is some oligomer 
present for WTArg. We do not think that is the case because HDX of WTArg is the same as that of 
W48A/F79A for peptide 26–33 and W48A/F79A is a pure monomer.  
 
Figure 2.23 2.5: Com parison of  continuous HDX of W T and W48AF79A  
Figure 2.5 Continuous HDX kinetic plots of selected peptides of 0.75 μM CsgE double mutant 
W48A/F79A (blue), 0.75 μM CsgE with 5 mM Arginine (red) and 0.75 μM CsgE WT (green). 
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The W48A/F79A substitutions reduce local conformational rigidity in regions 39–51 and 67–79 
without apparently affecting other regions, resulting in higher deuterium uptake in these two 
regions. On the other hand, peptide 26–33 shows the same HDX extent as WTArg because 
W48A/F79A exists as monomer owing to the interruption of critical self-association residues. 
This comparison between W48A/F79A, WT and WTArg further confirms the importance of 
residues W48 and F79 in CsgE self-association. 
2.4.3 Structural Rearrangement Revealed by Pulsed HDX and MS 
The recent discovery of a CsgE nonamer12 leads to a proposal that the CsgE monomer is 
relatively biologically inactive and must oligomerize to achieve some of its function in vivo. 
Little progress has been made, however, towards understanding CsgE oligomerization.  Zhang et 
al.23 have demonstrated that pulsed HDX is a useful tool for studying soluble A as an 
aggregation system. Here, we applied this method to follow CsgE conformational changes 
accompanying oligomerization. In this study, CsgE was allowed to oligomerize extensively at 25 
°C with continuous stirring. At given incubation times, we used a 30 s pulse of HDX to take a 
“snapshot” of the soluble protein oligomeric states at 4 °C.  
We compared the HDX of each peptide at given incubation times to that at t = 0 (i.e., before 
starting incubation with continuous stirring). A heat map of the differential uptake between given 
incubation times and t = 0 of representative peptides is shown in Figure 2.6. In contrast to the 
aggregation of Aβ42, for which deuterium uptake of all peptides decreased (protection increased) 
in a modified sigmoidal behavior23, CsgE exhibits some interesting local behaviors. HDX of 
peptides 4–10, 52–58, 63–66, 67–79, 89–97, and 98–114 showed a significant decrease in HDX 
(shown in blue) attributable to the accumulation of higher order structures, as expected for an 
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oligomerizing system. Most of the peptides that showed increased protection with 
oligomerization, with the exception of the N terminus, comprise the C-terminal half of the 
protein. 
Surprisingly, deuterium uptake of peptides of most of the N-terminal half (amino acids11–51) 
and 80-88 underwent increased HDX (shown in red), suggesting more open local structures are 
formed upon oligomerization. These results suggest that various regions play different roles in 
CsgE oligomerization. Deuterium uptake plots as a function of incubation times of selected 
peptides, provided in Figure 2.7, indicate that the most significant HDX changes among all 
peptides happened within 10 h. This interesting “alternating increase or decrease” of HDX 
behavior suggest that there is a significant structural rearrangement of the monomer as it 
oligomerizes. 
 
 
Figure 2.24 2.6: Dif ferentia l heat map  of W T CsgE  
Figure 2.6 Differential Heat Map of pulsed HDX peptic peptides of 10 μM CsgE at 25 °C with 
continuous stirring. Incubation times are labeled on the left. Each number is the deuterium 
uptake difference between a certain time point and t = 0 of the same peptide. The color code is 
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given above the sequence. Regions identified in self-association are boxed in green along the 
protein sequence.  
 
Figure 2.25 2.7: Deuterium uptake plo ts o f pulsed HD X  
Figure 2.7 Deuterium uptake plots of selected peptides of pulsed HDX of 10 μM CsgE WT as a 
function of incubation times at 25 °C with continuous stirring. Most exchanges happened within 
10 h. 
 
Because peptide-level information obtained from HDX is the average of all species in solution, it 
is unclear whether the HDX is sampling principally the monomer or soluble oligomers. 
Nevertheless, both monomer and oligomers must exist along an equilibrium oligomerization 
pathway, and any monomer in the mixture also reports on the structural rearrangement because 
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monomer is in equilibrium with oligomer. A possibility is that monomer undergoes 
conformational rearrangement as it equilibrates to give dimer.  The dimer and other small 
oligomers then form large oligomers in which the structure of the monomer is conformationally 
isomerized. More evidence is needed to deconvolve HDX properties of the monomer, isomerized 
monomer, and oligomers, possibly by coupling HDX with chromatography.  
Nevertheless, we can look more closely at the oligomerization by examining the deuterium 
distributions of the various peptic peptides. As expected, most peptides display a single binomial 
distribution representing deuterium patterns for the peptide molecular ions. Surprising exceptions 
are peptides encompassing residues 11–22, 23–38 and 89–97, which exhibit broad isotopic 
envelopes comprised of two and even three deuterium distributions (Figure 2.8). We fit the mass 
spectral distributions by using a customized program with two binomial distributions for peptides 
11–22, 89–97 and three distributions for peptide 23–38. At least three modes pertain to peptide 
23–38 because we could not obtain a satisfactory fit with two modes.  
For peptide 11–22, the higher mass distribution (less protected) increases with incubation time 
whereas the low mass (presumably monomer) decreases. For peptide 89–97, the lower mass 
(more-protected) distribution appeared in addition to the high-mass (i.e. less-protected) 
distribution as revealed by comparing the distribution at t = 0. The less-protected species is 
presumably the monomer.  For peptide 23–38, two less-protected species appear with incubation 
time and coexist with the monomeric species. The deuterium uptakes represented by the mass 
centroids of the various distributions are nearly invariant whereas the relative intensities of the 
distributions change with incubation time. 
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Figure 2.26 2.8: Mass spectra of  peptides showing b road HDX  iso topic pa tterns  
Figure 2.8 Mass spectra of peptides showing broad HDX isotopic patterns at different incubation 
times. Peptides 11−22 and 89−97 are fit with two distributions (red and blue dotted lines) while 
peptide 23−28 is fit with three distributions (red, blue and green dotted lines). The total fit is 
represented by black dotted line. A vertical dashed line colored the same of each distribution is 
included to help direct eyes. 
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Although some of these multiple distributions resemble that of an EX1 HDX mechanism 
wherein the HDX rate is much faster than protein-closing rate36, 37, we interpret the multiple 
distributions to indicate the oligomerization-dependent isomerization invoked above. This is not 
a manifestation of changes in HDX because it is time-independent (the HDX time window is a 
constant-width pulse). For peptide 11–22, the relative intensities of signals for less-protected 
structures increased, whereas deuterium uptake of less protected structures decreased slightly, 
sharing similar features of the EXX HDX mechanism wherein EX1 and EX2 HDX occur 
concurrently.38 Peptide 23–38 showed a more complicated isotopic envelope indicating at least 
two species besides the normal monomer and suggesting that CsgE may exist in two oligomeric 
forms.  The distribution of peptide 89–97, however, is most clearly not that of an EX1.  Rather 
the low mass distribution (more protected) increases with incubation time.  The multiple species 
distribution is also representative of a mix of oligomers of different structures. Given that each 
peptide is a reporter of the protein states and cannot be contradictory, we suggest that there are at 
least three major conformations present in solution during the oligomerization occurring with 
stirring at room temperature. 
The disubstituted protein, W48F/F79A, interestingly and perhaps coincidentally, is modified at 
the junction of two regions (red and blue, Figure 2.6). Although peptides in both regions 23–51 
and 67-79 are involved in self-association (enclosed in green box), as revealed by continuous 
HDX, region 23–51 opens and becomes more flexible (less protected) whereas 67–79 closes and 
shows more protection by pulsed HDX. 
79 
 
2.5 Conclusion 
Continuous HDX at different concentrations indicates that regions 26–33, 39–51 and 67–79 of 
CsgE are involved in self-association at 4 °C.  This outcome directed effective site-directed 
mutagenesis and preparation of a monomeric doubly substituted W48A/F79A.  Re-examination 
of the substituted protein demonstrates that HDX not only compares two states (monomer vs. 
oligomer) but also provides useful guidance for monomeric-mutant design.  
Pulsed HDX gives insight on the oligomerization and suggests a significant structural 
rearrangement occurs accompanying oligomerization, as demonstrated by the presence of a 
conformationally alternating open and closed structure. Regions involved in self-association at 4 
°C, as indicated by continuous HDX, exhibit different conformational changes during more 
extensive oligomerization at 25 °C; peptides 26–33 and 39–51 become more exposed whereas 
peptide 67–79 stays more protected. Coupling molecular-weight-based separation with pulsed 
HDX should elucidate more fully the complex oligomerization pathway. Nevertheless, these 
results from continuous and pulsed HDX, taken together, provide early insight about CsgE’s 
structure and its conformational changes during oligomerization. 
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Chapter 3: Understanding Curli Amyloid-
protein Aggregation by Hydrogen–
Deuterium Exchange and Mass 
Spectrometry*2 
 
 
 
 
 
 
 
 
 
                                                 
* This work is based on the following publication: Wang, H., Shu, Q., Rempel, D. L., Frieden, C., and Gross, M. L. 
Understanding Curli Amyloid-protein Aggregation by Hydrogen–Deuterium Exchange and Mass Spectrometry, Int. 
J. Mass Spectrom, 2016, DOI: 10.1016/j.ijms.2016.10.006. Wang, H. performed all the MS experiment and 
analyzed the HDX data. Shu, Q. provided the protein CsgA, and performed TEM and ThT experiment. Rempel, D. 
L. wrote the algorithm for HDX multi-species analysis. 
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3.1 Abstract 
Bacteria within Curli biofilms are protected from environmental pressures (e.g., disinfectants, 
antibiotics), and this is responsible in part for intractable infections. Understanding aggregation 
of the major protein component of Curli, CsgA, may uncover disease-associated 
amyloidogenesis mechanisms. Here, we report the application of pulsed hydrogen–deuterium 
exchange and mass spectrometry (HDX-MS) to study CsgA aggregation, thereby obtaining 
region-specific information. By following time-dependent peptide signal depletion, presumably a 
result of insoluble fibril formation, we acquired sigmoidal profiles that are specific for regions 
(region-specific) of the protein.  These signal-depletion profiles not only provide an alternative 
aggregation measurement, but also give insight on soluble species in the aggregation. The HDX 
data present as bimodal isotopic distributions, one representing a highly disordered species 
whereas the other a well-structured one. Although the extents of deuterium uptake of the two 
species remain the same with time, the relative abundance of the lower mass, less-exchanged 
species increases in a region-specific manner. The same region-specific aggregation properties 
also pertain to different aggregation conditions. Although CsgA is an intrinsically disordered 
protein, within the fibril it is thought to consist of five imperfect -strand repeating units (labeled 
R1–R5). We found that the exterior repeating units R1 and R5 have higher aggregation 
propensities than do the interior units R2, R3, and R4. We also employed TEM to obtain 
complementary information of the well-structured species. The results provide insight on 
aggregation and a new approach for further application of HDX-MS to unravel aggregation 
mechanisms of amyloid proteins. 
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3.2 Introduction 
Although amyloid proteins are commonly associated with Alzheimer’s1, Parkinson’s2, and other 
neuro-degenerative diseases, some play a critical role in normal cellular physiology.3, 4 Of 
particular interest are curli, extracellular amyloid fibers produced by Salmonella spp., 
Escherichia coli, and other enteric bacteria.5, 6 These fibers are involved in the adhesion of 
bacteria and biofilm formation, protecting bacteria from the environmental stress of disinfectants 
and antibiotics.3, 5, 6. Biofilms are the cause of persistence and recurrence of many infections.7, 8 
Understanding the curli amyloid production process provides a unique perspective on the 
molecular mechanism underlying amyloidogenesis and its related cellular toxicity and function. 
The major component of the curli fiber is CsgA, initially synthesized as an intrinsically 
disordered protein with a molecular weight of 13 kDa. The 22 N-terminal residues serve as a 
signal peptide for CsgA secretion through the outer membrane. The remaining residues 23–131 
correspond to an amyloid core region in the curli fiber and consist of five imperfect, repeating 
strand-loop-strand units. CsgA consists primarily of serine, glutamine, glycine, and asparagine 
residues.9 Its aggregation in vitro has been studied using various conventional techniques 
including Thioflavin T (ThT) fluorescence and circular dichroism (CD) spectroscopy.10-12 
Cherny et al.13 identified prion-like hexa-repeats within CsgA and showed that chemically 
synthesized hexapeptides of CsgA with aromatic residues are able to self-associate into well-
ordered fibrillary species. Wang et al.14 showed, by using either synthesized peptides 
corresponding to each repeating unit or proteins with each repeating unit deleted, that repeats R1, 
R3 and R5 of the five imperfect repeating units in the amyloid core of CsgA are the regions 
responsible for polymerization. The latter group also showed that mutations of four conserved 
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residues in R1 and R5 slow CsgA aggregation in vitro and completely disable curli assembly in 
vivo.15  
Mass Spectrometry (MS)-based approaches have become highly sensitive and effective tools for 
investigating biomolecules in their native or near-native state.16-18 Hydrogen–deuterium 
exchange and mass spectrometry (HDX-MS), for example, allows experimentalists to probe the 
protein conformation at moderate structural resolution, providing critical insights into higher-
order structures of protein complexes.16-18 By measuring deuterium exchange differences, one 
can characterize changes in protein dynamics and conformation induced by protein/ligand 
binding,19, 20 post-translational modification21 and aggregation22-25. This is applicable because 
protein backbone amide hydrogens undergo HDX based on solvent accessibility and hydrogen 
bonding. Regions that show greater amide hydrogen exchange rates represent flexible or solvent-
accessible areas, whereas those that show smaller exchange rates are likely involved in a 
relatively rigid conformation or buried environment. In the work presented here, we focused on 
using HDX-MS to study the aggregation behavior of CsgA. 
3.3 Materials and Methods 
3.3.1 Materials 
Wild-type CsgA containing a 6-His-tag at the C-terminus wass expressed and purified as 
previously reported.11 CsgA stock was stored in solution containing 200 mM imidazole, 50 mM 
potassium phosphate buffer (pH 7.2), and 6 M guanidine hydrochloride (GdnHCl) at -20 °C to 
prevent aggregation. Prior to the HDX experiment, the protein solution was exchanged into 
phosphate buffer saline (PBS, pH 7.4) using a Sephadex G25 desalting column (HiTrap GE 
Healthcare, Pittsburgh, PA). 
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D2O was purchased from Cambridge Isotope Laboratories Inc. (Andover, MA). Angiotensin I 
peptide and all other chemicals were purchased from MilliporeSigma (St. Louis, MO). 
3.3.2 Pulsed HDX-MS 
Following removal of GdnHCl, 10 µM CsgA was incubated at 22 °C and monitored as a function 
of time. The first time point was approximately 1 min after protein was passed through the 
desalting column to remove the GdnHCl. Three different incubation conditions were tested: 
continuous stirring, quiescent (no stirring), and one following a freeze/thaw cycle of the buffer-
exchanged CsgA. Samples (20 µL) obtained at different incubation times, were centrifuged at 
13,000 rpm (Eppendorf Microcentrifuges 5418, Hamburg, Germany), at 4 °C for 10 min. All 
incubation times did not include the 10 min centrifugation at 4 °C. The top 10 µL of the 
supernatant was discarded to concentrate the large, soluble oligomers that will preferentially 
populate the lower solution after centrifugation.  
Pulsed deuterium labeling was achieved by diluting the lower 10 µL solution into 40 µL of D2O 
buffer for 30 s at 4 °C. Ice-cold, reducing quench buffer containing 3 M urea with 1% 
trifluoroacetic acid (TFA) was added to each reaction solution at a ratio of 1:1 (v:v) to quench 
the HDX reaction. Angiotensin I peptide (60 pmol) was spiked into the quenched solution as an 
internal standard. Online pepsin digestion and HPLC separation were performed as previously 
described.26 Briefly, protein samples were digested while flowing through a custom-packed 
online pepsin column. The resulting peptides were trapped and desalted on a C8 trap column 
(Agilent Inc., Santa Clara, CA). Separation of the peptide mixtures was carried out on a 1.9 µm 
reversed-phase C18 column (Hypersil Gold Thermo Fisher Scientific, Waltham, MA) with a 5.5 
min linear gradient. All experiments were performed in triplicate. 
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MS analysis of the eluted peptides was conducted on a MaXis 4G quadrupole time-of-light 
instrument (Bruker, Billerica, MA) by using positive-ion electrospray ionization (ESI) mode. 
The ESI spray voltage was set to 4 kV. The temperature and nebulizer gas were 180 °C and 0.8 
bar, respectively. The drying gas flow rate was 6 L/min. 
3.3.3 HDX-MS Data Analysis 
Identification (mapping) of peptic peptides was achieved in a preliminary LC/MS/MS 
experiment by submitting peptic peptides to collision-induced dissociation (CID) fragmentation 
in a data-dependent mode on a Thermo LTQ XL Orbitrap (San Jose, CA). Product-ion spectra 
were then submitted to MassMatrix (version 2.4.2)27 for identification, followed by manual 
inspection. Among all identified peptides, eight with relatively strong signals that represent the 
complete sequence were chosen for following the CsgA aggregation (Figure 3.1).  
 
Figure 27 3.1: The eigh t selected peptides mapped on to CsgA sequence  
Figure 3.1 The eight selected peptides mapped onto CsgA sequence. Five repeating units (R1–
R5) are labeled on the left. The starting and ending numbers of each peptide are labeled above 
the sequence. 
 
GVVPQYGGGGNHGGGGNNSGPN
R1 SELNIYQYGGGNSALALQTDARN
R2 SDLTITQHGGGNGADVGQGSDD
R3 SSIDLTQRGFGNSATLDQWNGKN
R4 SEMTVKQFGGGNGAAVDQTASN
R5 SSVNVTQVGFGNNATAHQYHHHHHH
1
25
48
69
93 106
137
26 37 38
49
70 83 84
94 105
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A custom-developed program implemented in MathCAD (v14, Parametric Technology Corp., 
MA) was used to fit the HDX isotopic envelopes of each CsgA peptide with two binomial 
distributions.  The program outputted centroid masses and peak areas of both species. Peak area 
of Angiotensin I was obtained from a peak fit using a binomial distribution. Relative abundances 
of MS-detectable CsgA peptides with regard to the internal standard were calculated by 
normalizing peak areas of CsgA peptides to those of Angiotensin I ions of all charge states. The 
deuterium uptake percentage was calculated by using eq 3.1: 
𝐷% =  (
𝑚𝐻𝐷𝑋− 𝑚𝑐𝑜𝑛𝑡𝑟𝑜𝑙
(𝑁−2) × 0.80
)  ×  100%  eq 3.1 
where 𝑚𝐻𝐷𝑋 and 𝑚𝑐𝑜𝑛𝑡𝑟𝑜𝑙 are the centroid mass of the deuterated and non-deuterated peptides, 
respectively, 0.80 corresponds to the final D2O content of the buffer system, and  (𝑁 − 2) 
represents the number of the amide hydrogens that are exchangeable, assuming first two residues 
retain no deuterium by the time of measurement.  
The fractional species B (at lower m/z region) was calculated according to   
𝐼𝐵
𝐼𝐴 + 𝐼𝐵
, where 𝐼𝐴 and 
𝐼𝐵 are the abundances of species A and B, respectively. Curve fitting with four parameter 
sigmoidal curves, calculating the first-derivatives of the sigmoidal curves, and all data plottings 
were performed with Prism 6 (GraphPad, La Jolla, CA). 
3.3.4 Transmission Electron Microscopy (TEM) 
CsgA solutions (2.5 μL, 4 μM) were transferred onto the surface of a glow-discharged carbon-
coated 200-mesh copper grid (Electron Microscopy Sciences, Hatfield, PA). The grid surface 
was negatively stained with 1% uranyl acetate solution. Excess solution was removed by blotting 
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with filter paper. The grid was left to air dry and then viewed using a JEOL 100CX Transmission 
Electron Microscope (Peabody, MA) with a 100 kV acceleration voltage.  
3.3.5 Thioflavin T (ThT) Assay 
Amyloid polymerization of CsgA was followed by the change in fluorescence of ThT as 
described in previous reports11. CsgA was 4 μM in 20 mM potassium phosphate buffer 
containing 150 mM NaCl and 25 μM ThT (pH 7.4), in a total volume of 1 mL in a glass tube and 
incubated at 25 °C with stirring. The ThT fluorescence change was recorded as a function of 
time on a spectrofluorometer (PTI, Photon Technology International, Edison, NJ) by using an 
excitation wavelength of 438 nm and emission 490 nm.  
3.4 Results and Discussion  
3.4.1 MS-detectable Materials Decrease as a Result of Aggregation 
Insoluble materials (e.g., fibrils), are formed during the protein aggregation process. When 
HDX-MS is employed to follow the formation of intermediates or conformational changes 
during protein aggregation, DMSO can be used after deuterium labeling to dissolve insoluble 
materials before MS detection.22, 28 DMSO treatment, however, restricts HDX analysis to the 
global level as enzymes are not compatible with a high organic solvent content. To achieve 
higher resolution at the peptide level, one can either use a supersaturated urea solution to 
dissolve aggregates followed by significant dilution23, or focus on those soluble species that can 
be transferred directly into the mass spectrometer24, 29, 30. The latter may be the appropriate 
approach because soluble oligomers, rather than fibrils, are proposed to be toxic species in 
different neurodegenerative diseases,31, 32 making them potential targets for therapeutic drugs.2, 33 
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Thus, we focused on soluble species utilizing a MS-friendly quenching and digestion protocol in 
which some but not all fibrils are also investigated.24  
To understand better the species sampled by HDX, we first investigated the depletion of peptide 
intensities as a function of time. The time course of soluble-species depletion reports the stages 
of CsgA aggregation and informs us when useful HDX observations should be made. 
Additionally, the depletion of soluble species as measured by MS should be considered as 
another measurement dimension for protein aggregation. We monitored the relative abundance 
of MS-detectable CsgA peptides with respect to an internal standard peptide (Figure 3.2). The 
large signal losses we see are likely caused by the formation of insoluble fibrils. We did not 
include data for peptide 94–105 because we were unable to follow it after peptide signals started 
to decrease significantly following the lag phase, owing to its low signal intensity and other 
interferences in its m/z region.  All other peptides display sigmoidal profiles, which are similar to 
the ThT fluorescence profiles for CsgA aggregation.  
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Figure 28 3.2: Relative abundance of CsgA with respect to the internal s tandard  
Figure 3.2 (A) Relative abundance of CsgA peptides with respect to the internal standard as a 
function of incubation time for peptide 1–25 (   ), 26–37 (   ), 38–48 (   ), 49–69 (   ), 70–83 (   ), 
84–93 (   ) and 106–137 (   ). Data were fit with sigmoidal curves (dotted line). Error bars are 
standard deviation at each time point. (B) t1/2 value of each peptide extracted from sigmoidal 
curve fitting with errors indicating t1/2 ranges at 95% confidence level.  
All the depletion curves show an initial lag phase for approximately 60 min, followed by an 
exponential decrease for another 60 min; all peptides finally reach a plateau after 120 min. To 
characterize better each peptide, we fit our data with four-parameter sigmoidal curves (Figure 
A
B
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3.2A) and extracted t1/2 values for each peptide (Figure 3.2B). All peptides show nearly identical 
behavior with similar t1/2 values of approximately 72 min. We expected the behavior at the 
peptide level to be constant over the protein because each peptide is a representative of the whole 
protein. The sigmoidal curves derived from HDX-MS data break slightly earlier than that for 
ThT fluorescence (Figure 3.3). The aggregation of CsgA (4 μM) as followed by the ThT assay 
showed a sigmoidal curve with a lag phase of approximately 120 min, a growing phase of about 
8 h to a plateau phase. 
 
Figure 29 3.3: ThT of  CsgA  
Figure 3.3 Typical sigmoidal ThT curve as a function of incubation times. Here the lag phase is 
about 2 h, followed by a growth phase of about 8 h. 
95 
 
 
An earlier paper reported that the ThT lag time of CsgA decreased 2-3 fold with a 20-fold 
increase in protein concentration, and the lag phase was approximately 90 min for 10 μM CsgA 
at neutral pH.10 The ThT lag time of CsgA aggregation varied from 1 to 3 h depending on 
conditions, as described elsewhere.10, 11, 14 Considering that the ThT assay follows formation of 
amyloids that are highly insoluble, our peptide-level quantitation results that report on soluble 
species depletion are consistent with those of the ThT assay, showing that both report on 
nucleation, elongation and fibrillation. 
We used this quantitative approach on the mass spectra to avoid using the extracted ion 
chromatograms of the peptide signals during HDX (described next), which are complex owing to 
the broad isotopic envelopes characteristic of HDX. We also combined signals from all the 
charge states to eliminate charge variations at ESI.  It is to note that peptides representing regions 
near the N-terminus generally provide higher ion signals than those close to the C-terminus. The 
differences in the initial relative abundances of each peptide likely result from differences either 
in ESI ionization efficiency or pepsin digestion but not from structure because each CsgA 
monomer lacks structure and exists as an intrinsically disordered protein (IDP).34 Furthermore, 
the protein is already denatured before digestion.  
3.4.2 HDX Reveals Two Species During CsgA Aggregation 
We next turned to HDX in an effort to follow region-specific aggregation, an opportunity easily 
achieved with MS. We first added 6 M GdnHCl to prevent the aggregation of CsgA and 
measured the extent of HDX as seen in the mass spectrum of peptide 106–137 in the presence of 
6 M GdnHCl (Figure 3.4A).  We complemented this measurement with those in the absence of 
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GdnHCl (Figure 3.4B) incubated at selected time points. As all peptides show two species with a 
time-dependent abundance change during CsgA aggregation, we chose peptide 106–137 as a 
representative case for illustration and discussion. Although peptide signals decrease 
significantly with incubation times (Figure 3.2), the amount of soluble species remains detectable 
at the longest incubation time, a manifestation of the high dynamic range of most modern mass 
spectrometers. The abundance of peptide 106–137 relative to the internal standard during HDX 
(Figure 3.2), is also described in Figure 3.3 caption.  
In the presence of GdnHCl, a single, highly deuterium exchanged species exists that is the 
denatured monomer. The average deuterium uptake for all peptides of this denatured monomer is 
70% (no back-exchange correction). Not one but two populations, denoted as species A and B, 
are present, however, and exhibit distinct deuterium uptake during CsgA aggregation. Species A, 
representing the highly exchanged population, has the same HDX behavior as that of the 
denatured CsgA monomer, indicating that these soluble species possess little or no defined 
structure. It is not surprising to observe a highly exchanged species A with this IDP protein. 
Weis and co-workers35 showed that IDP proteins undergo high HDX even on the time scale of 
seconds. In contrast to the disordered species A, of higher m/z, species B undergoes significantly 
lower deuterium uptake, suggesting a relatively more ordered structure. 
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Figure 30 3.4: HDX mass spectra o f representa tive peptide 106-137  
Figure 3.4 HDX mass spectra of peptide 106–137 molecular ion (A) in the presence of GdnHCl 
and (B) in the absence of GdnHCl incubated for 0, 90, 120, 480, and 1440 min. The isotope 
cluster at higher m/z range is denoted as species A (blue) whereas the one at lower m/z range is 
denoted as species B (red) (C) Deuterium uptake of both species A (blue) and B (red) as a 
function of incubation time for all peptides. The relative abundance of peptide 106–137 to the 
internal standard is 21%, 4%, 1%, 0.9%, 0.5% at 0, 90, 120, 480, and 1440 min, respectively, as 
plotted in Figure 3.2. 
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To characterize formation of species A and B more completely, we applied a two-binomial 
functional distributions to fit the HDX patterns of all the peptides. Deuterium uptake for both 
species A and B plotted as a function of incubation time are shown in Figure 3.4C. We have no 
data for peptide 94–105 after 240 min because its signal was no longer detectable. Our HDX 
results show that the deuterium uptake of both species A and B remain relatively constant during 
the aggregation process; specifically, the deuterium uptake of species A and B are ~ 60–80% and 
~ 5–10%, respectively. Chapman and co-workers34 proposed that unfolded CsgA forms a 
transient oligomeric pool with an average molecular weight of approximately 66 kDa; this low-
energy state contains dynamic and amorphous conformers once aggregation is triggered. 
Although species A shows the same HDX as the denatured monomer, we propose that species A 
is this dynamic, less structured oligomer. The subtle structural difference between the dynamic 
amorphous oligomer pool and completely unstructured monomer, however, is not revealed by 
HDX, possibly because the labeling time window is not sufficiently short for capturing small 
differences.  
Species B, on the other hand, must be well-structured, not highly solvent-accessible because it 
undergoes a remarkably low extent of HDX. When carefully inspecting the mass spectra, we 
observed that species B is present immediately after GdnHCl is removed. This suggests that 
CsgA starts aggregating once GdnHCl is removed, consistent with previous reports.14, 34 As the 
incubation time increases, species B becomes relatively more abundant than species A (Figure 
3.4B), indicating a change from an IDP to a more ordered structure accompanying aggregation. 
Species A remains detectable at the longest incubation time even though it has been seriously 
depleted (Figure 3.2), illustrating the high dynamic range of MS-based methods. However, MS 
detection has a high bias towards the readily soluble materials. The actual abundance of species 
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A relative to the total protein is low because the majority of the protein has formed fibrils, most 
of which cannot be easily detected under our experimental setup. It is not possible, however, for 
us to distinguish whether species A at the end of aggregation process represents the original 
dynamic conformers that have not been converted to fibrils, or some products from the 
equilibrium between solid (i.e., fibril) and solution phases.  
Although this bimodal isotopic distribution is similar to that arising from an EX1 mechanism36, 37 
that occurs when local protein refolding rates are slower than deuterium labeling rates, we do not 
invoke EX1 mechanism changes to explain the data. Similar phenomena were reported in other 
aggregation systems using pulsed HDX.26, 38 We hypothesize that pulsed HDX reveals various 
populations of molecules that co-exist in solution; species A represents soluble, dynamic and 
amorphous conformers whereas species B the highly ordered. The origin and function of species 
B will be discussed below. 
3.4.3 The Five Regions (R1–R5) of CsgA Exhibit Different Aggregation 
Propensities 
Returning to a signal-depletion analysis, we investigated the B fractional species changing with 
time for each peptide (Figure 3.5) with the goal of obtaining region-specific information during 
conformational change from IDP to ordered fibrils. This species-dependent measurement is made 
possible by HDX but it has a more limited dynamic range than that for the data in Figure 3.2. 
The sigmoidal curve fitting of the data (Figure 3.5A) shows that, for all peptides, the fractional 
species B remains less than 3% before ~90 min and then increases afterwards. Peptides 26–37 
and 106–137 display the most rapid increase in the fraction B species, followed by peptide 38–
48. The last time points of peptides 84–93 and 106–137 are missing because their corresponding 
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MS signals become very weak at long aggregation times. Although we are only able to follow 
peptide 94–105 for 240 min, the B fractional species appears to display a similar trend to that of 
the other peptides 1–25, 49–69, 70–83 and 84–93; that is, they all increase at a slower rate. We 
then compared the extracted t1/2 for each peptide (Figure 3.5B; error bars here indicate ranges at 
95% confidence intervals). Peptides can be divided into two groups: peptides 26–37, 38–48, and 
106–137 (group I) have significantly smaller t1/2 values compared to the peptides 1–25, 49–69, 
70–83 and 84–93 (group II) at 95% confidence. Noticeably, peptides in group I have entered a 
stationary phase while peptides in group II have not completed aggregation (after 1000 min). If 
the slow aggregating regions, as represented by group II peptides, could be measured to 
completion, their t1/2 values would be even longer, and the difference between the two groups of 
peptides, therefore, would be larger.  
To confirm the difference between two groups of peptides, we also analyzed the increasing rates 
of formation of the fraction B species by calculating the first-derivatives of the fitting curves 
(Figure 3.5C). This method allows us to make a direct comparison between all peptides whether 
or not they have stationary phases. Peptides 26–37 and 106–137 have the largest maximum 
values, followed by peptide 38–48. The peptides of group II have similar and the smallest 
increasing rates of the fraction B species. Both statistical methods show that regions represented 
by peptides from group I (26–37, 38–48, and 106–137) aggregate faster than the remaining 
regions of the protein. The observation that these peptides (26–37, 38–48, and 106–137) have 
significantly different abundance at starting points (Figure 3.2) ensures that their faster 
aggregation propensities are not artifacts caused by variable peptide signals.  
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Figure 31 3.5: Fractional species B as a function of incubation t ime 
Figure 3.5 (A) Fractional species B as a function of incubation time for peptide 1–25 (    ),  26–
37 (    ), 38–48 (    ), 49–69 (    ), 70–83 (    ), 84–93 (    ), 94–105 (    ) and 106–137 (    ). Data 
were fit with sigmoidal curves (dotted lines). (B) t1/2 value of each peptide extracted from 
sigmoidal curve fitting in A with errors indicating t1/2 ranges at 95% confidence level. Color 
were coded the same way as in A. (C) Increasing rates of fraction B species (i.e., the first 
A
B
C
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derivative of fraction B species against incubation time) as a function of incubation time. Color 
coding is the same as in A. 
To visualize the results, we also mapped the HDX results onto a predicted CsgA structure39 
(Figure 3.6). This structure is a left-handed monomer subunit existing in the fibrils, and it has 
similar energy to one with a right-handed topology.39 Peptide 26–37 falls completely onto R1, 
38–48 located at the end of R1 and the beginning of R2, and peptide 106–137 spans the end of 
R4 and the entire R5. Thus, our HDX results indicate that R1 and R5 become structured most 
rapidly among the five repeating units. 
 
Figure 32 3.6: Relative increas ing rates of fraction B species mapped onto a computed CsgA structure  
Figure 3.6. Relative increasing rates of fraction B species mapped onto a computed CsgA 
monomer structure. Colors were coded the same way as in Figure 3.4: 26–37 in red, 38–48 in 
orange, 106–137 in dark red, and the remaining peptides in gray. Surface areas of amyloid core 
(23–131) that contains five imperfect repeats, calculated in UCSF Chimera,40 are shown as the 
R1
R5
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background to backbone structure. Dashed line indicates the proposed primary fibril growth 
direction. 
 
This finding coincides with that of Chapman and co-workers14, indicating that R1, R3 and R5 are 
amyloidogenic, and R1 and R5 are the most significant contributors. The primary growth 
direction of CsgA fibrils is suggested to be perpendicular to the β-strands (dashed line), along 
with lateral fibril association induced by polar and acidic amino-acid side chains.39 This is 
consistent with the observation that R1 and R5 become ordered first, followed by the remaining 
regions. 
3.4.4 TEM Suggests Origins of Species B from Large Aggregates to Fibrils 
As discussed earlier, species A is likely to be a highly dynamic, amorphous oligomer that 
undergoes HDX within the pulse-labeling window as that of the denatured monomer. CsgA 
needs to escape from this low-energy pool to generate nucleation seeds for amyloid formation.34 
Therefore, species A is of little interest, and we suggest that species B is more important. Both 
their abundances, relative to that of the internal standard, and the fraction B species of all 
peptides exhibit sigmoidal profiles as a function of incubation time. If species B is part of the 
nucleation seeds, one would expect the lag phase monitored by either method to be the same. 
The fractional species B, however, starts to increase significantly after 90 min when soluble 
materials are already largely depleted. In other words, region-specific aggregation propensities 
are observed when large amount of insoluble fibrils are already formed. Additionally, species B 
is formed immediately after denaturant removal. Although the fraction B species increases with 
incubation time, the absolute quantity of species B remains at a constant, low level. Thus, we 
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suspect that species B represents different large components in the CsgA aggregation than does 
species A.   
To test our hypothesis and capture a more complete picture of CsgA aggregation, we employed 
TEM as a complementary analysis (Figure 3.7). MS detects soluble materials whereas negative 
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Figure 333.7: TEM o f CsgA  
Figure 3.7. TEM images of CsgA incubated with continuous stirring at (A) 30 min, (B) 1 h, and 
(C) 5 days. Two figures at each incubation time point were provided with a different scale.  
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stain and TEM provide morphology of protein molecules from large oligomers to aggregates, 
especially the relatively large, insoluble species that are unlikely to be detected by MS. The 
protein aggregates observed in the early phase of CsgA aggregation (Figure 3.7A and B) are 
morphologically different than the amyloid fibrils formed at the plateau phase (Figure 3.7C). 
There are a few large, amorphous aggregates and clumps of different sizes observed at the lag 
phase (Figure 3.7A, 30 min). Beside the amorphous aggregates, needle-like short fibrils (Figure 
5B, right panel) start appearing at the early growth phase (Figure 3.7B, 1 h). In a previous study, 
the authors described the formation of needle-like protofibrils at the early process of CsgA 
aggregation.10 The appearance of short fibrils in the sample incubated for 1 h indicates formation 
of potential nucleation speices;10 that time correlates with the time course determined by large 
depletion of the peptide signals. Based on both HDX-MS and TEM experiments, we propose that 
species B represents a soluble part of the large amorphous aggregates at early time points, 
possibly as protofibrils or fibrils along the aggregation pathway. It is unclear whether species B 
signals growth-competent protofibrils (i.e., on-pathway oligomers). Nevertheless, our HDX 
results show that R1 and R5 fold faster than the remaining regions, suggesting they have higher 
amyloidogenic properties.  
3.4.5 CsgA Aggregation Depends on Conditions 
We also followed CsgA aggregation at two other sample handling conditions by monitoring 
changes in the fraction B species. We did not detect significant changes in that fraction for all the 
peptides when incubating CsgA without stirring for as long as 144 h (data not shown). It is not 
surprising that the fractional species B under quiescent conditions increases more slowly for each 
region than under agitation where seed fibrils are fragmented under mechanical stress. 
Interestingly, one flash freeze-and-thaw cycle of freshly purified CsgA (denoted as freeze/thaw) 
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followed by incubation under the quiescent condition resulted in much more rapid appearance of 
a bimodal distribution than for freshly prepared CsgA under the same quiescent incubation. The 
fraction B species for all peptides shows a significant increase after 120 min (Figure 3.8). This 
finding suggests that one freeze/thaw cycle of CsgA monomers promotes seed formation, 
thereby shortening the lag phase. In a manner similar to that of freshly prepared CsgA studied 
under continuous stirring, fractional species B for peptides 26–37, 38–48, and 106–137 show 
more rapid increases than do the remaining peptides. This result further supports the finding that 
R1 and R5 have higher aggregation propensities than the interior regions.  
 
 
Figure 343.8: Fraction species B af ter a freeze/thaw cycle 
Figure 3.8. Fractional species B as a function of incubation time after a freeze/thaw cycle of 
freshly purified CsgA. Group II peptides, 26–37, 38–48, and 106–137 display faster fraction B 
species growth. 
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3.5 Conclusion 
Unlike protein aggregation and amyloid formation in neurodegenerative diseases,1, 2, 4 CsgA 
aggregation into a functional amyloid occurs by a well-regulated mechanism5. To compensate 
for the usual limitation that HDX detects principally soluble species without regard to their 
relative abundance, we followed the abundance of each peptide relative to an internal standard. 
These profiles are sigmoidal with a lag phase consistent with that determined by ThT 
fluorescence. HDX-MS reveals two species during the aggregation with distinctly different 
extents of labeling. One species (denoted A) exchanges rapidly similar to that of a denatured 
monomer, whereas the other species (denoted B) is structured and well-protected. Although 
HDX extents of both species are nearly constant with respect to incubation time, the fraction of 
the ordered species B increases significantly after the lag phase. We also found that among 
fractional species B, certain regions of the protein (26–37, 38–48, and 106–137) develop 
structure more quickly than others, in agreement with the observation that CsgA nucleation 
specificity is encoded mainly by repeating units R1 and R5.14  Thus, we see that HDX and MS 
can make significant contributions to understanding amyloid formation. 
TEM, which probes large or insoluble materials that are less likely to be observed by mass 
spectrometry, shows large amorphous aggregates during the lag phase whereas mass 
spectrometry detects mainly dynamic conformers and a small fraction of high-order structure. 
The protofibrils and then the mature fibrils can be seen by TEM during the time that fractional 
species of ordered-structure B starts to increase noticeably. Based on these data, we hypothesize 
that the species B uncovered by HDX-MS represents heterogeneous large components in the 
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CsgA aggregation. Studies under different aggregation conditions further confirm that region-
specific aggregation information can be extracted from the fractional species B.  
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Chapter 4: Deamidation slows Curli 
Amyloid-Protein Aggregation*3 
 
  
                                                 
* Wang, H. performed all the MS experiment and analyzed the data. Shu, Q. provided the protein CsgA, and 
performed ThT and CD experiment.  
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4.1 Abstract 
Non-enzymatic deamidation of asparagine and glutamine in proteins and peptides is one of the 
most frequent modifications both in vivo and in vitro. The biological effect is not completely 
understood, but it is often associated with protein degradation and loss of biological function. 
Here we describe the deamidation of CsgA, the major protein subunit of curli. Curli are 
functional amyloid fibers produced in a highly regulated process; they are similar to disease-
associated amyloids. CsgA has high content of Asn and Gln, a feature seen in several other 
proteins with self-propagating aggregation propensities. Studying CsgA could help understand 
other uncontrolled amyloid formation. Curli participate in bacterial community behavior and are 
an important proteinaceous component of biofilms, affording protection for bacteria from 
environmental stress, impacting antibiotic resistance and recurrence of infections. We first 
applied a fast approach for monitoring deamidation by following the globally centroid mass shift 
to provide a guidance for studies at the residue level. Based on the global mass measurement, we 
then identified extensive deamidation at several Asn residues by LC–MS/MS and discovered 
three “Asn–Gly” to be the hottest spots for deamidation. The ability of fibrilization for 
deamidated CsgA was measured using thioflavin T (ThT) fluorescence, circular dichroism (CD), 
and a previously reported hydrogen–deuterium exchange (HDX) platform. Deaminated materials 
exhibit a longer lag phase and less final ThT fluorescence, strongly suggesting slower and less 
amyloid fibril formation. CD spectra show that extensively deamidated CsgA remains 
unstructured during the entire aggregation process and loses its ability to form aggregates. HDX-
mass spectrometry also shows that this deamidated protein also aggregates significantly more 
slowly than WT CsgA. Taken together, the results show that deamidation of CsgA prevents its 
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fibrilization and disrupts its function. Purposeful and controlled deamidation may be an approach 
to modulate CsgA aggregation to affect curli and biofilm formation. 
4.2 Introduction 
Biofilms raise concerns in disease and in medical and industrial settings because bacteria are 
protected by biofilms and, therefore, become recalcitrant to environmental stresses and host 
defense.1, 2 The major proteinaceous component of biofilm, curli, are extracellular amyloid fibers 
that are also involved in initial surface adhesion and cell-cell contact in Escherichia coli, 
Salmonella spp., and other enteric bacteria.3, 4 Unlike disease-associated amyloid proteins, such 
as A 42 in Alzheimer’s Disease,5 the functional curli fiber formation is a highly-regulated 
mechanism.3, 4 Studying aggregation behavior of the major curli subunit CsgA and factors 
affecting CsgA aggregation propensities is attractive because CsgA is a potential target for 
interrupting biofilm formation.6, 7 Additionally, this functional amyloid biogenesis may provide 
hints for understanding disease-associated amyloid formation. CsgA is an intrinsically disordered 
protein (IDP), and rapidly converts to amyloid fibrils at the cell surface. The first 22 residues at 
the N-terminus is responsible for CsgA outer-membrane secretion, and the rest of sequence is 
composed of five imperfect, strand-loop-strand repeating units in the fibril. The primary 
sequence of CsgA has a high content of Asn (16 residues, 12%), Gln (11 residues, 8 %), Gly (28 
residues, 20%), Ser (12 residues, 9%), and Thr (9 residues, 7%).  
Deamidation is commonly associated with reduction or loss of protein function; thus, Robinson 
and Robinson8 suggested it as a “Molecular Clock” in biological systems. Enzymatic 
deamidation of peptides and proteins only occurs at Gln naturally,9 for which there is a large 
interest in the food industry.10 Free asparagines, not asparagine residues in peptides and proteins, 
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can be deamidated to aspartic acids by asparaginase.9, 11 Non-enzymatic deamidation of Asn and 
Gln are widely observed both in vitro and in vivo,9, 12 most of which are associated with human 
aging and cataract formation.13, 14 As a common degradation that affects monoclonal-antibody 
function, non-enzymatic deamidation has increasing attention in pharmaceutical and 
biotechnology industries.13, 15 The deamidation half-lives of Asn and Gln vary extensively, from 
days to years, depending on the protein and multiple intrinsic and environmental factors.8, 9 Asn 
has much faster deamidation rate than Gln.9 At neutral pH, deamidation of Asn occur via a 
succinimide intermediate, hydrolysis gives Asp and iso-Asp, causing a mass shift of 0.984 Da 
(Figure 4.1).9, 16 The first-order deamidation rate is largely determined by primary sequence; 
residues with low steric hindrance or dipole moments at the carboxyl side of Asn and Gln 
accelerate deamidation, with Gly causing the largest effect, followed by His and Ser.8 The 
deamidation rate is significantly slowed when Asn and Gln residues are involved in secondary 
and higher-order structures.9, 12 Temperature, buffer type, pH, and ionic strength also affect 
protein deamidation kinetics.8, 9  
Proteins containing rich Asn and Gln regions have high propensity for self-propagating amyloid 
formation.17 Polyglutamine-containing aggregates may be critical in Huntington’s disease.18 
Asn/Gln-rich regions may promote protein–protein interaction, and, therefore, induce protein 
aggregation, because of the hydrogen-bond network formed by their polar side chains (also 
known as “polar zippers”).17, 19 Deamidation of certain Asn/Gln residues and isomerization of 
Asp may be linked to several neurodegenerative diseases.9 Therefore, deamidation is a 
particularly important post-translational modification for amyloids. Characterizing deamidation 
of amyloidal CsgA that contains high content of Asn/Gln could provide a unique perspective for 
other amyloid proteins.  
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Figure 4.1 Mechanism of Asparagine deamidation. 
Mass Spectrometry (MS) is the major tool for characterizing protein deamidation because it has 
high sensitivity and specificity.13 Accurate and reliable approaches from chromatographic 
separation to spectral analysis can overcome problems of co-eluting isomeric products and 
overlapping isotopic patterns.13 In this paper, we describe an MS approach to quantify 
deamidation of amyloid CsgA at the residue level and multiple biophysical approaches to assess 
the effect deamidation on CsgA aggregation. 
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4.3 Materials and Methods 
4.3.1 Materials 
D2O was from Cambridge Isotope Laboratories Inc. (Andover, MA). All other chemicals unless 
specified were purchased from MilliporeSigma (St. Louis, MO). 
4.3.2 Analysis of CsgA Deamidation with MS 
Global-level information of deamidated samples at 25 °C or 37 °C was collected on a Bruker 
MaXis Q-TOF instrument (Billerica, MA). For each analysis, 5 pmol of CsgA was desalted and 
eluted from a C8 trap column (Agilent, Santa Clara, CA) in a 3 min linear gradient of 30% – 
60% acetonitrile with 0.1% formic acid (FA) at a flow rate of 200 μL/min delivered by a LEAP 
3x Ti pump (Carrboro, NC). Molecular weights were obtained with MagTran 1.03 (a freeware 
deconvolution software developed by Dr. Zhongqi Zhang). Each global-level experiment was 
done in duplicate. 
 For residue-level identification and quantification, 1 μL deamidated CsgA stock solution was 
incubated at 37 °C for different times, diluted into 50 μL of 2 M urea and 0.1% trifluoroacetic 
acid, and passed through a self-packed pepsin column in 1 min. The peptic peptides were trapped 
on the C8 column and eluted with a 5 min linear gradient of 5% – 60% acetonitrile (ACN) with 
0.1% FA at 50 μL/min. The eluent was collected, dried in a Savant SpeedVac concentrator 
SC110 (Thermo Fisher, San Jose, CA), and reconstituted in water with 0.1% FA for autosampler 
loading. About 2 pmol of CsgA peptic peptides were loaded onto a 100 μm × 2 cm C18 PepMap 
RP trapping column (Thermo Fisher, San Jose, CA) and desalted at 5 μL/min for 10 min. 
Separation was achieved on a 100 μm × 18 cm column custom-packed with 5 μm Magic C18 RP 
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beads (Michrom Bioresources Inc., Auburn, CA) and connected to a stainless steel emitter 
(Thermo Fisher, San Jose, CA). A gradient was delivered by a nano Ultimate 3000 (Dionex, Co.) 
at 500 nL/min; 2–32% ACN with 0.1% FA in 44 min, 32–80% ACN with 0.1% FA in 5 min, 
held at 80% ACN with 0.1% FA for 5 min, returned to 2% ACN in 2 min and re-equilibrated at 
2% ACN for 10 min. Mass spectra were collected on a Thermo Q Exactive plus Orbitrap mass 
spectrometer (San Jose, CA) operated in a data-dependent acquisition mode (top 15 most 
abundant ions). Product-ion spectra were submitted to Byonic for identification (Protein Metrics, 
San Carlos, CA). The search results along with raw files were loaded into Byologic (Protein 
Metrics, San Carlos, CA) for manual validation and further analysis with their deamidation 
quantification feature enabled. For each residue, the deamidation extent was calculated by 
dividing the peak areas of the deamidated species at this residue by the sum of all peak areas of 
the peptide at the same charge state. At each time point, two independent digestions and two 
injections into the mass spectrometer were employed. Data fitting was performed with one-phase 
exponential association that is used for the first-order kinetics in Prism 6 (GraphPad, La Jolla, 
CA). 
4.3.3 Thioflavin T (ThT) Assay 
Aggregation of intact (WT) or deamidated CsgA was followed by the change in fluorescence of 
Thioflavin T (ThT) as previously reported20 with minor modification. Briefly, CsgA was 2 μM in 
50 mM potassium phosphate buffer containing 150 mM NaCl and 25 μM ThT (pH 7.4). The 
samples (volume of 1 mL) were incubated at 25 °C with continuous stirring in a glass tube. The 
change of ThT fluorescence was recorded as a function of time on a spectrofluorometer (Photon 
Technology International, PTI, Edison, NJ) by using an excitation wavelength of 438 nm and 
emission at 490 nm. 
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4.3.4 Circular Dichroism (CD) 
Three deaminated CsgA samples (8 μM) after zero time (i.e. WT protein), 2 days, and 19 days 
were analyzed by CD to illustrate the effect of deamidation on the secondary structure of CsgA. 
The samples were buffer exchanged into 50 mM potassium phosphate buffer (pH 7.4) to start 
aggregation. Far-UV CD spectra were recorded on a Jasco-715 spectropolarimeter (Tokyo, 
Japan) at room temperature as an average of 8 scans from 190 to 260 nm and using a 0.1-cm path 
cell. The scan rate was 50 nm/min with a response time of 1 s. All samples were manually mixed 
before taking each reading. The first data point was ~ 12 min after the start of aggregation.  
4.3.5 Hydrogen–Deuterium Exchange (HDX) 
Pulsed HDX of a 5-day deamidated sample was performed the same way as recently published.21 
Briefly, following buffer exchange, 10 μM deamidated CsgA was incubated at 22 °C and 
monitored as a function of aggregation time by diluting 1:5 into D2O for 30 s at 4 °C. The HDX 
was quenched and subjected to online pepsin digestion. The resulting peptic peptides were 
desalted on the C8 trap column and separated on a 1.9 µm reversed-phase C18 column (Hypersil 
Gold Thermo Fisher Scientific, Waltham, MA). Data were collected on a Bruker MaXis Q-TOF 
instrument (Billerica, MA), and analyzed with a custom-developed program implemented in 
MathCAD (v14, Parametric Technology Corp., MA). Two binomial distributions were used to fit 
the HDX isotopic envelopes of peptides 26–37, 38–48, and 106–137.  The species at high m/z 
was termed A and that at low m/z B. The fractional species B, which is used to characterize 
CsgA aggregation propensity, was calculated as   
𝐼𝐵
𝐼𝐴 + 𝐼𝐵
, where 𝐼𝐴 and 𝐼𝐵 are the signal intensities 
for species A and species B, respectively.  
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4.4 Results and Discussion  
4.4.1 Global Analysis allows a quick view of CsgA deamidation 
The primary sequence of CsgA is prone to deamidation because there is a high content of Asn, 
Gln, Gly, and Ser. High concentrations (6–8 M) of guanidine hydrochloride (GdnHCl) are often 
utilized to prevent CsgA aggregation during purification and storage,20, 22 which could potentially 
increase its deamidation rates as well. To establish a relatively short experimental time frame for 
following CsgA deamidation at the residue-level, we first employed global-level experiment at 
25 °C and 37 °C. The goal is to obtain information about the time scale of CsgA deamidation in 
a fast and relatively simple manner to set the stage for residue-level analysis. Therefore, we used 
a trap column and eluted all forms of CsgA with a short gradient without separation. Because 
each deamidation site results in 0.984 Da increase in mass, the isotopic distribution of CsgA 
continues to shift to higher m/z values (Figure 4.2A), which are a measure of deamidation at the 
global level. This fast, global-level experiment requires no method chromatographic method 
development and provides guidance for residue-level analysis. We followed the centroid mass 
shift as a function of time at both 25 °C and 37 °C (Figure 4.2B). Both datasets fit well with one-
phase exponential equation, suggesting that CsgA deamidation follows first-order kinetics, as 
expected, when the pH is held constant.  
Our results show that the deamidation rate is highly temperature-dependent; the mass shift after 
19 days of incubation at 25 °C is similar to that of 3-day sample at 37 °C. On the other hand, 
purified CsgA stored in 6 M GdnHCl at -20 °C showed little to no deamidation for at least 6 
months. Thus, we paid attention to the temperature of preparation and storage and kept them as 
low as possible to minimize the deamidation and maintain pure CsgA.  
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Figure 354.1: CsgA  deamida tion a t the g lobal level 
Figure 4.2. Deamidation of CsgA monitored at the global level. (A) Isotopic distributions of 
charge state 14 at deamidation day 0 (black), day 5 (blue), and day 19 (red) at 37 °C. (B) 
Centroid mass shift of deamidated CsgA compared to WT as a function of different deamidation 
times at 25 °C (blue) and 37 °C (red). Data were fit with first-order kinetics. 
4.4.2 Identification and Quantification of Deamidation by LC–MS/MS 
We chose to perform detailed characterization of CsgA deamidation at 37 °C for several selected 
time points selected on the basis of global-level information. The commonly used trypsin in a 
proteomics experiment is not suitable for CsgA because there are only four Arg/Lys out of 137 
residues. Three tryptic peptides that are longer than 30 residues contain multiple Asn/Gln, 
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making identification and quantification at the residue-level more difficult than for the short 
peptic peptides. Additionally, pepsin produces multiple overlapping peptides that could increase 
confidence in data analysis. Although the result of each residue was derived from the most 
abundant and short peptide spanning a site, the result must be consistent with the information 
obtained from at least one other peptide monitored with good signal intensity and 
chromatographic peak shape. Deamidation occurs during long enzyme digestion at elevated 
temperature (i.e. 37 °C), leading to overestimation of the original level of deamidation.23 Our fast 
online digestion and sample handling protocol greatly avoids such artifacts. 
Although many of the deamindated peptides can be separated from the WT peptides with RP 
nanoflow HPLC, co-elution does occur, making quantification difficult. Deamidation in the 
region represented by peptide 38–48 (2+) is used as an example showing how quantification was 
carried out using a built-in feature in Byologic (Figure 4.3A). XIC of the monoisotopic mass 
1203.5964 ± 18 ppm of WT is in red (labeled #1). XIC of the monoisotopic mass 1204.5804 ± 
18 ppm of the deamidated peptide contains two peaks (#2 in grey and #5 in green). Compared to 
the isotopic distributions from the tail of peak #1, those from peak #5 suggest a single 
deamidation site for this peptide (Figure 4.3B, top and bottom panels). Because peak #5 is well-
separated from peak #1, its peak area can be directly used for quantification. However, the 
isotopic pattern of the components in the leading edge of peak #2 suggests a mixture of WT and 
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Figure 36 4.2: CsgA deamida tion at the res idue level  
Figure 4.3 (A) Extracted ion chromatogram of WT (top) and deamidated (bottom) peptide 38–48 
(2+). (B) isotopic distributions at peak #1 (WT), 4 (mix of WT and deamidated), and 5 
(deamidated). (C) MS/MS spectrum at peak #4 (mix of WT and deamidated). Isotopic patterns of 
b3 and y6 are zoomed in. Major peaks are annotated. All identified b and y ions are marked on 
the peptide sequence, with the deamidation site highlighted in red. 
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deamidated peptides (Figure 4.3B, middle panel). The theoretical intensity of the first 13C isotope 
from the WT is constructed in Byologic based upon that of peak #1 (peak #3, red trace at the 
bottom panel in Figure 4.3A). The corrected XIC of the deamindated form, colored in green 
(peak #4), is accomplished by subtracting peak #3 from peak #2. Diagnostic ions b3, b4 and y4–
y8 series from the MS/MS scans confirm that deamidation occur at the N8 for both peak #4 and 
#5 (Figure 4.3C for peak #4). Because the deamidated and WT peptides co-elute at peak #4, the 
isotopic distributions of product ions containing the deamidation site display a mixed pattern, as 
seen for y6. It is likely that peak #4 is iso-Asp and #5 is Asp, based on the previous report that 
iso-Asp eluted earlier than Asp in RP HPLC at low pH.24 Although electron-capture dissociation 
or electron-transfer dissociation are required to further differentiate iso-Asp from Asp,25, 26 we 
combined areas from both peaks to quantify deamidation at N8. A shorter peptic peptide 37–41 
shows that less than 1% deamidation occurs at Q3 even after 19 days of incubation. This 
information is not easily revealed by peptide 38–48 because the two deamidated forms co-elute 
and there is MS/MS interference from the intense N8 deamidated peptide. Nevertheless, co-
elution is not a big concern for quantification at N8 deamidation because that deamidation extent 
at Q3 is much lower. 
We identified a total of fourteen Asn residues showing extensive deamidation (Figure 4.4). We 
also observed low deamidation (estimated to be less than 1% even at the longest incubation time) 
for Gln29, Gln40, Gln74, Asn116, Gln119, and Gln130. Deamidation at Gln is much slower than 
that of Asn and mostly likely occurs in a long-lived protein in vivo.9 Contributions from slow 
deamidation are assumed to be less substantial than that of fast deamidation in this study, and 
therefore, not included. Peptide 1–25, the most abundant peptide in this region selected for 
quantification, did not allow us to quantify deamidation of each Asn residues due to the poor 
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chromatographic separation. Considering that the first 22 residues of CsgA are not as deamidated 
as the five repeating units,4 we reported the summed results for the first four Asn. Deamidation at 
Asn124/125 was also quantified as one group because co-elution did not allow further resolution. 
All the residue-level data were fit with the first-order kinetics (Figure 4.4A), as obtained at the 
global-level. A list of t1/2 extracted from each fit is provided in Table 4.1. Among the eight Asn 
whose quantifications were done at the residue level, the t1/2 values for Asn 57, 87, and 102 are 
significantly smaller than for Asn 34, 45, 79, 90, and 112 at 95% confidence. Mapping onto the 
primary sequence of CsgA (Figure 4.4B) makes clear that the differences in deamidation kinetics 
are caused by the residues on the carboxyl side of Asn. Asn 57, 87, and 102 are the only three 
residues followed by Gly, which is known to be the “hottest spot” for deamidation owing to 
minimal steric effects.9 Asn 34, 45, 79, 90, and 112 are followed by a polar residue Ser that can 
enhance deamidation by stabilizing succinimide intermediate.9 The primary sequence of CsgA 
seems to be the major determinant for fast deamidation. These hot spots for deamidation are in 
CsgA from different enteric bacteria. It is interesting to ask why CsgA would employ such an 
unstable primary sequence when its role is to form highly controlled amyloid fibril. 
4.4.3 ThT Assay Indicates Deamidation Effect 
Thioflavin T(ThT) fluorescence increases upon binding to β-sheet-rich surfaces, and is 
frequently used to observe amyloid fibril formation in vitro 27, 28. Curli are functional amyloids 
that share most biophysical properties of disease-associated amyloids, and the major protein 
subunit CsgA, once fibrillated, can bind ThT 29. Thus, the ThT assay has been widely used in 
monitoring the aggregation/fibrilization of CsgA in vitro.6, 20, 22, 30-32 To examine the effect of 
deamidation on the biological function of CsgA, we followed the kinetic change of ThT 
fluorescence during the aggregation/fibrilization of CsgA. The deamidation of CsgA show 
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sigmoidal curves in ThT fluorescence change like the WT for up to 10 days but with different lag 
phases and plateaus (Figure 4.5A). CsgA that is more deamidated shows longer lag phases and 
less ThT fluorescence, indicating both a slower and less extensive fibril formation. CsgA 
deamidated for 19 days shows little or no ThT fluorescence, suggesting inability to form β-sheet 
fibrils. These results indicate that the deamidation content in CsgA slows the rate and 
concentration of forming ThT-positive aggregates/fibersh. 
 
Figure 374.3: Kinet ics of CsgA deamidation  
Figure 4.4 (A) Quantification of CsgA deamidation at the residue level. All data were fit with 
first-order kinetics. Identified residues are labeled on the right. (B) Deamidated residues mapped 
onto the primary sequence of CsgA. 
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Table 4.1 Summary of t1/2 of the first-order kinetics fit for deamidation. 
Table 1 4 .1: t1/2 of the fir st-order kinet ics fi t fo r deamida tion  
Residue t1/2 (Day) 95% confidence intervals 
N102 2.5 2.2–2.9 
N87 4.5 4.0–5.1 
N57 5.3 4.4–6.6 
N11/N17/N18/N22 4.7 4.1–5.4 
N124/N125 8.5 6.0–14.6 
N79 15.3 10.2–30.4 
N34 19.5 11.5–65.0 
N45 24.8 15.9–56.3 
N90* > 25 --- 
N112* > 25 --- 
*t1/2 of N90 and N112 are large and cannot be estimated because the increase of DA is very 
limited.  
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Figure 38 4.4: ThT of  CsgA aggrega tion  
Figure 4.5 Fibrilization of intact and deaminated CsgA as monitored by Thioflavin T (ThT) 
fluorescence. (A) Time course of ThT fluorescence change. (B) Emission scan of different 
deaminated CsgA at the plateau phase (~24h) of ThT assay.   
4.4.4 CD analysis  
To understand coarse structural features of the products formed by the deamidated CsgA, we 
compared, using CD, the secondary structural changes of WT and deamidated CsgA after 2 and 
19 days of aggregation. The WT (intact) CsgA shows a time-dependent structural change with a 
decrease in disordered random coil (minimum at ~ 200 nm) and an increase in ordered structure 
(minimum at ~ 220 nm), indicating aggregation and a transition from disordered random coil to 
ordered fiber with β-sheet structure (Figure 4.6A). In contrast, CsgA deamidated for 2 days 
shows a less ordered structure and a slower decrease of disordered structure (Figure 4.6B). As 
shown in Figure 4.6D, the kinetics of protein aggregation as monitored by CD at 200 nm after 
deamindation for 2 days compared to no deamidation were fitted to a single-exponential 
function; the rate constants are 0.019 ± 0.004 and 0.044 ± 0.005, respectively.  Aggregation time 
dependence for the protein deamidated for 19 days fits a linear function. CsgA deamidated for 2 
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days aggregates ~ 2-fold slower than the WT (Figure 4.6D), whereas CsgA deamidated for 19 
days shows no further change compared to that after 2 days, maintaining its disordered structure 
(Figure 4.6C). Thus, deamindated CsgA, after 2 days is still able to form aggregates/fibers, as 
shown by binding to ThT. CsgA aggregates/fibers give a ThT-positive signal but show slower 
aggregation by CD was reported previously.20 This may be attributed to some deamidation of the 
CsgA sample during the purification. 
 
Figure 39 4.5: Far-UV CD of CsgA aggregation  
Figure 4.6 Aggregation of CsgA as monitored by Far-UV CD, A-C) CD spectra of CsgA at 
different incubation time of aggregation. (A) Intact CsgA (labeled as: deamidated 0 day), (B) 
CsgA deaminated 2 days (deamidated 2 days) and (C) 19 days (deamidated 19 days). (D) Kinetic 
change of disordered structure of different CsgA sample as shown by CD at 200 nm.   
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4.4.5 HDX 
We previously applied HDX to study conformation and follow aggregation of curli proteins.21, 33 
In an application to CsgA, we discovered two species with distinct deuterium labeling extents 
during aggregation. Species A at higher m/z exchanges rapidly similar to that of a denatured 
monomer, whereas species B at lower m/z is structured and well-protected.21 The relative 
abundance of species B compared to that of A reflecting aggregation propensities can be used to 
follow the aggregation at the peptide-level.  
We utilized the same HDX protocol to study aggregation of CsgA deamidated for 5 days and 
compared the results to those of the WT. HDX of the deamidated and WT CsgA at the beginning 
of aggregation are similar because both forms are highly dynamic, disordered, and solvent 
exposed. The buildup of fractional B species, however, is much slower for the deamidated CsgA 
than for the WT (Figure 4.7), indicating that the deamidated protein loses its ability to form 
fibrils. For the times used here, we only observed slight increases of fractional B species for the 
three peptides 26–37, 38–48, and 106–137 representing R1 and R5, which also show faster 
aggregation for the WT.21  
 
Figure 40 4.6: HDX of W T and deamidated CsgA  
Figure 4.7 Fractional species B of WT (blue) and deamidated (red) as a function of incubation 
time for peptides 26–37, 38–48, and 106–137. 
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4.4.6 Effect of Deamidation on Curli Fibril Formation 
Our studies using ThT fluorescence, CD, and HDX taken together indicate that deamindated 
CsgA loses its ability to form fibrils. We mapped the extensive deamidated Asn residues onto a 
predicted left-handed CsgA structure34 in the fibril (Figure 4.8). The three fastest deamidation 
sites are colored in red, and the remaining Asn residues are in cyan. All of the deamidated sites 
locate at or near the loop regions of the structure, most of which point outwards from the 
amyloid core. That CsgA aggregation is significantly slowed after 1 and 2 days of deamidation is 
consistent with the large effect caused by the three fast deamidating residues, Asn57, 87, and 
102, despite their location in the less amyloidogenic repeating units R2, R3, and R4.21, 22 There 
are at least three possibilities to explain why deamidated CsgA loses its aggregation capabilities. 
The first is that Asn is critical for CsgA amyloid formation. It is suggested that the polar side 
chains of Asn and Gln form hydrogen bonds with local backbone, and thereby increase the 
stability of the β-sheet of the amyloid fibril.19, 34, 35 The second is the effect introduced by the 
negative charge of Asp or iso-Asp made available as a result of deamidation. One of the 
strategies employed by proteins to avoid edge-to-edge aggregation between β-sheets is inward-
pointing charges.36 Alternatively, the loss of function could be uniquely assigned to the iso-Asp 
product, which introduces an additional α-carbon into protein backbone and thereby significantly 
alters protein structure and function.37-39 Although iso-Asp may be favored over Asp in the 
hydrolysis of succinimide intermediate,16 it is difficult to differentiate iso-Asp from Asp with 
MS-based collision-induced dissociation (CID). Thus we are unable to identify any specific 
effect from iso-Asp.  
Wang et al30 showed that Ala substitutions of eight internally conserved Gln’s and five Asn’s 
increase SDS solubility of curli, suggesting that these polar residues can help stabilize the 
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amyloids. However, only four residues, Gln29, Asn34, Gln119, and Asn124, impede CsgA 
aggregation in vivo and in vitro.30 None of these residues are identified as the fast deamidation 
site in this work. Loss of Asn is unlikely to be the most important factor here. The same group 
also found several Asp and Gly residues as “gatekeepers”.40 Substitutions of the four Asp with 
two Leu, one Asn, and one His, along with three Gly substitutions, result in faster CsgA 
aggregation. DePace et al41 reported that substitutions of Gln and Asn, mostly to positively 
charged residues, lead to increased solubility of prion protein Sup35p, or even cause curing of 
amyloids in vivo. Both suggest the significant impact of charged residues on amyloid proteins. 
Therefore, we propose that the negative charges introduced by the iso-Asp or Asp are important 
in preventing CsgA amyloid formation. This hypothesis can be tested with future mutagenesis 
studies. 
 
Figure 41 4.7: Deamidated residues map ped onto  a predicted CsgA structure  
Figure 4.8 Deamidated residues mapped onto a predicted CsgA structure34 in fibrils. The three 
fast deamidation sites are labeled and colored in red. 
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4.5 Conclusion 
Interrupting biofilm formation by targeting CsgA aggregation may be an effective approach.6, 7 
Furthermore, studying the functional amyloid CsgA, the major curli component, provides a 
useful reference for understanding disease-associated, uncontrolled amyloid formation. The 
primary sequence of CsgA is highly susceptible to deamidation because most Asn residues are 
followed by other residues enhancing deamidation rates.8, 9 We found extensive deamidation 
occurred at fourteen Asn residues in CsgA, particularly at three hot spots “Asn–Gly”. ThT 
fluoresence assays show slower formation of fibers when CsgA is deamidated under stress. WT 
CsgA forms a highly organized β-sheet whereas deamidated CsgA remains unstructured as 
observed by both CD and HDX. The negative charges introduced by deamidation increase 
electric repulsions between protein units and likely prevent further fibril formation. Site-directed 
mutagenesis in the future will pinpoint the critical Asn residues among candidates identified in 
this work. Purposeful and controlled deamidation might be used as an approach to module CsgA 
aggregation. For example, adding a synthetic “asparaginase” can accelerate deamidation rates of 
“Asn–Gly”42 and may significantly disrupt curli fiber formation.  
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Chapter 5: ApoE: In Vitro Studies of a Small 
Molecule Effector*4 
 
 
 
 
 
 
 
 
 
 
 
                                                 
* This work is based on the following publication: Mondal, T., Wang, H., DeKoster, G. T., Baban, B., Gross, M. L., 
and Frieden, C. ApoE: In Vitro Studies of a Small Molecule Effector, Biochemistry, 2016 55, 2613-2621 (Mondal, 
T. and Wang, H. contributed equally to this work). Mondal, T. performed fluorescence titration and analytical 
ultracentrifugation experiment. Wang, H. performed HDX experiment and data analysis. DeKoster, G.T. and Baban, 
B. performed pyrene experiment. Baban, B. expressed and purified all protein samples. 
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5.1 Abstract 
Apolipoprotein E4 (apoE4), one of three isoforms of apoE, is the major risk factor for 
developing late onset Alzheimer’s disease. The only differences between these isoforms (apoE2, 
apoE3 and apoE4) are single amino acid changes. Yet these proteins are functionally very 
different. One approach to ameliorating the effect of apoE4 with respect to Alzheimer’s disease 
would be to find small molecular weight compounds that affect the behavior of apoE4. Few 
studies of this approach have been carried out in part because there was no complete structure of 
any full-length apoE isoform until 2011. Here we focus on one small molecular weight 
compound, EZ-482, and explore the effects of its binding to apoE. Using hydrogen-deuterium 
exchange, we determined that EZ-482 binds to the C-terminal domains of both apoE3 and 
apoE4. The binding to apoE4, however, is accompanied by a unique N-terminal allosteric effect. 
Using fluorescence methods, we determined an apparent dissociation constant of approximately 
8 μM. Although EZ-482 binds to the C-terminal domain, it blocks heparin binding to the N-
terminal domain. The residues of apoE that bind heparin are the same as those involved in apoE 
binding to LDL and LRP-1 receptors. The methods and the data presented here may serve as a 
template for future studies using small molecular weight compounds to modulate the behavior of 
apoE. 
5.2 Introduction 
The family of apoE lipoproteins in humans consists of three major isoforms called apoE2, apoE3 
and apoE4 with differences between isoforms being single amino acid changes 
(arginine/cysteine) within the 299 amino acid protein. In apoE3, the arginine at position 112 in 
apoE4 is changed to cysteine, while in apoE2 arginines at positions 112 and 158 are both 
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changed to cysteine,1 these changes being in the N-terminal domain of the protein. An NMR 
structure of a full length monomeric mutant of apoE3 shows extensive interaction between the 
N- and C- terminal domains.2 Although there is only a single amino acid change between apoE4 
and apoE3, the function of these two isoforms is quite different. The functional difference may 
result from conformational differences in the C-terminal domain as a result of the cysteine to 
arginine difference in the N-terminal domain.3, 4  
ApoE proteins play a key role in the lipid metabolism of the cardiovascular and central nervous 
systems.5, 6 Importantly, it has been known since 19937, 8 that apoE4 is a risk factor for the 
development of late onset Alzheimer’s disease. Indeed, it is now clear that apoE4 is the major 
risk for this disease9, 10 while apoE3 appears to have little or no effect of the development of 
Alzheimer’s disease. Compared to individuals with no ε4 alleles, the increased risk for 
Alzheimer’s disease is 2–3 fold in people with one ε4 allele and approximately 12-fold in those 
with two ε4 alleles.  
While the underlying reasons for this difference remain unclear, one approach to affecting the 
development of late onset Alzheimer’s disease would be to modulate the properties of apoE4 
relative to apoE3. This approach was suggested as early as 2006 by Mahley et al.,11 and there 
have been some, but relatively few, studies using this idea12, 13 as recently discussed by 
Michaelson.14 One problem, however, was that before 2011 there was no complete structure of 
any apoE isoform. Thus, early discussions of modulating apoE4 behavior were based on the 
known structure of the N-terminal domain and proposed interactions between the N- and C-
terminal domains.5 In that model, it was suggested that there were interactions between the N-
and C-terminal domains for apoE4 but not for apoE3.5  
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In 2011, Chen et al. determined the NMR structure of a full length monomeric mutant of apoE3 
obtained by making five amino acid substitutions in the C-terminal domain.2 As shown by Chen 
et al. and as discussed by Frieden and Garai, 3, 4 this structure shows strong interactions between 
the N- and C-terminal domains of apoE3 in contrast to the previously proposed model.5 On the 
basis of hydrogen–deuterium exchange studies carried out by Huang et al.15 Frieden and Garai 
suggested that structural differences between apoE3 and apoE4 occurred in the C-terminal 
domain3 and that these differences could be the basis for exploring small molecular weight 
compounds that could bind to apoE and modulate its behavior. In this paper, we describe one 
such small molecule and procedures for finding other molecules that may affect such behavior. 
We find that the compound used here binds to regions in the C-terminal domain of nonlipidated 
apoE with micromolar affinity and blocks heparin binding even though the heparin binding site 
is located in the N-terminal domain. Since the heparin binding site on apoE is also the site for 
receptor binding, this compound could also interfere with binding of apoE to the cell surface. 
5.3 Materials and Methods 
5.3.1 Protein Expression and Preparation 
Apolipoprotein E (apoE) was expressed as a thioredoxin fusion protein in Escherichia coli 
(strain BL21, DE3 competent cells, Stratagene), which was grown in LB media to OD600 = 0.6. 
An N-terminal 6X-Histag was used for purification of the fusion protein and a PreScission 
peptide, which is cleaved with PreScission protease, was placed between the two proteins. This 
process removes the 6X-Histag and thioredoxin but leaves two amino acids (Gly-Pro) on the N-
terminal end of apoE. The procedure avoids the earlier preparation that involved adding lipid 
prior to a thrombin cleavage.16 Mutations were introduced into the c-DNA of apoE using the 
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QuikChange site-directed mutagenesis kit (Agilent) and all sequences were verified using DNA 
sequencing.  
Stock solutions of apoE were dialyzed overnight at 4 ºC either in 1X PBS (10 mM PO4
3−, 137 
mM NaCl, and 2.7 mM KCl. pH 7.4) or 20 mM HEPES, 150 mM NaCl, pH 7.4, by using Slide-
A-Lyzer dialysis cassettes (10,000 molecular weight cutoff). For apoE3, 0.1% β-mercaptoethanol 
was added. The buffer was exchanged for fresh buffer and again dialyzed overnight at 4 ºC. The 
concentration of the final protein solution was established by absorbance measurement at 280 nm 
(ε = 44950 cm-1 M-1). The protein was flash frozen in liquid nitrogen and stored at −80 ºC. 
5.3.2 Materials 
Rhodamine labeled heparin was obtained from Creative PEGWorks (North Carolina) and stored 
at −20 C. The average molecular weight of this heparin is 18000 Da with 95% purity. 
According to the supplier, there was at least one dye per heparin polymer. A specific amount of 
rhodamine-labeled heparin was dissolved 20 mM HEPES buffer with 150 mM NaCl, pH 7.4, 
divided into small aliquots and stored at 4 ºC before use. At high concentrations, rhodamine 
labeled heparin appears to form higher molecular weight species, resulting in fluorescence 
quenching. Diluting the heparin resulted in dissociation and an increase in fluorescence. 
Therefore, before adding protein (or compound), it was necessary to wait for approximately 
10,000 s to allow the fluorescence to stabilize prior to data collection. 
The compound used in these experiments, (C23H19ClN4O5S), N-{5-[(3-chlorophenyl)sulfamoyl]-
2-hydroxyphenyl}-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide (molecular weight 
498.94) was obtained from Enamine LLC. The compound number was MolPort-004-651-765. 
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The structure is shown in Figure 5.1. In this paper, the name of the compound was shortened to 
EZ-482 for ease of use. 
 
Figure 42 5.1: Structure of E Z-482  
Figure 5.1 Structure of EZ-482. 
SYPRO Orange, pyrene maleimide, and ANS were obtained from Sigma-Aldrich (St. Louis, 
MO). No structure is available for SYPRO Orange. Tetramethyl-rhodamine maleimide and 
Alexa Fluor-488 maleimide were obtained from Invitrogen (Carlsbad, CA). Chicken egg 
phosphatidyl choline (Egg PC) and other lipids were obtained from Avanti Polar Lipids 
(Alabaster, AL).  Egg PC was used to make small unilamellar vesicles (SUVs). Briefly, Egg PC 
in chloroform was dried as a film under nitrogen gas on the wall of a glass tube and lyophilized 
to remove chloroform. The lipid film was hydrated in PBS buffer and extruded through 0.05 μM 
filter. The final concentration of egg PC SUVs in the pyrene fluorescence experiments was 0.4 
mg/ml. All other materials used were of reagent grade. 
5.3.3 Hydrogen–Deuterium Exchange and Mass Spectroscopy (HDX-MS) 
Protocol 
ApoE stock solutions containing EZ-482 were prepared by incubating a 10 μM apoE stock 
solution in phosphate buffer saline, pH 7.4 (PBS). For apoE3, the solution contained 2 mM 
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dithiothreitol (DTT). When EZ-482 (in DMSO) was used, the stock was diluted 1:25 at 25 °C 
and incubated with the protein for 2 h before HDX analysis. Compound-free apoE was prepared 
the same way but contained DMSO (2%) equivalent to that in solution containing the EZ-482. 
Continuous HDX was initiated by diluting 4 μL apoE stock solution 1:9 into D2O buffer (PBS, 
pD 7.4) at 25 °C for various incubation times (30 s, 1 min, 2 min, 3.5 min, 5 min, 10 min, 30 
min). A sequential digestion with fungal XIII and pepsin was used to achieve 98.7% sequence 
coverage. The HDX was quenched by mixing with 60 μL of 1 mg/mL fungal XIII, 3 M urea, and 
1% formic acid for 2 min on ice, and then injected into a self-packed immobilized pepsin column 
(2 mm × 2 cm). The resulting digested peptides were trapped and desalted on a C8 trap column 
(2.1 mm × 1.5 cm, Agilent, Santa Clara, CA) for 4 min at 300 μL/min in 0.1% trifluoroacetic 
acid via an Agilent 1100 HPLC (Santa Clara, CA). The peptides were then eluted from the trap 
column and separated on a C18 analytical column (2.1 mm × 5 cm, 3 μm Hypersil Gold, Thermo 
Fisher, Waltham, MA) with a linear gradient (4−40% CH3CN, 0.1% (v/v) formic acid) at 180 
μL/min delivered by a LEAP 3x Ti pump (Carrboro, NC) for 11 min. All steps were performed 
in a water–ice (~0 °C) bath to minimize back exchange. Each HDX experiment point was done 
in duplicate. HDX data were collected on a maXis quadrupole time of flight (Bruker, Bremen, 
Germany) mass spectrometer in the positive-ion electrospray ionization mode with the following 
instrument settings: capillary voltage, 3.8 kV; nebulizer gas, 1.6 bar; drying gas flow rate, 8 
L/min and temperature, 200 °C. For establishing a back-exchange correction, the apoE stock 
solutions were incubated in D2O buffer at 25 °C for 48 h. 
5.3.4 HDX Data Analysis 
Preliminary to HDX, peptides from pepsin and fungal XIII digestion were identified in a data-
dependent mode with a Thermo LTQ 7 T FT-mass spectrometer (San Jose, CA). The top six 
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most abundant ions were submitted to collision-induced dissociation (CID) fragmentation. 
Product-ion spectra were then submitted to MassMatrix (version 2.4.2)17 for identification, and 
manually inspected. Only verifiable peptides were used for HDX analysis. Data analysis of 
continuous HDX was carried out with HDExaminer (version 2.0, Sierra Analytics, Inc., 
Modesto, CA).  
5.3.5 Analytical Ultracentrifugation 
A Beckman Optima model XL-A analytical ultracentrifuge (Brea, CA) was used for 
sedimentation velocity experiments. Samples were loaded into a conventional double-sector 
filled Epon centerpiece (path length 1.2 cm).  Data were collected in continuous mode at 290 nm. 
Experiment were performed in PBS buffer using 10 μM apoE4 and EZ-482 concentrations of 0, 
10 and 20 μM. Data were analyzed using Sedfit.18  
5.3.6 Fluorescence Labeling of ApoE4 
For fluorescence studies, single cysteine mutants, A102C, S139C, and A285C, of apoE4 were 
prepared. The cysteine mutants were labeled by thiol- reactive chemistry using either Alexa488 
maleimide, TMR maleimide or pyrene maleimide. The labeling reactions were performed in 1X 
PBS buffer.  Reduction of disulfide bonds was carried out by adding 20 mM DTT and incubating 
the protein for 1–2 h at 37 C. Excess DTT was removed with a PD-10 column and a 10-fold 
molar excess of maleimide dye was added slowly with continuously shaking to the reaction 
mixture. The reaction mixture was then kept at 4 C overnight. Excess dye was removed by 
passing the reaction mixture over a PD-10 column, and the labeled apoE was then dialyzed 
against 1X PBS buffer. The absorbance at 280 nm and 490 nm (for Alexa488), 550 nm (for 
TMR) and 342 nm (for pyrene) was used to determine the concentration and the extent labeling 
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for all of the samples. For all samples, the extent of labeling was generally over 90%. ApoE3 
(A285C) was labeled with TMR, but the extent of labeling at position 112 was unclear. All 
titration experiments were performed by incubating the protein for 1 h at room temperature prior 
to stepwise addition of EZ-482.   
Pyrene-labeled apoE4 was used to measure binding to egg PC SUVs in the presence of EZ-482. 
The time course of apoE4 pyrene emission was followed at 385 nm with excitation at 342 nm. 
Pyrene-labeled apoE4 (0.3 μM) was incubated in a stirred cuvette with or without varying 
concentrations of EZ-482 in PBS buffer for 3 minutes before data collection. Data collection was 
started and 1 minute later, egg PC SUVs were added to a final concentration of 0.4 mg/ml.   
5.4 Results 
5.4.1 Determination of Dissociation Constants for Compound Binding to 
ApoE 
A typical method for determining the dissociation constant to a protein utilizes the change in 
tryptophan fluorescence as a function of ligand concentration. This method proved unusable for 
at least two reasons: the ligands themselves absorb strongly at the absorption maximum of 
tryptophan, and any fluorescence change at a single tryptophan due to compound binding is 
masked by the presence of six other tryptophan residues present in apoE.  Isothermal titration 
calorimetry was not suitable because the solvent for many compounds is DMSO, which greatly 
affects the calorimetric data. Therefore, we turned to other methods to test 80 compounds.  
We chose EZ-482 to examine in detail since it was reasonably soluble in DMSO and initial 
studies indicated a low micromolar dissociation constant. Four different methods were used to 
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measure the apparent dissociation constant of EZ-482 to apoE. In the first, the fluorescence of 
apoE4 labeled with Alexa488 was used. The method is best suited to apoE4 since there the wild 
type does not contain cysteine. The apparent dissociation constant was determined by following 
the decrease in Alexa488 fluorescence of a cysteine mutant (S139C) as a function of EZ-482 
concentration. We did, however, label a cysteine mutant of apoE3 (A285C) with TMR. In this 
case, there are two cysteine residues since apoE3 has a cysteine at position 112. The ratio of dye 
to protein was determined to be 1:1. Even though the extent of labeling of the two cysteines was 
unclear, titration of this protein with EZ-482 gave the same dissociation constant for apoE3 as 
that determined for apoE4 under these conditions (Table 5.1).  
Table 5.1 Apparent Dissociation Constant of EZ-482 Using Different Methodsa 
Table 2 5 .1: Apparen t Dissociation Constant o f EZ-482Using Dif ferent Methods  
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A second approach uses the fluorescent protein dye SYPRO Orange. As shown below (next 
section), this dye binds to the same region of apoE3 as does EZ-482, and thus an apparent 
dissociation constant can be obtained by displacing SYPRO Orange with EZ-482. SYPRO 
Orange has an emission maximum of 608 nm. On addition of apoE to SYPRO Orange, there is 
an increase in fluorescence and a shift of the emission maximum to 575 nm. Subsequent titration 
with EZ-482 decreases the SYPRO Orange fluorescence to that of apoE alone. Figure 5.2 shows 
a titration of SYPRO Orange-apoE3 with EZ-482, and Table 1 lists the apparent dissociation 
constants for both apoE4 and apoE3. Both apoE3 and apoE4 gave similar dissociation constants. 
 
  
Figure 5.2. Left: Fluorescence spectra of 1x SYPRO Orange using 0.5 μM apoE3 as a function of 
EZ-482 concentration 0 (), 3.5 μM (), 11.5 μM () and 21.5 μM (). Right: Titration of all 
fluorescence data at 575 nm fit to a dissociation constant of 7.3 μM. All experiments performed 
in PBS buffer, pH 7.4 with 1mM DTT and 1 mM EDTA at 25 C.  
Figure 43 5.2: A ti trat ion o f SYP RO Orange-apoE3 with E Z-482 
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A third approach uses wild-type protein to titrate Alexa488 labeled apoE4 in the presence of EZ-
482 as a function of wild-type apoE. In these experiments, the EZ-482 was added to 
fluorescently labeled apoE, and subsequent fluorescence decrease was followed as described 
above. The subsequent addition of unlabeled apoE3 removes EZ-482 from the Alexa488 protein 
with fluorescence returning to that in the absence of compound. Since the wild type protein is not 
labeled, this experiment distinguishes the binding of the ligand to the protein from binding to, for 
example, the fluorescent label.  
A final approach was to use ANS. It has been shown that ANS fluorescence is increased on 
addition of apoE.19 Addition of EZ-482 quenches the increased ANS fluorescence. Table 1 gives 
the dissociation constants for both apoE3 and apoE4 using all of these methods. Overall, the 
results from all four methods are essentially the same, yielding a dissociation constant of 
approximately 8 μM under the conditions used.  
5.4.2 HDX: Location of EZ-482 and SYPRO Orange Binding Sites 
To determine the sites of EZ-482 binding to apoE, we used differential HDX methodology. 
Experiments were performed using 1 μM WT apoE in the presence and absence of 25 μM EZ-
482. This EZ-482 concentration is 3 times the apparent dissociation constant (Table 1). The 
HDX experimental temperature (25 °C) and the on-exchange time points were chosen for 
optimum display of HDX differences induced upon ligand binding. To get nearly complete 
coverage (99%) of the protein, we performed a sequential fungal XIII then pepsin digestion 
because the coverage with pepsin alone, reported in our previous work, was less than 80%.15  
HDX kinetic curves for several apoE3 and apoE4 peptides show decreases in HDX as a result of 
EZ-482 binding. These are shown in Figure 5.3a (apoE3) and b (apoE4), respectively. Large 
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protection was observed only in the C-terminal domain (229–235/234–243 and 258–265) for 
both isoforms, an indication of binding at these sites. The fact that both isoforms show visually 
similar kinetic curves in these regions indicates that EZ-482 binds to apoE3 and apoE4 in a 
comparable manner, consistent with results from other biophysics methods discussed above. 
When examined carefully, peptides 229–235/234–243 show different HDX kinetics compared to 
that for other regions. The differences between apoE bound to EZ-482 for peptides 229–
235/234–243 are relatively small at early time points and increase over the time course before 
decreasing. For peptide 258–265, however, the maximum HDX differences are at the shortest 
time and disappear gradually. Additionally, larger maximum HDX differences are observed for 
regions represented by peptides 229–235/234–243 than for peptide 258–265. These observations 
indicate that 229–235/234–243 and 258-265 are EZ-482 binding sites. One peptide in the N-
terminal domain (44–51) and an additional one in the C-terminal domain (206–217) show some 
differences between apoE4 and apoE3 in the presence of EZ-482. The differences between 
bound and unbound apoE4 are relatively small and diminish faster than those of peptides 229–
235/234–243 and 258–265. We suggest that the differences observed in peptides 44–51 and 206–
217 reflect N-terminal conformational changes of apoE4 upon EZ-482 binding, as discussed 
later. One of the drawbacks of HDX, or of any footprinting approach, is that conformational 
changes caused by direct interaction are difficult to distinguish those caused by allosteric effects. 
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Figure 44 5.3: HDX of E Z-482 and SYPRO Orange bind ing to apoE  
Figure 5.3. HDX kinetic curves of peptides that showed protection upon ligand binding: (a) 1 μM 
apoE3 (light red) in the presence of 25 μM EZ-482 (black), or 1× SYPRO Orange (blue) and (b) 
1 μM apoE4 (green) and in the presence of 25 μM EZ-482 (dark red). The data for apoE4 do not 
include the use of SYPRO Orange. Differential deuterium uptake over the full sequence between 
(c) apoE3 in the presence of EZ-482 compared to apoE3 alone and (d) apoE4 in the presence of 
EZ-482 compared to apoE4 alone at three selected time points. Secondary structure elements and 
peptide residues numbers are labeled on the left. The color scale of heat map is shown at the 
bottom. All differential deuterium uptake numbers are in the unit of percentage. Regions colored 
blue are protected from deuterium labeling upon EZ-482 binding while those colored red are de-
protected upon ligand binding. An allosteric effect in the N-terminal domain is observed in 
apoE4 but not in apoE3. 
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Noticeably, in the C-terminal domain, there is a long helix from 236 to 266 in the apoE3 NMR 
structure of a monomeric mutant.2 Rapid HDX at the earliest time point of peptides 243–251 
(>70%) and 252–258 (>80%) of the WT, however, contrasts with the slower HDX that occurs at 
neighboring regions represented by peptides 234–243 (<30%) and 258–265 (<50%, Figure 5.4). 
Unlike in the mutant monomeric apoE3 structure, there may not be a single long -helix 
spanning residues 236–266 in the wild-type structure. Rather, residues 243–258 in wild-type 
apoE3 are in a relatively flexible region, providing an opportunity for EZ-482 to interact with 
both sites 229–243 and 258–265.  
We also applied the same HDX method to apoE3 in the absence and presence of 1X SYPRO 
Orange dye to verify that its binding sites are similar to those of EZ-482. With respect to SYPRO 
Orange, the concentration of 1X SYPRO Orange was not supplied by the company and is 
therefore unknown. SYPRO Orange binds to the same region of apoE3 as EZ-482; the only 
difference is an additional peptide 252–258 shows protection at shorter time points (Figure 5.3a). 
Similar dissociation constants using or not using SYPRO Orange may reflect the possibility that 
SYPRO Orange binds only weakly to apoE. 
Although we did not detect significant differences between the isoforms in terms of binding 
sites, we did observe a significant conformational change of apoE4 N-terminal four-helix-bundle 
domain upon EZ-482 binding, whereas apoE3 N-terminal remained unaffected. Figure 5.3c and 
d show results of differential deuterium uptake over the whole length of apoE3 and apoE4. These 
heat map data are shown as percentage differences in deuterium uptake between ligand bound 
and unbound protein as a function of time. Interestingly, some regions of apoE4 N-terminus 
show more HDX upon EZ-482 binding. They are located near the centers of four helices: 27–37 
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in Helix 1, 63–68 in Helix 2, 102–115 in Helix 3, and 148–161 in Helix 4. This observation 
suggests to us that the N-terminal structure of apoE4 is altered by the EZ-482 binding to the C-
terminal domain. In contrast, apoE3 shows no such allosteric effect. The unique allosteric effect 
for apoE4 could serve as a guide for future studies to modify its properties. 
Figure 5.4 shows HDX results for the C-terminal domain of apoE3 in the absence and presence 
of EZ-482 and Sypro Orange and apoE4 in the absence and presence of EZ-482. 
 
 
(a) 
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Figure 45 5.4: HDX kinetic curves of peptides in the C-termina l doma ins o f apoE in the absence and presence of E Z-482 and  Sypro Orange  
Figure 5.4. Kinetic curves of peptides in the C-terminal domains of (a) apoE3 in the absence 
(red) and presence of EZ-482 (black) and Sypro Orange (blue), and (b) apoE4 in the absence 
(red) and presence of EZ-482 (black). 
 
5.4.3 Analytical Centrifugation 
To examine whether EZ-482 affected the oligomerization properties of apoE, we performed 
analytical ultracentrifugation sedimentation velocity experiments using 10 μM apoE4 in the 
absence and presence of 10 or 20 μM EZ-482. The distribution of apoE oligomers was 
essentially unaffected by the presence of the EZ-482. The data are shown in Figure 5.5.  
(b) 
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Figure 46 5.5: Analyt ical centri fugation sed imentat ion velocity of apoE4 and E Z-482  
Figure 5.5. Analytical centrifugation sedimentation velocity of apoE4 at different concentrations 
of EZ-482. The apoE4 concentration was 10 μM. The EZ-482 concentrations were 0 (black), 10 
μM (red) and 20 μM (blue). Experiment were performed in PBS buffer at 25 C. The major peak 
is tetramer while the minor peak is the monomer. Species showing larger sedimentation values 
are higher molecular weight aggregates.  
 
5.4.4 The Effect of EZ-482 on Heparin Binding: Using Fluorescently Labeled 
Heparin 
The interaction of apoE with heparin has been known for many years.20, 21 While it had been 
suggested that the N- and C- terminal domains each bind heparin,22 Saito et al. had shown that 
the C-terminal site is unavailable for heparin binding and that the N-terminal domain binding is 
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dominant.23 In this domain, residues 140–145 are involved in heparin binding.23 Dong et al.24 
characterized the binding of an octasaccharide to apoE4 in this same region. More recently, 
Futamura et al.25 using SPR, characterized binding as a two step process: apoE initially binds to 
heparin with fast association and dissociation rates, followed by a step exhibiting much slower 
kinetics.  
 
Figure 47 5.6: Effect of  EZ-482 on hepar in b inding  
Figure 5.6 Effect of EZ-482 on heparin binding. In all experiments, heparin was diluted from the 
stock solution to a final concentration of 3 μM and allowed to incubate for 3 h (not shown). After 
3 h, 0.5 μM apoE4 was added resulting in an increase of fluorescence due to heparin binding to 
apoE4 (top curve). In the remaining curves EZ-482 was incubated with apoE4 for 1 h, and the 
apoE4-EZ-482 complex was added to the preincubated heparin solution. EZ-482 concentrations 
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0 (), 0.5 μM (), 1 μM (), 5 μM (), 10 μM (+). Experiments were performed in 20 mM 
HEPES buffer, pH 7.4 containing 150 mM NaCl at 25 °C.  
Because the heparin used here is a mixture of many oligomeric species, it was not possible to 
directly examine the binding by HDX. Therefore, to determine whether EZ-482 affected heparin 
binding, we used rhodamine labeled heparin in the presence of EZ-482. Adding apoE to 
rhodamine labeled heparin (after equilibration) results in a time dependent increase in 
fluorescence as shown in Figure 5.6 (top curve). EZ-482 prevents this increase in a 
concentration-dependent manner indicating that EZ-482 blocks heparin binding. Figure 5.6 
shows that the increase in fluorescence is at least biphasic and that both phases are too slow to 
represent the actual binding step for heparin to apoE as determined from the data of Futamura et 
al.25 Rather, we believe that the slow time course is the re-equilibration of different molecular 
weight forms of rhodamine labeled heparin. When apoE binds heparin, the concentration of 
unbound heparin changes as does the equilibrium between labeled heparin species. This results 
in a small change in fluorescence. Heparin fluorescence is not affected by EZ-482 indicating that 
there is no interaction between heparin and EZ-482 (data not shown). EZ-482 does not bind 
directly to the heparin binding site but blocks heparin binding since the two binding sites (for 
heparin and EZ-482) are physically close as discussed later.   
5.4.5 Effect of EZ-482 on Lipid Binding 
Lipid binding to apoE is complex. First, it appears that only the apoE monomer binds to lipid.26, 
27 The dissociation of oligomers to monomer is slow.28 Second, apoE undergoes a large 
conformational change, a partial unfolding, such that the protein wraps around the lipid particle 
with the C-terminal domain in close contact with the lipid.5, 29 Thus, there could be time 
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dependent issues that complicate these studies. Finally, the residues important for lipid binding 
have not been clearly defined. Nguyen et al.,30 using surface plasmon resonance, analyzed the 
measured binding of two plasma lipoprotein particles (VLDL and HDL3) to apoE. They 
observed that both the isolated N- and C- terminal domains could bind the lipoprotein particles, 
but binding to the C-terminal domain was tighter than that to the N-terminal domain or to the 
full-length protein. On the basis of results using C-terminal truncated forms of apoE, Weisgraber 
and colleagues31, 32 suggested that a region of the C-terminal domain 250–299 was critical for 
lipid binding. A mechanism involving these steps has been discussed by Chen et al.2  
 
Figure 48 5.7: Ti trat ion o f pyrene-apoE4 with EZ-482  
Figure 5.7 Change in fluorescence of apoE4 labeled with pyrene at position 285 as a function of 
time at different concentrations of EZ-482. Concentrations used 0 (), 7.5 μM (). 15 μM (). 
30 μM (). The data are normalized assuming the starting point in the absence of lipid is 0. 
Experiment performed in 10 mM phosphate buffer, pH 7.4 in the presence of 0.15 M NaCl and 
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0.4 mg/mL egg yolk phosphatidyl choline small unilamellar vesicles. The data for the first 60 s 
were obtained prior to the addition of lipid.  
To examine whether EZ-482 affected lipid binding, we used an assay utilizing pyrene 
fluorescence.33, 34 This fluorescent probe shows an increase in fluorescence as a consequence of 
binding pyrene-labeled apoE4 to egg phosphatidylcholine. For this experiment, a pyrene probe 
was attached to position 285 of apoE4 that had been mutated to cysteine. The data, as a function 
of EZ-482 concentration (Figure 5.7), show that the extent of the fluorescence change is 
dependent on the concentration of EZ-482. Normalization of these data, however, shows that the 
increase in fluorescence follows exactly the same time course for all concentration of EZ-482. 
Garai and Frieden28 determined the rate and equilibrium constants for apoE oligomerization, and 
a model that is consistent with their results suggests that the rapid phase reflects EZ-482 binding 
to apoE, while the slower phase reflects lipid binding as apoE oligomers dissociate to the 
monomer. The time courses observed here are very similar to that observed by Mizuguchi et al.27 
who reached a similar conclusion. Because the time course of the slow fluorescence change is 
independent of the EZ-482 concentration, this model suggests that EZ-482 does not directly 
affect apoE binding to lipid.  
Other attempts at investigating the effect of EZ-482 on lipid binding, such as fluorescently 
visualizing apoE on vesicles, direct binding of fluorescently labeled lipids, or direct competition 
by EZ-482, were not definitive.  
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Figure 49 5.8: HDX mapped on to an NMR s tructu re 
Figure 5.8 Averaged differential deuterium uptake of apoE3 (left) and apoE4 (right) across all 
time points mapped onto NMR structure of apoE3 monomeric mutant (PDB: 2L7B) for visual 
convenience. The apoE structures are shown in the same orientation. The color scale is shown on 
the bottom right: yellow, orange, orange red and red correspond to increased HDX of more than 
5%, 10%, 15%, and 25%, respectively; regions that are more protected upon EZ-482 binding are 
colored in light green, green, blue and dark blue with decreased HDX of more than 5%, 10%, 
15%, and 25%, respectively. Shown in magenta is the 140–145 region of apoE that binds 
heparin. Two binding sites (dark green, blue/dark blue) are indicated with arrows. 
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5.5 Discussion 
There are many studies directed toward preventing the development of late onset Alzheimer’s 
disease. The majority of recent studies focus on A, either preventing its formation by inhibiting 
the - or -secretase, or using antibodies that bind to various forms of the A plaques.35 
Currently such studies have achieved limited success. Only a few studies have focused on 
attempting to modify the behavior of apoE4, the major risk factor for the development of late 
onset Alzheimer’s disease. Chen et al.12 did examine a large library to identify small molecular 
weight compounds that might alter the behavior of apoE4 to reduce detrimental effects on 
neurons in culture. Using an in vivo assay, they identified several phthalazinone derivatives that 
appeared to bind apoE. The compound used in our studies is based in part on using a fragment of 
the molecules they observed to be effective. Both Sadowski et al.36 and Liu et al.37 examined a 
number of apoE peptides to map the apoE/A interaction to serve as a guide for inhibitor 
binding. Goyal et al.,38 in contrast, carried out in silico screening of natural compounds against 
the N-terminal domain of apoE4 identifying two possible candidates although neither was tested 
experimentally. A recent paper 39 suggests a therapeutic strategy as relates to the development of 
cognitive deficits in Alzheimer’s disease would be to target PIP2 homeostasis by modifying 
apoE4 phenotypes.  
In this work, we used multiple biophysical tools including hydrogen–deuterium exchange 
coupled to mass spectrometry (HDX-MS) to understand the interaction between EZ-482 and 
apoE, affording the most complete characterization of any small molecular weight compound 
binding to apoE. We can summarize the outcome as follows and in the following paragraphs. 
EZ-482 binds to sites on apoE that are in the C-terminal domain encompassing residues 229–243 
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and 258–265. The dissociation constants for binding are within the range of 5–10 μM. The 
uncertainty of whether there are one or two sites for EZ-482 binding may relate to formation of 
the apoE oligomer. Thus, the two regions shown by HDX may be close to each other in the 
oligomer, and a single EZ-482 may overlap both sites.   
As shown in Figure 5.8 we also map residues that are affected by EZ-482 binding both apoE3 
and apoE4 onto the monomeric mutant NMR of apoE3. The differential HDX are the average 
values across all time points. As discussed above, various N-terminal regions of apoE4 show 
allosteric changes (deprotection from HDX) upon ligand binding, whereas no differences occur 
for the N-terminal of apoE3. Interestingly, these regions are located near the center points of four 
α-helices and are spatially close to the binding sites.  
Two additional regions of apoE4 that show some protection in the bound state, 44–51 and 206–
217 (colored in light green in Figure 5.8) are located close to each other and to regions that show 
increased HDX but opposite to the binding sites. Therefore, we think the protection in these 
regions is part of the N-terminal allosteric effect. Other than this allosteric effect, there is no 
difference between apoE3 and apoE4 (EZ-482 binding sites are indicated by arrows in Figure 
5.8). Perhaps this is not unexpected; we proposed earlier that there are conformational 
differences between apoE3 and apoE4 in the C-terminal domain.3 Those differences, however, 
are not in the region to which EZ-482 binds. As pointed out by Frieden and Garai, there are 
conformational differences between apoE isoforms in the C-terminal domain indicating that 
there may be compounds with preferential binding to different isoforms.3 The fact that 
denaturation curves also differ between isoforms also strengthens this possibility.40  
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Binding of EZ-482 prevents heparin binding even though heparin is bound to the N-terminal 
domain. We proposed above that EZ-482 does not bind directly to the heparin binding site (140–
145, colored in magenta) but blocks access to that region of the non-lipidated protein, as shown 
in Figure 5.8. The heparin and the EZ-482 binding sites, although in different domains, are quite 
close in space. One possible binding mode that could affect heparin binding is for EZ-482 to fit 
in the groove between the C- and N- terminal domains. Blocking access to the heparin binding 
site has important consequences for apoE binding to the cellular receptors LDLR and LRP-1. For 
example, Lalazar et al. found that mutations in the region 136–150, and particularly a Lys146Ala 
mutation, led to decreased LDL receptor binding.41 Croy et al.42 have shown that LRP-1 binds to 
two regions of the N-terminal receptor binding domain (130–149) and (141–155), the same 
regions affected by EZ-482 binding. Thus, EZ-482 may affect apoE binding both the LRP-1 and 
LDL receptors.  
In one approach we used SYPRO Orange as a reporter for small molecule binding. HDX shows 
that both this dye and EZ-482 bind to the same region of apoE3 and that as a consequence the 
SYPRO Orange fluorescence decreases in the presence of EZ-482. It is possible that the use of 
this dye will only detect binding of small molecules at this particular region. However, some 
small molecules we have tested show an increase of SYPRO Orange fluorescence indicating 
binding to a different region (data not shown). It is important to test other fluorescent dyes with 
respect to where other small molecular weight compounds bind to apoE. The dissociation 
constant obtained using competition with SYPRO Orange is similar to those determined using 
fluorescently labeled apoE4 (Table1). Although one can legitimately ask whether it is a SYPRO 
Orange–EZ-482 complex that binds to apoE, this is not the case since the same dissociation 
constant for EZ-482 is obtained in the absence of SYPRO Orange.  
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This study has made extensive use of hydrogen–deuterium exchange methods, currently an 
important tool for characterizing protein and small molecule therapeutics interaction.43-45 Protein 
structural information can be coupled to mass shift and detected by mass spectrometry. The 
protein backbone amide HDX reports on solvent accessibility and hydrogen-bond networking,46-
48 characterizing conformational changes induced by small molecule ligand binding.49 
5.6 Conclusion 
In summary, we describe methods that can be used to differentiate apoE3 from apoE4. This 
particular compound, EZ-482, binds equally well to both apoE3 and apoE4 with dissociation 
constants of ~8 μM under the conditions used. However, the binding to apoE4 is accompanied by 
the N-terminal allosteric effect. Although EZ-482 binds to the C-terminal domain of the protein, 
it blocks the heparin binding region in the N-terminal domain. The results presented here are 
important because the region of apoE that binds heparin also interacts with apoE receptors such 
as LDLR and LRP-1 which are known to be involved in the pathogenesis of late onset 
Alzheimer’s disease. 
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Chapter 6: A HDX-MS Based Platform 
Characterizes the Interaction between 
apolipoprotein E3 and a small molecular 
weight compound: PLIMSTEX and 
SUPREX experiments at the peptide level*5 
 
  
                                                 
* Wang, H performed all MS experiment and data analysis. Rempel, D.L. wrote the algorithm for PLIMSTEX and 
statistical analysis for SUPREX. Baban, B. from Frieden lab provided the apoE protein sample. 
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6.1 Abstract 
A platform utilizing two hydrogen–deuterium exchange (HDX) based methods coupled with 
mass spectrometry (MS) is developed to characterize interaction between a protein, 
apolipoprotein E3 (apoE3), and a small molecule drug candidate. The ApoE family is important 
in lipid transportation and is implicated in neurodegenerative diseases including Alzheimer’s. 
We extended PLIMSTEX (protein–ligand interactions by mass spectrometry, titration, and H/D 
Exchange) by incorporating enzymatic digestion to acquire binding information at the peptide 
level. In one experiment, we not only identified putative binding sites, but also obtained affinities 
of 6.0, 6.8, and 10.6 μM for the three sites. A single binding affinity of 7.4 μM was generated by 
fitting the three peptides as a single binding site, giving an overall binding affinity that agrees 
well with literature values determined by accepted methods. Unlike those methods, however, 
PLIMSTEX provides site-specific binding information. Using the second approach, modified 
SUPREX (stability of unpurified proteins from rates of H/D exchange) coupled with electrospray 
ionization (ESI), we achieved detailed information about protein unfolding and changes of 
unfolding upon ligand binding. The three sites, along with an additional peptide which may be 
important for lipid binding, show increased stability upon ligand binding. By employing a single 
parameter ∆𝐶1/2%, we were able to compare relative changes of denaturation between peptides. 
This integrated platform provides orthogonal information to commonly used HDX kinetics 
experiment, and is a novel approach for studying protein–ligand interactions. 
6.2 Introduction 
Protein–ligand interaction is one of the key biological processes. Understanding stoichiometry, 
binding interface, conformational change, thermodynamics and kinetics are fundamental for 
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most studies. Commonly used fluorescence-based methods1 and Surface Plasmon Resonance 
(SPR)2, provide essential binding constants. They are limited, however, because they often 
require specific reporter labels and afford limited if any spatial or site-specific information. High 
resolution methods (e.g., Nuclear Magnetic Resonance (NMR)3 and X–ray Crystallography4), are 
often not appropriate because they require relatively large amounts of sample and considerable 
time. Hydrogen–deuterium exchange (HDX) has become one of the most applied mass 
spectrometry-based footprinting approaches in studying protein conformational change and 
locating protein–ligand interactions because it is sensitive, gives spatial resolution in the protein, 
and is relatively simple to execute.5-9 Ligands will directly or indirectly affect protein local 
hydrogen-bond networks and change solvent accessibility. Backbone amide hydrogen exchange 
with D2O responds to these changes while producing nearly no perturbation to structure in the 
exchange. In HDX, as most commonly practiced, the protein needs only to be incubated in D2O 
for a series of time points and the kinetics of HDX followed.  Plots of deuterium uptake extent 
against exchange times, inform on binding regions when comparing HDX in the presence and 
absence of a ligand.7  
Two HDX-based methods have been advanced to determine protein–ligand binding affinities 
(introduced in section 1.7.3 and 1.7.4). One is PLIMSTEX (protein–ligand interactions by mass 
spectrometry, titration, and H/D Exchange)10, in which a protein in solution with increasing 
ligand concentrations is submitted to HDX at a pre-determined time. A plot of HDX against 
ligand concentration produces a PLIMSTEX curve, from which binding affinity can be extracted 
by mathematical model fitting.11 If the protein concentration is much greater than the ligand 
binding constant, the PLIMSTEX curve will not be suitable for determining affinity but can be 
used to determine binding stoichiometry or purity of the protein.10, 12 PLIMSTEX is a titration-
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based platform employing essentially the same idea as conventional fluorescence based titration 
methods, but without the need for fluorophore, which often requires amino acid substitutions. 
With an HDX method, a protein can be investigated in solution at the native or near native state. 
PLIMSTEX has been successfully applied to a variety of complicated systems in which binding 
affinities estimated at the global level agree well with literature values.10, 11, 13-15  Obtaining 
region-specific binding affinity directly from peptide-level PLIMSTEX, however, has developed 
slowly because the metal-binding systems previously tested at a global level involve multiple, 
more complicated binding processes14, 15 than do the more tractable 1:1 systems.  Additionally, 
early experiments were at high protein concentrations because mass spectrometers were less 
sensitive than today; at high concentration and thus could only be used for stoichiometry or 
purity.13  
SUPREX (stability of unpurified proteins from rates of H/D exchange), is another HDX-based 
method for measuring protein folding energy changes and binding constants.16 Although 
SUPREX was originally developed and has been mainly applied using matrix-assisted laser 
desorption/ionization (MALDI) MS, it is also suitable for electrospray ionization (ESI) MS17. In 
SUPREX, protein in the presence and absence of ligand is incubated with different 
concentrations of denaturant and then submitted to HDX at varied deuterium exchange times. 
Each SUPREX curve is constructed by plotting protein mass shift against denaturant 
concentration, and fit to a four-parameter sigmoidal equation by nonlinear regression to 
determine a transition midpoint  𝐶1/2
SUPREX. Multiple 𝐶1/2
SUPREX determinations at varied exchange 
times are used to calculate an m value18 (i.e., dependence of folding free energy change on 
denaturant) and ΔGf (i.e., the folding free energy in the absence of denaturant). The binding 
constant can then be calculated from ΔΔGf between bound and unbound states.19-21 
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Thermodynamic information for domains22 or large peptides23 can also be accomplished with 
SUPREX coupled with enzyme digestion.  
We recently measured the usual differential HDX kinetics of bound and unbound states of 
apolipoprotein E (apoE) and a small molecule effector (drug candidate).24 The ApoE family has 
three isoforms with a single amino acid change at two sites: apoE2 (Cys112/Cys158), apoE3 
(Cys112/Arg158), and apoE4 (Arg112/Arg158).25 ApoE4 is a major genetic risk factor for late 
onset Alzheimer’s disease (AD)26, whereas apoE3 have no such detrimental effect and apoE2 has 
deleterious effects.27 Three putative binding sites in the C-terminal domain were discovered for 
both isoforms: 229–235, 234–243 and 258–265.24 To explore the potential of PLIMSTEX and to 
characterize this system more fully, we extended PLIMSTEX by coupling it with tandem 
protease digestion and obtained binding constants at peptide levels representing regions of the 
protein. Additionally, a modified peptide-level SUPREX protocol was utilized to investigate 
regional binding-induced unfolding changes. 
6.3 Materials and Methods 
6.3.1 Materials and Reagents 
As previously reported24 and briefly described here, apoE3 was expressed as a thioredoxin fusion 
protein in E. coli that was grown in LB media to OD600 = 0.6.  After purification using an N-
terminal 6X-Histag, thioredoxin was removed with a PreScission peptide via PreScission 
protease (GE Healthcare, Pittsburgh, PA). Phosphate buffer saline (PBS), dimethyl sulfoxide 
(DMSO), dithiothreitol (DTT), urea, formic acid, trifluoroacetic acid, porcine pepsin, fungal 
XIII, HPLC grade water and acetonitrile were purchased from Sigma-Aldrich (St. Louis, MO). 
D2O was from Cambridge Isotope Laboratories Inc. (Andover, MA). The compound, N-5-[(3-
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chlorophenyl)sulfamoyl]-2-hydroxyphenyl-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-
yl)acetamide (C23H19ClN4O5S, name shortened to EZ-482), was from Enamine LLC (Monmouth 
Junction, NJ). The structure of this compound is provided in Figure 5.1 (chapter 5). 
6.3.2 Sample Preparation 
For PLIMSTEX, 10 μM apoE3 (PBS containing 2 mM DTT, pH 7.4) was incubated with 
different concentrations of EZ-482 (dissolved in DMSO) for 1 h at 25 °C prior to HDX analysis. 
All stock solutions contained 2% DMSO including the apoE3 sample without ligand.  
In the originally described SUPREX experiment, the protein was dissolved and submitted to 
denaturant and D2O exchange by including the denaturant in deuterated exchange buffers. In this 
work, we first pre-incubated unbound and bound (1:50 protein:ligand) apoE3 solutions for 1 h at 
25 °C. Then various concentrations of urea were added to the master solutions and incubated for 
1 h at 25 °C again before HDX analysis. The final urea concentration was measured by a hand-
held refractometer (Atago U.S.A., Bellevue, WA). 
6.3.3 HDX Protocol 
Both PLIMSTEX and modified SUPREX followed the same HDX protocol24 after sample 
preparation. Briefly, HDX was initiated by 10-fold dilution of 4 μL stock solution into D2O 
buffer (PBS, pD 7.4) for 2 min at 25 °C, followed by mixing 2:3 (v/v) with 1 mg/mL fungal XIII, 
3 M urea, and 1% formic acid on ice for additional 2 min. The quenched and fungal XIII 
digested peptides were then submitted to online pepsin digestion, trapped and desalted on an 
Agilent C8 trap column (2.1 mm × 1.5 cm, Santa Clara, CA). The sequentially digested and 
desalted peptides were then separated over 11 min on a C18 column (2.1 mm × 5 cm, 3 μm 
Hypersil Gold, Thermo Fisher, Waltham, MA). Data were collected on a Bruker maXis 
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quadrupole time of flight (Bremen, Germany) mass spectrometer via positive-ion ESI. The entire 
procedure was carried out in a custom-built water-ice bath to minimize back exchange. All data 
points were taken in duplicate. 
6.3.4 Data Analysis 
Peptides from sequential digestion prior to HDX analysis were submitted to collision-induced 
dissociation fragmentation (CID) on a Thermo LTQ 7 T FT-MS (San Jose, CA) in a data-
dependent mode. Product-ion spectra were identified in MassMatrix (version 2.4.2),28 and 
manually verified. Deuterium uptake of each peptide was deconvoluted with HDExaminer (2.0, 
SierraAnalytics, Inc., Modesto, CA). 
Peptide-level PLIMSTEX data were analyzed by a customized program11 implemented in 
MathCAD (v14, Parametric Technology Corp., Needhad, MA). Briefly, a general model for 
specific binding was used to calculate species fractions as a function of postulated binding 
affinities and experimental ligand concentrations. Postulated species mass shifts were weighted 
by the corresponding species fractions to obtain a signal function, which was compared with the 
titration experiment data in a nonlinear least-squares fit. Satisfactory results were obtained with a 
1:1 binding model in this case by fitting the data either independently for each of three binding 
regions or, after combining, considering that each peptide region is part of a single binding site. 
The first approach allowed each peptide to be independently fit with different ligand-binding 
models and signal functions, producing binding affinities for each peptide. In contrast, the 
simultaneous fit constrained the data from three peptides that displayed HDX difference to be fit 
with a single binding model but different signal functions to obtain a single binding affinity. A 
Bootstrap resampling strategy29 was employed for statistical evaluation of binding affinities, in 
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which 4 k trial datasets were constructed by randomly resampling experimental data with 
replacement. Resampling times equaled the number of replicates at all ligand concentrations. 
Standard deviations were calculated from all trial Kd that were generated by each newly 
constructed PLIMSTEX curve. 
SUPREX curves were fit to a four-parameter sigmoidal equation 6.1 using a nonlinear regression 
procedure30 and MathCAD. Because the percentage deuterium exchange used in this work is 
proportional to the mass shift, these two quantities were used interchangeably.  
ΔMass[𝑈𝑟𝑒𝑎] = Δ𝑀0 +
𝑎
1+ⅇ
−([𝑈𝑟𝑒𝑎]−𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋)/𝑏
  eq 6.1 
In equation 6.1, ΔMass[𝑈𝑟𝑒𝑎] is the mass shift compared to non-deuterium exchanged mass as a 
function of urea concentration. The term Δ𝑀0 models mass shift before globally protected 
protons exchange with deuterium. [𝑈𝑟𝑒𝑎] is the molar concentration of urea before HDX.  
𝐶1/2
𝑆𝑈𝑃𝑅𝐸𝑋 is the half-way transition point of a SUPREX curve. 𝑎 and 𝑏 are unknown parameters 
describing amplitude and steepness of the transition region of a SUPREX curve.  
The Bootstrap strategy was again performed for statistical evaluation of  𝐶1/2
SUPREX precision with 
16 k trial datasets. Each newly constructed SUPREX curve generated a trial  𝐶1/2
SUPREX. By using 
a Monte Carlo method,29 4 million random pairs of  𝐶1/2
ℎ𝑜𝑙𝑜 (i.e.  𝐶1/2
SUPREX for holo state) and  𝐶1/2
𝑎𝑝𝑜
 
(i.e.  𝐶1/2
SUPREX for apo state) were used to calculate  ∆𝐶1/2% with equation 6.2. The results for 
each peptide were compiled by using a histogram distribution with 101 bins. Empirical, two 
tailed p-values were calculated to report the significance of the difference between pairs of 
peptide  ∆𝐶1/2% distributions.  
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∆𝐶1/2% =
𝐶1/2
ℎ𝑜𝑙𝑜−𝐶1/2
𝑎𝑝𝑜
𝐶1/2
𝑎𝑝𝑜 %  eq 6.2  
6.4 Results and Discussion  
6.4.1 Putative Binding Sites 
HDX reveals peptides that are involved in conformational changes upon ligand binding. 
Decreased HDX of the holo state compared to the apo state suggests, however does not 
guarantee, the binding sites. To avoid confusion, we refer “sites” or “putative binding sites” to 
the peptides that show decreased HDX upon ligand binding in the text.  
 
Figure 50 6.1: Schematic of peptide-level PLIMSTEX workflow 
Figure 6.1 Schematic representation of peptide-level PLIMSTEX workflow. Protein (cyan) is 
first incubated with a solution containing increasing concentrations of ligand (blue). Deuterium 
buffer (red) is then mixed with protein stock for a fixed time (tfix). HDX is quenched and the 
protein subjected to protease digestion. Centroid deuterium incorporation for the responsive 
peptide is decreased from unbound to bound state. Binding affinity is extracted from fitting of 
PLIMSTEX curve that is obtained by plotting HDX against ligand concentration. 
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The workflow of PLIMSTEX includes initial incubation of protein with increasing ligand 
concentration, then initiation of HDX at a fixed time (tfix), followed by sample purification 
(quench and digestion), MS detection and data analysis (Figure 6.1). It is important to find an 
appropriate tfix at which there is a significant HDX difference between bound and unbound states 
(i.e., large difference between the starting and end point on the titration curve) so that the 
PLIMSTEX curve can be defined with high accuracy. The precision of the measurements can be 
further improved if deuterium exchange at this time point is nearly constant. The HDX kinetics 
experiment serves as useful reference for choosing tfix in PLIMSTEX. Based on our previous 
HDX study,24 we chose to sample the system at 2 min at which time the HDX difference 
between the bound and unbound states is sufficient for analysis and kinetic curve of the bound 
state is not steep and time-sensitive. Considering that there is no difference of EZ-482 binding 
properties to the C-terminal domains of apoE3 and apoE4 as determined by multiple methods,24 
we carried out this work with apoE3  for the purpose of characterizing more completely this 
system and demonstrating the power of PLIMSTEX and SUPREX at peptide level.  
PLIMSTEX curves showed three different sites at regions revealed by the peptide-level data; 
each could be used for obtaining binding affinities (Figure 6.2; curves covering the entire protein 
sequence are in Figure 6.3). Only the three regions, 229–235, 234–243 and 258–265, exhibit a 
decrease in HDX when increasing the amounts of EZ-482 (Figure 6.2A–C; data fitting of the 
three peptides is discussed in the next section). Decreasing HDX with increasing ligand 
concentrations indicates increased protection either by direct interaction with ligand or as a 
remote conformational change. Nearby regions adjoining 243–251 and 264–271 display no HDX 
change with increasing ligand concentrations (Figure 6.2E–F). Another peptide, 116–123, which 
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shows no HDX change, is included to represent regions in the N-terminal domain that do not 
change (Figure 6.2D). 
 
Figure 51 6.2 PLIMSTEX curves o f selected peptides  
Figure 6.2 PLIMSTEX curves of (A)–(C) of peptides representing putative binding sites that 
show a gradual HDX decrease; (D)–(F) representative peptides from both N-terminal and C-
terminal domains displaying no HDX response against ligand concentration; (G)–(I) 
representative peptides in N-terminal domain showing increased HDX at high concentration of 
the ligand. Red lines in (A)–(C) are 1:1 fitting curves, and horizontal lines at averaged HDX 
across all time points in (D)–(I). 
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Figure 6.3 PLIMSTEX results of peptides representing the entire protein sequence. 
Figure 526.3: PLIMSTEX of peptides over the entire protein sequence 
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A horizontal line (red) at the average HDX value across all time points is drawn in the figure to 
guide the eye. This constant HDX extent in the PLIMSTEX curves of three peptides, ranging 
from protected areas (~ 20% HDX) to intermediate (~ 60% HDX) and flexible regions (~ 80% 
HDX), represents the majority of the protein and can be viewed as a negative control for those 
regions that change in PLIMSTEX (Figure 6.3). Only peptides showing gradual HDX decrease 
are likely involved in ligand binding, although we can’t rule out that peptides with no HDX 
response may also be involved in ligand binding (this concern also applies to HDX kinetics).31  
Interestingly, there is a third class of behavior seen for representative peptides, 34–37, 63–68, 
and 148–161 (Figure 6.2G–I), but also including peptides 27–30 and 52–62 (Figure 6.3). HDX is 
constant and starts to increase at high concentration (50 and 75 μM) of the ligand. We did not 
observe this de-protection in the N-terminal domain of apoE3 in previous kinetics experiments 
because the ligand concentration of the bound state was 25 μM. We do not know the cause of 
this weak effect but suggest that the ligand acts as a denaturant at high concentration. The ligand 
could affect local environment of the N-terminal domain, either directly or through the C-
terminal domain. This reduced stability of the N-terminal domain may not be noticeable until 
ligand concentration reaches high values.  
6.4.2 Binding Affinities at Peptide Level 
Next, we want to determine binding affinities at regional level by fitting the three putative 
binding sites (i.e. 229–235, 234–243 and 258–265) independently. A satisfactory fit of each 
peptide (R2 = 0.99) with a 1:1 binding model affords binding constants of 6.0 ± 0.3, 6.8 ± 0.3, 
and 10.6 ± 0.5 μM, respectively. We did not constrain the last titration point as 100% bound state 
because the highest ligand concentration we can achieve without experiencing solubility issues 
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after dilution was 75 μM (compared to 1 μM protein concentration). Results from independent 
fits of three peptides indicate their binding constants are essentially the same (within a factor of 
2), strongly suggesting that each is part of a single binding region. Assuming the three regions 
are part of a single binding site, we also fit simultaneously the data for the three peptides and 
acquired a single binding constant of 7.4 ± 0.3 μM. The R2 value of overall fit was slightly 
improved compared to individual fits, probably because more titration points were involved. This 
treatment views binding at global level because contributions from all sites are considered. 
Indeed, this single “global” dissociation constant (7.4 μM) is very close to the averaged value of 
three locally fit results (7.8 μM).  
In mass spectrometry-based footprinting methods, regional differences between two states can 
occur either because they are direct binding sites or they are remote conformational changes 
resulting from the binding. We assume that if any of the responsive peptides were not the direct 
binding site, the “global” fitting would be less accurate than the individual local fitting as regions 
that are not involved directly in ligand binding may introduce uncertainty in the “global” fitting. 
Indeed, PLIMSTEX at global level (i.e., no enzyme digestion) gives a readout that is a 
combination of responses of both direct interaction and conformational change to ligand binding. 
Thus, executing PLIMSTEX at peptide level to obtain regional binding affinities, even for the 
simplest 1:1 binding system, is preferred.  
For comparison, several fluorescence-based techniques, including measurement of fluorophore 
signals of a cysteine mutant, also gave binding affinities of EZ-482 to apoE, as described in our 
previous report.24 These methods all assumed a 1:1 binding system, yielding binding affinities 
within a range of 5–10 μM under different conditions. Binding affinities determined by 
PLIMSTEX (i.e., 6.0, 6.8, 10.6 μM for individual fits, and 7.4 μM for simultaneous fit) agree 
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well with that range. PLIMSTEX, however, does not require the introduction of specific probes 
or additional amino acids for fluorescence that may perturb protein structure. Additionally, 
conformational changes and binding affinities of each putative binding site can be monitored in a 
single PLIMSTEX experiment. 
One of the complications of apoE proteoforms in biophysical studies is their tendency to self-
associate. ApoE exists in a lipid-free solution as a mixture of monomer, dimer, and primarily 
tetramer even at low micromolar concentrations.32-34 Peptides 229–235, 234–243 and 258–265, 
which are involved in ligand binding, also overlap with the protein self-association interfaces35. 
Although it is unclear how each apoE subunit is oriented in the oligomer, it is possible that the 
ligand binds to region 229–235 and 234–243 on one subunit and affects peptide 258-265 on 
another subunit in the oligomer, for example. On the other hand, the interaction between EZ-482 
and apoE3 could be multi-valent and all three sites interact with one ligand directly.  
The fact that the binding interfaces overlap with the oligomer interface raises a concern that the 
binding affinities measured by PLIMSTEX may be compromised with oligomer 
association/dissociation because both processes can affect signal readout (HDX). Fortunately, the 
distribution of apoE oligomers is not affected by EZ-482 binding according to analytical 
centrifugation.24 Additionally, PLIMSTEX results are consistent with binding affinities 
measured by fluorescence experiments, in which protein concentrations were slightly lower (0.5 
μM) and the fluorophores were introduced at non-oligomerization interfaces.24 These 
observations suggest that oligomerization is not an important issue when considering the ligand 
binding to apoE. Therefore, we interpret the successful fit as indicating this is a 1:1 binding 
system as one ligand per binding site independent of the protein oligomeric states. 
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6.4.3 SUPREX is Consistent with Kinetics and PLIMSTEX at the peptide 
level 
ApoE must undergo partial unfolding to interact with lipids.36 Studying the effect of EZ-482 
binding on protein unfolding at the peptide level should provide insight into how this ligand 
affects apoE lipid binding. SUPREX, another approach involving HDX but reporting on 
thermodynamic-stability changes should be useful for this purpose. Thus, we modified the 
canonical SUPREX approach to evaluate unfolding profiles at the peptide level upon ligand 
binding. SUPREX is analogous to the chemical denaturation equilibrium assay typically 
measured by circular dichroism (CD) at the global level of a protein. Reasons to choose 
SUPREX are that it can provide information at the peptide or regional level and it has high 
throughput. High sequence coverage is not required because one single peptide with a well-
defined SUPREX curve is sufficient to represent the global or sub-global stability change 
induced by ligand binding.23 Prerequisites for representative peptides in domains of interest are 
sub-globally protected, insensitive to local fluctuations, and not solvent accessible.22 We 
intentionally chose, however, to characterize denaturation behaviors associated with peptides 
from entire sequence, with interest in the C-terminal domain of ApoE where the putative binding 
sites are located, to gain more information about ligand binding. We acquired only a single time 
point of the SUPREX curve for each state because performing SUPREX at different exchange 
times with our ESI-based HDX platform is labor intensive; further, we are mainly interested in 
qualitative comparisons having characterized the binding constants. We used the same exchange 
time (i.e., 2 min) as that used in the PLIMSTEX study to permit comparisons of the two 
approaches independent of HDX kinetics. Because the protein was incubated with denaturant 
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before diluting with D2O, we assume a rapid re-equilibrium between native and unfolding states 
upon addition of D2O and dilution of the urea concentration. 
 
Figure 53 6.4: SUPREX o f selected peptides  
Figure 6.4 SUPREX results of the same set of peptides as in Figure 6.2. Red squares are data 
from the unbound state and black dots are from the bound state. Data fitting is performed with 
four peptides showing complete unfolding profiles (A)–(C), (F). 
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We plotted the deuterium uptake of bound and unbound states as a function of urea concentration 
(after deuterium exchange dilution) to obtain SUPREX curves and found good consistency 
between the SUPREX and PLIMSTEX experiments with the same sets of peptides, as shown in 
Figure 6.4 (SUPREX curves of peptides from the entire sequence are in Figure 6.5). The 
SUPREX curves are particularly informative for the three sites 229–235, 234–243 and 258–265 
(Figure 6.4A–C). There are HDX differences between the bound and unbound states in the 
absence of denaturant, which is consistent with the PLIMSTEX results (the bound state 
undergoes less HDX than the unbound). The SUPREX curve of the bound state shifts to the right 
of that of the unbound state for all three peptides, indicating increased stability induced by ligand 
binding. Unlike these peptides, most of the other peptides that do not show an HDX difference 
between bound and unbound states in kinetics experiment24, display a flat curve as a function of  
Figure 6.5 SUPREX results of peptides representing the entire protein sequence. Red squares are 
data from the unbound state and black dots are from the bound state. 
Figure 54 6.5 SUPREX o f representative peptides over the entire sequence 
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ligand concentration in PLIMSTEX and afford identical SUPREX curves for both bound and 
unbound states (Figure 6.4D and E for representative peptides). Those peptides representing 
flexible or solvent-accessible regions do not carry much information about protein unfolding 
over the exchange time. The only exception is peptide 264–271 in the C-terminal domain. There 
is initially no HDX difference between two states in the absence of denaturant for this peptide, 
consistent with the kinetics and PLIMSTEX results (Figure 6.4F). The SUPREX curve of the 
bound state, however, is shifted to the right of unbound state, indicating increased stability upon 
ligand binding. This peptide must be relatively rigid or located at a solvent-inaccessible region, 
considering the low initial HDX extent (~ 20%) compared to other peptides. Behavior of this 
region of apoE3 demonstrates an advantage of SUPREX that a peptide representing a protected 
region can reveal the stabilizing influence of ligand binding whether or not there is 
conformational change upon ligand binding. Interestingly, region 261–272 is reported to be 
important for lipid binding,37, 38 suggesting that the EZ-482 ligand could affect protein–lipid 
interactions. This detail will be missed if the entire protein sequence is not covered in the HDX 
experiment.  
Peptides without high initial HDX in the N-terminal domain do not produce complete SUPREX 
curves (Figure 6.5) because the denaturation used in this work is designed to probe the C-
terminal domain and not sufficient for the highly ordered N-terminal helix bundle36, 39. It is 
known that the N-terminal and C-terminal domains unfold independently.40 The isolated N-
terminal domain starts to denature at denaturant concentrations at which the isolated C-terminal 
domain has completely unfolded. For those regions that show increased HDX at high ligand 
concentration (50 and 75 μM) in the PLIMSTEX experiment (Figure 6.2G–I), the corresponding 
SUPREX curves of the bound state (50 μM ligand concentration) start at a higher HDX, decrease 
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to the same level as that of the unbound state before increasing again in a similar way as the 
unbound state (Figure 6.4G–I). Although both ligand dissociation and denaturation can cause the 
higher HDX, separating these two factors cannot be done for the C-terminal domain. In the N-
terminal domain, however, the ligand interaction reduces its stability. Decreasing the effective 
ligand concentration should reverse this “denaturant” effect, and thus return HDX to a lower 
level. That HDX of representative peptides in the N-terminal domain decreases before increasing 
indicates that urea initially attenuates the ligand interaction before unfolding the protein. 
6.4.4 SUPREX reports different local binding-induced changes of 
denaturation 
Next, we were interested in investigating the changes of denaturation upon ligand binding for the 
four peptides 229–235, 234–243, 258–265, and 264-271 in the C-terminal domain to identify the 
most sensitive region to ligand binding. We employed a single parameter, ∆𝐶1/2%, the relative 
changes of denaturation upon ligand binding for comparison. Denaturation signals are not only a 
result of free energy changes (ΔGf) but also affected by the dependence of ΔGf on denaturant 
(m).41 Both parameters contain information about changes induced by ligand binding. Therefore, 
we chose the relative changes of denaturation ∆𝐶1/2%, instead of absolute halfway transition 
shift 𝐶1/2
ℎ𝑜𝑙𝑜 − 𝐶1/2
𝑎𝑝𝑜
, for a fair comparison between different peptides.  
 To utilize full statistical value of the data, we combined Bootstrap and Monte Carlo 
approaches29 to generate a histogram of ∆𝐶1/2% (Figure 6.6). The peak point of each distribution 
is the most probable, and the width of the distribution is a measure of the precision of ∆𝐶1/2% 
(Table 1). We also calculated two-tailed empirical p-values for statistical evaluation of the 
differences between each distribution.  ∆𝐶1/2% for peptide 234–243 is significantly larger than 
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the other three (p = 0.001 when compared to the closest distribution), indicating that this region 
is the most sensitive to unfolding changes after ligand binding. Unfolding responses of peptide 
229–235 and 264–271 are similar (p = 0.3), whereas ∆𝐶1/2% of peptide 258–265 is significantly 
smaller than that of peptide 264–271 (p = 0.002). When compared to peptide 229–235 (p = 0.07), 
peptide 258–265 does not have a significantly smaller ∆𝐶1/2%  using a p-value cutoff 0.05. 
However, this p = 0.07 value approaches the borderline of significance, and possibly suggests the 
difference.  
 
Figure 55 6.6: Histogram o f ∆𝐶1/ 2%  
Figure 6.6 Histogram of ∆𝐶1/2% for peptides 229–235 (blue), 234–243 (green), 258–265 
(yellow), and 264–271 (magenta). Each empty circle is a bin for grouping Monte Carlo random 
sampling results. Each p-value for comparing two peptides is listed above the two profiles. 
 
There is a correlation between ∆𝐶1/2% and the amplitude of PLIMSTEX curve ΔHDX% (i.e. 
HDX change from the beginning to the end) for the three peptides representing putative binding 
sites (Table 6.1). Peptide 234–243 possesses the largest ∆𝐶1/2% and ΔHDX%, whereas peptide 
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258–265 has the smallest values for both. Peptide 264–271, a region not directly involved in 
ligand binding, is a negative control showing that PLIMSTEX and SUPREX report information 
from different dimensions. We suggest that region 234–243 is the most sensitive to ligand  
binding followed by 229–235 and 258–265, considering both methods point to the same trend. It  
is of interest to test whether this correlation between the two methods holds up with other 
protein/ligand systems.     
Table 6.1  ∆𝐶1/2% from SUPREX
a and ΔHDX% from PLIMSTEXb for the four peptides of 
interest in the C-terminal domain. 
 
Table 3 6 .1: ∆𝐶1/2 %  from SUPREX and 𝛥𝐻𝐷𝑋%  from PLIMSTEX  
 
 
 
 
 
 
a See equation 6.2 and experimental section for calculation details. 
b HDX difference between unbound and bound state. 
 
     ∆𝐶1/2%     ∆HDX% 
229–235 30 ± 1 20 ± 1 
234–243 35.4 ± 0.7 30 ± 1 
258–265 26 ± 1 16 ± 1 
264–271 31 ± 1 1.6 ± 0.5 
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6.5 Conclusion 
Compared to conventional spectroscopic approaches, HDX-MS based methods require no site-
specific mutagenesis for introducing optical probes, thus avoiding perturbation of native protein 
structure. Unlike most other methods, HDX can give structural resolution when it is coupled with 
enzyme digestion. The two approaches used in this work can be viewed as orthogonal 
approaches to the widely adopted HDX kinetics experiment. With standard differential HDX 
kinetics, a protein with or without ligand is incubated in D2O buffer as a function of time. A 
comprehensive picture of protein structure and dynamics emerges because the wide range of 
exchange times (seconds to days) expands our view. Typically, however, only one unbound state 
and one bound state at a certain amount of ligand are examined. For PLIMSTEX, HDX is 
followed at a single time point as a function of ligand concentration to give, additionally, binding 
affinities at both regional and “global” levels.  We show here that affinities extracted from these 
experiments are consistent with results from other methods. Peptide-level results should also be 
more precise because regions that are not directly involved in ligand binding may “dilute” the 
global-level information and peptides respond more sensitively to MS than do whole proteins. 
Ongoing research in our group includes applying peptide-level PLIMSTEX to more complicated 
systems involving binding of more than one ligand. The SUPREX experiment provides 
information in another dimension by monitoring HDX with increasing denaturant concentration 
to follow denaturation of both the bound and unbound states. Unlike “high-turnaround” 
SUPREX, which gains a throughput advantage at the expense of reduced structural resolution by 
focusing only on a portion of a domain,22 SUPREX measurements over the entire sequence 
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inform us on ligand-induced changes of denaturation at different sites of the protein. The three 
putative binding sites show increased stability upon ligand binding, demonstrating the 
consistency between the three methods discussed in the text. An additional peptide, 264–271 in 
the C-terminal domain, displays the same behavior, reflecting a sub-global stability change upon 
ligand binding. Statistical analysis shows that peptide 234–243 is the most sensitive to ligand-
induced changes of denaturation.  
Binding interfaces, affinities, and thermodynamics are key to protein–ligand interactions. In 
studies where detailed information about protein–ligand interaction from different perspectives is 
desired, this expanded HDX platform is recommended.  
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Chapter 7: Native ESI-MS Coupled with Ion 
Mobility and Electron Capture Dissociation 
Reveals Gas-phase Structures of 
Apolipoprotein E oligomers*6 
 
  
                                                 
* Wang, H. performed all MS experiment and data analysis. Eschweiler, J. from Ruotolo lab built the coarse-grained 
model. Baban, B. from Frieden lab provided the apoE protein sample. 
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7.1 Abstract 
Apolipoprotein E (apoE) is an essential protein in lipid and cholesterol metabolism. Although the 
three common isoforms in human only differ at two sites, their consequences in Alzheimer’s 
disease (AD) are dramatically different. The ε4 allele is the major genetic risk factor for late-
onset Alzheimer’s disease. The isoforms exist as a mixture of oligomers, primarily tetramer, at 
low μM concentrations in a lipid-free environment. This self-association is involved in 
equilibrium with the lipid-free state, and the oligomerization interface overlaps with lipid 
binding region. Elucidation of apoE wild-type (WT) structures at any oligomeric states, however, 
has not been achieved yet. To address this structural need, we used native electrospray ionization 
and mass spectrometry (called native MS) coupled with ion mobility (IM) to exam the monomer 
and tetramer of the three WT isoforms. Collision-induced dissociation (CID) outcomes cannot 
distinguish the isoforms. A monomeric mutant (MM) of apoE3 shows higher stability when 
submitted to CID than the WT monomer. From ion mobility measurements, we obtained the 
collision cross section and built a coarse-grained model for the tetramer. Application of electron-
capture dissociation (ECD) to the tetramer caused unfolding starting from the C-terminal 
domain, is in good agreement with solution denaturation data and provides additional support for 
the C4 symmetry of the tetramer. 
7.2 Introduction 
Apolipoprotein E (apoE) is highly expressed in the liver and central nervous system to regulate 
lipid homeostatis via lipid transport and cholesterol metabolism.1-3  The APOE gene is a major 
genetic factor for later-onset Alzheimer’s disease (LOAD); among the three allelic variants in 
human, ε4 is the strongest risk factor, ε3 appears neutral, whereas ε2 is protective.4-6 Difference 
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between the three isoforms are single-site changes to 299 constituent amino acids. ApoE2 has 
cysteines at sites 112 and 158, whereas the prevalent isoform apoE3 has arginine at site 158 and 
apoE4 has arginines at both sites. Isoform-dependent biochemical properties and functions of 
apoE are likely to be caused by these single amino acid polymorphisms.2, 3 
In a lipid-free environment, apoE exists with two independent-folded domains connected by a 
protease-sensitive hinge region.2 The N-terminal domain, which contains a receptor-binding 
region, is a four-helix-bundle.7 High resolution structures of the lipid-binding C-terminal domain 
or the wild-type (WT) full-length protein are unknown owing to the disorder and propensity to 
self-associate of the C-terminal domain.2, 8-12 Lipid-free apoE exists as a mixture, primarily 
tetramer at low micromolar concentrations, but will dissociate to the monomer when the 
concentration is lowered.8-13 Thus far, only one NMR structure of a apoE3 monomeric mutant 
(MM), for which five residues in the C-terminal domain were substituted to interrupt self-
association, has been reported.14 The concentrations of apoE is 40–70 μg/mL (1–2 μM) in 
plasma, and 3–5 μg/mL (~0.1 μM) in the cerebrospinal fluid.6 Lipid-bound apoE, the prominent 
species in vivo, is likely in equilibrium with lipid-free apoE.15 The presence of lipid-poor or 
lipid-free reservoirs of apoE in vivo likely makes its self-association important for function12 
especially given that the lipid-binding region overlaps with the self-association region.2, 12 
Sedimentation methods8, 9, 15, fluorescence correlation spectroscopy16 for the equilibrium 
constants, and mass-spectrometry based footprinting17, 18 can approach equilibrium and 
conformational changes between WT and MM. Although footprinting couple with bottom-up 
MS analysis can report on changes in this heterogeneous system, at the peptide and even residue 
level, they do not directly provide compositional information of the solution species.17-22 
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Native electrospray ionization MS (native MS) introduces proteins and protein assemblies into 
the gas phase in a native or near-native state, preserving many non-covalent interactions 
(described in section 1.8).23-25 It can provide an overall view of the protein state ranging for small 
peptides26 to large mega-Dalton complexes27. Additional low-resolution information about 
protein shape and structure becomes available when native MS is coupled with ion mobility (IM; 
introduced in section 1.3.5) and coarse-grained modeling.28, 29.30, 31 Submitting the protein to 
increasing collision energy prior to IM causes collision-induced unfolding (CIU), reporting on 
protein stability in the gas phase and possibly in solution.32-37 Combining collisional activation 
with  top-down electron-capture dissociation (ECD; introduced in section 1.3.4) provides 
sequence information on flexible regions35, 38, 39 and on exposed protein surfaces.40  
In this study, we examine the oligomeric compositions of the three WT apoE isoforms and 
apoE3MM14 by native ESI. We compare the conformation and stability of each isoform at 
monomeric and tetrameric states from their CCS and their CIU. These results are combined to 
support a coarse-grained model of the apoE tetramer that is consistent with the top-down ECD 
results. 
7.3 Materials and Methods 
7.3.1 Materials 
Three apoE WT isoforms and one MM of apoE3 were expressed and purified as described 
earlier.41 Mutations of apoE3, introduced into the c-DNA using Agilent QuikChange site-
directed mutagenesis kit (Santa Clara, CA), were accomplished as previously reported (PDB: 
2L7B)14. Ammonium acetate (≥ 99.999% trace metals basis) and HPLC-grade water were 
obtained from MilliporeSigma (St. Louis, MO). 
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7.3.2 Sample Preparation for Native MS 
ApoE protein solutions were buffer exchanged with 200 mM ammonium acetate (pH = 7) with a 
Vivaspin 10 kDa molecular weight cut off filter (Sartorius AG, Goettingen, Germany) at 4 ⁰C, 
and diluted to desired concentrations as needed with the same buffer (5 or 15 μM). About 5 μL 
sample solution was loaded in a nanoESI emitter (Thermo Fisher, Waltham, MA) and injected 
into mass spectrometers. 
7.3.3 Ion Mobility MS Analysis 
Mass spectra for the native ESI and ion mobility were collected on a Waters hybrid ion-mobility 
quadrupole time-of-flight mass spectrometer SYNAPT G2 HDMS (Milford, MA) with following 
settings: capillary voltage 1.6–1.7 kV, sampling cone 20 V, extraction cone 10 V, and source 
temperature 30 ⁰C. The backing pressure was 5.6–5.8 mBar for transferring intact protein ions. 
Nitrogen was used as the carrier gas in ion mobility experiments at a flow rate of 35 mL/min. 
IMS wave velocity and wave height were 500 m/s and 20 V, respectively. Collision voltages in 
trap region were varied between 10-200 V to unfold protein oligomers42, while the transfer 
region was maintained at 20 V. The Ion mobility measurements of CCS were calibrated as 
previously reported.35 Data were exported from Masslynx (v 4.1) and Driftscope software (Water 
Inc., Milford, MA). Native MS spectra were processed with UniDec.43 Collision cross-section 
(CCS) of apoE3MM (PDB file: 2L7B) was calculated by MobCal28 using projection 
approximation (PA)44 method. CIU fingerprint contour plots were constructed by plotting CCS 
against trap collision voltages with normalized intensities by using OriginPro 9.0 (OriginLab 
Corp., Northampton, MA). 
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7.3.4 ECD MS Analysis 
ECD product-ion mass spectra were acquired on a Bruker Daltonics 12 T FTICR mass 
spectrometer (Bremen, Germany). The source settings were: capillary voltage 1.5–1.7 kV, drying 
gas temperature 25 ⁰C, drying gas flow rate 2.0 L/min. The skimmer 1 voltage was varied 
between 20 to 200 V to pre-activate ions. Other ion-optics parameters were adjusted to optimize 
signal intensities. Ions accumulation time was 2 s, and the time-of-flight was 2.5 ms. All charge 
states in a narrow distribution were subjected to ECD with a pulse length of 0.04 s, bias of 0.4 V, 
lens of 10 V, and hollow-cathode current of 1.6 A. Peak picking was performed with SNAP 
centroid peak on Bruker DataAnalysis. Data were processed with Bruker Daltonics BioTools, 
and manually verified by comparing to theoretical fragment ions predicted by Protein Prospector 
(University of California–San Francisco MS facility).  
7.3.5 Coarse-grained Modeling 
Coarse-grained modeling was performed using a Monte-Carlo annealing algorithm built within 
the Integrative Modeling Platform library in Python. Experimental data were input in the form of 
spherical radii corresponding to measured collision cross sections, and in some cases distance 
restraints between multiple spheres that optimized agreement with experimental cross sections. 
Ensembles of 10000 models were generated according to scoring functions with and without C4 
symmetry constraints, and models with tetrahedral symmetry were generated by applying the 
appropriate transformation to the C4 models. For each ensemble, the CCS values were calculated 
using the IMPACT projection approximation and considered only models within ± 3% of the 
experimental cross section. Models agreeing with all CCS datasets were then clustered into an 
average-linkage hierarchy by using a pairwise RMSD matrix, and the probability density 
function of each cluster was estimated using Gaussian kernels.  
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7.4 Results and Discussion  
7.4.1 Native MS Reveals Heterogeneity of ApoE  
Native mass spectra obtained on the IM-QToF instrument at the lowest collision energy (10 V) 
reveal the oligomeric heterogeneity of WT apoE solution at 5 μM for all three isoforms (Figure 
7.1). For apoE2WT (Figure 7.1A), the most abundant species is a tetramer with a narrow charge-
state distribution from 24+ to 19+ centered at approximately m/z 6500 (M.W. = 138.2 kDa). The 
second most abundant species that displays three charge states 11+ to 9+ from m/z 3000–4000 is 
a monomer (M.W. = 34.35 kDa). Small amounts of dimer spanning 16+ to 14+ (M.W. = 68.80 
kDa) and trimer from 20+ to 17+ (M.W. = 103.5 kDa) were also observed, and their presence 
may not be easily identified by other biophysical methods because of the low relative 
abundances. The peak at m/z = 5750 represents both trimer at 18+ and tetramer at 24+, according 
to the resolved arrival time distributions (ATDs) of ions with this m/z in the IM experiment, and 
supported by the clear presence of a trimer at 17+. Mass spectra are simplified, and the relative 
abundances of monomer, dimer, and trimer are reduced when protein concentrations are 
increased to 15 μM (Figure 7.2). This concentration-dependent behavior is consistent with 
chemical equilibrium and suggests that the oligomers in the gas phase are relevant to conditions 
in solution. Although we carefully maintained the source-region energy to be low as possible, we 
can’t rule out the possibility that a fraction of the small oligomers are formed from 
decomposition of large oligomers in the gas phase.  
In contrast to the WT protein, we saw only peaks representing the monomer for native MS of the 
apoE3MM (Figure 7.1D). This is a good negative control establishing that the oligomers are not 
formed by non-specific interactions. The charge distribution of the monomer in apoE3MM is the 
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same as that of WT, ranging from 11+ to 9+. The native ESI data not only establish the different 
oligomeric compositions of WT and MM, but also provide direct evidence of different 
oligomeric species that agree with the previously proposed apoE self-association process8, 9, 16.  
 
Figure 56 7.1: Na tive MS spectra o f apoE at 5 μM  
Figure 7.1 Native MS spectra of (A) apoE2WT, (B) apoE3WT, (C) apoE4WT and (D) 
apoE3MM at 5 μM. Monomer (blue), dimer (green), trimer (yellow), and tetramer (red) are 
labeled respectively. 
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Figure 57 7.2: Native MS spectra o f apoE at 5 μM  
Figure 7.2 Native MS spectra of (A) apoE2WT, (B) apoE3WT, and (C) apoE4WT at 15 μM. 
Monomer (blue), dimer (green), trimer (yellow), and tetramer (red) are labeled respectively. 
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7.4.2 IM Measurement 
It is important to ensure minimal gas-phase unfolding of protein structure when using native MS. 
We first converted the ATDs of the monomeric species (6–9 ms) and the tetrameric species (11–
16 ms) of the three WT isoforms at presumably their lowest energy (i.e., collisional activation 
voltage is at the lowest value, 10 V) into CCS distributions (Figure 7.3A for apoE3WT; also see 
Figure 7.4 for apoE2WT and apoE4WT; median CCS values of all recorded charge states are 
provided in Table 7.1). For the monomeric species, the three charge states show almost identical 
widths and median values of the CCS distributions. Median CCS values of the tetrameric species 
at different charge states are similar (standard deviation is less than 2%), yet with a trend that the 
median CCS values gradually decrease as charge increases. Overall, the CCS distributions of 
both monomers and tetramers are not charge-state dependent, and their peak shapes indicate the 
presence of one major conformation. Additionally, the median value of the CCS distribution for 
apoE3MM at 10+ (2440 Å2) under the same experimental setup is in good agreement with a 
theoretically calculated CCS of the solution NMR structure using PA method (2320 Å2). A near-
native structures of both monomer and tetramer are preserved in the transition to the gas phase. 
The width of the CCS distribution of the tetrameric species, approximately 1000 Å2, is only 
about 2-fold broader than that of monomeric species, and relatively narrow compared to some 
similarly sized proteins45. This indicates that the tetrameric species also has a nearly singular and 
stable conformation.  
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Figure 58 7.3 CCS d istr ibutions o f apoE 3 WT and comparison to al l other iso forms  
Figure 7.3 (A) The CCS distributions of WT apoE3 monomeric (left) and tetrameric species 
(right) at different charge states. (B) The CCS distributions of the monomeric species (M) of all 
isoforms at charge state 10+, and the tetrameric species (T) of three WT isoforms at charge state 
22+. 
 
 
Figure 59 7.4: CCS distributions o f apoE2 and apoE4 WT 
Figure 7.4 CCS distributions of (A) apoE2WT and (B) apoE4WT at different charge states. 
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Table 7.1 Median CCS values of the monomer and tetramer of three WT isoforms. 
Table 4 7 .1: Median CCS  values of the monomer and tetramer of three WT isofo rms.  
 
 
The CCS distributions at the most abundant charge states (i.e., 10+ for monomer and 22+ for 
tetramer) are the same the for three WT isoforms (Figure 7.3B), indicating their conformational 
similarities. Furthermore, ApoE3MM also possesses a similar conformation as the WT 
monomeric species because they display the same CCS distributions. This conclusion contradicts 
 
Charge 
State 
apoE2WT apoE3WT apoE4WT 
Monomeric 
Species 
9+ 2397 2427 2427 
10+ 2381 2417 2417 
11+ 2410 2408 2410 
Tetrameric 
Species 
19+ 7662 7756 7709 
20+ 7608 7608 7710 
21+ 7544 7600 7600 
22+ 7417 7540 7510 
23+ 7357 7423 7423 
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previous reports that apoE3MM and WT are significantly different, particularly in the C-terminal 
domain.17, 18 This is because these studies pertain to a solution structure,17, 18 which is a weighted 
average of all the oligomeric species of the WT. In contrast, we extracted information from the 
WT monomer and directly compared it to the MM. That the three apoE WT isoforms have 
similar structures according to the gas-phase CCS is consistent with previous reports.17, 18 
 
Figure 60 7.5: CIU f ingerpr ints of apoE 3WT and apoE 3MM  
Figure 7.5 CIU fingerprints of (A) apoE3WT monomer (B) apoE3MM monomer (C) apoE3WT 
tetramer. The scale of normalized ion intensities is labeled on the right. 
7.4.3 Collision Induced Unfolding (CIU) 
It is difficult to resolve closely resembled structures in IM at the ground-state. To evaluate 
further the higher-order structure of apoE, we applied a CIU strategy32-36 on the monomeric and 
tetrameric species, respectively. The CIU contour plots for the monomeric species of apoE3WT 
at 10+ (Figure 7.5A), apoE3MM at 10+ (Figure 7.5B), and the tetrameric species of apoE3WT at 
22+ (Figure 7.5C) show that all selected protein ions exhibit extended CCS as trap collision 
voltage increases. We chose to characterize CIU of monomeric species at 10+ charge state not 
only because this charge state is the most intense but also it is an optimal charge state choice for 
CIU of a 35 kDa protein according to the power-law correlation.46 By comparing the centroid 
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CCS at the ground-state (10 V) to that at the highest energy activation state in our experiment 
(160 V), we observed approximately a 23% structural extension. Three main features, including 
the initial native state, an intermediate partial unfolded state, and a stable major unfolded state, 
were observed for the WT monomer over the experimental activation frame. Our observation of 
the three features supports the two domain structure proposal because there is a general 
correlation between protein gas-phase unfolding intermediates and domain structures in solution, 
as proposed by Zhong et al46.  
Although monomeric species of apoE3WT and apoE3MM are iso-cross sectional at the ground-
state, apoE3MM produces a different CIU fingerprint than does apoE3WT. Transition from the 
first feature to the second feature occurs when the collision energy is adjusted corresponding to 
50 V for both isoforms. However, the first feature is more intense in apoE3MM compared to 
apoE3WT at 55 V, indicating that apoE3MM is more stable than apoE3WT. An additional fourth 
feature (CCS ~ 3100 Å2) for apoE3MM appears at 55 V, peaks at 65 V, and co-exists with the 
major unfolded state (CCS ~2900 Å2) but with gradual decreased relative abundance at higher 
energies. In contrast to the proposed WT structure2, the NMR structure of apoE3MM shows 
extensive salt-bridging and hydrogen bonding between the N-terminal and C-terminal domains.14 
Highly intermingled domain structures may induce additional features in CIU fingerprint,46 
which likely explains the fourth feature and broadened CCS distribution at higher collision 
voltages in the CIU of apoE3MM. To check whether CIU fingerprints only report CCS changes 
of ions within a specific m/z range, we checked the full m/z range of the mass spectra recorded at 
different activation energies. A fraction of higher charge state peaks at around m/z = 1500 and 
corresponding to the partially denatured protein ions, are observed for three WT isoforms in the 
range corresponding to 20 V to 120 V, but this is not significant for apoE3MM (Figure 7.6). 
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These observations additionally support the hypothesis that the monomeric species of apoE3MM 
is more stable than the WT. As a result, the fourth CIU feature corresponding to a conformation 
that is more extended than the major unfolding state may survive and exist for apoE3MM. In 
contrast, for the WT isoforms, any further energy increases may cause protein denaturation or 
fragmentation so that protein ions at the original m/z range are no longer tractable.  
 
Figure 61 7.6: CID of apoE isofo rms  
Figure 7.6 CID of monomeric species at different collision energies for (A) apoE3MM (B) 
apoE2WT (C) apoE3WT (D) apoE4WT. 
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Figure 62 7.7: CIU f ingerpr ints of apoE 2 and apoE4 W T 
Figure 7.7 CIU fingerprints of (A) apoE2 monomer (B) apoE4 monomer (C) apoE2 tetramer (D) 
apoE4 tetramer. The scale of normalized ion intensities is labeled on the right. 
The tetramer remains assembled while a fraction of the protein undergoes unfolding as the 
collision voltage increases, displaying four main features and one low intensity fifth feature. 
Centroid CCS of the fourth (~8800 Å2) and fifth (~9500 Å2) features were increased about 17% 
and 27%, respectively, compared to that of the ground-state conformation (~7500 Å2). The 
tetramer does not undergo a large extent of unfolding34. This is in part because the tetramers 
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have already a large CCS or undergo dissociation before further unfolding under the 
experimental setup. All three WT isoforms have essentially the same CIU fingerprints for both 
monomeric and tetrameric species (see Figure 7.7 for apoE2WT and apoE4WT). The unfolding 
differences we can detect for the three WT isoforms in solution are found in the N-terminal 
domain.47 We hypothesiz that gas-phase unfolding of the N-terminal domain does not occur in 
our CIU experiment. As a result, three WT isoforms displayed similar CIU patterns at both 
monomeric and tetrameric states. An ECD experiment, in which unfolding regions can be 
localized, would help test our hypothesis (discussed later). 
7.4.4 Coarse-grained Model of ApoE Tetramer 
ApoE has great tendency to tetramerize in a lipid-free environment via the C-terminal domain,2, 8, 
9, 17, 18 making it difficult to obtain structures for any WT oligomeric state by NMR or X-ray. The 
only available full-length structure is of apoE3MM by solution NMR.14 There is no report for 
structures of any apoE oligomers yet. With CCS constraints from both monomeric and tetrameric 
species, we are interested in constructing a model for the tetramer using coarse-grained 
approach30, 31. 
In a coarse-grained model, one protein chain is usually represented as one sphere whereas a 
complex would be seen as several overlapping spheres.30, 31 Our Initial attempts to model the 
apoE tetramer at subunit resolution, however, resulted in no models in agreement with both basic 
connectivity requirements and the experimentally derived CCS restraints. We hypothesized that 
the assumption of sphericity, which holds for many globular, single domain proteins, is not 
appropriate for the dynamic two-domain structure of apoE2. That tetrameric apoE cannot be 
calibrated as a globular protein based on size-exclusion chromatography has also been reported 
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earlier.15 Therefore, we developed a two-domain model for the monomer subunit, which agrees 
well with our experimental CCSs, based on the proposed structures for WT.2, 48 We used a 
computational model48 that has two distinct domains, in contrast to the NMR structure where the 
domains are intermeshed14. Residue 183 was used to "cut" the domains to make a two-body 
structure. We then assembled four copies of this two-domain monomer via the C-terminal 
domain for tetramer modeling. Symmetry is very common within protein complexes, and adding 
a symmetry restraint can reduce variability in model ensembly.30 We first assumed a C4 
symmetry, and that afforded two well-defined structural families that agreed with all the 
experimental data (Figure 7.8A). The most prominent family, cluster 1 (green), accounts for over 
80% of the possible solutions in our experiment. Mean structures of the two families sampled in 
our experiments are pictured in Figure 7.8B. The favored cluster 1 is non-planar compared to the 
cluster 2. We also explored the possibility of tetrahedral structures, and found that the CCSs of 
these structures were much larger than the experimental cross sections (Figure 7.8C), indicating 
that the tetrahedral symmetry is not preferred here. Models generated without any symmetry 
requirements appeared to converge around the same structural families found in the C4 
ensemble; however, the families were poorly defined.  
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Figure 63 7.8: Coarse-grained m odel of apoE tetramer  
Figure 7.8 Coarse-grained model of apoE tetramer. (A) The average-linkage hierarchy of all 
models examined. The dominant cluster 1 is colored in green, and cluster 2 in red. (B) The 
average structures of the cluster 1, cluster 2 and tetrahedron symmetry. The C-terminal domain is 
colored in gray, and the N-terminal domain in green. (C) The average CCSs of each cluster. 
Deviations compared to the averaged experimental values are in parenthesis.  
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7.4.5 ECD of ApoE Tetramer 
Both the IM-MS results and the coarse-grained model are at low-resolution. To improve the 
modeling, one can incorporate other structural information, such as EM to give the overall shape 
or collision-induced dissociation (CID) in the mass spectrometer to give topology.30 Using CID 
for the order of subunits is not very informative for a homo-oligomer, and there are no available 
EM data for apoE yet. Therefore, we turned to ECD to obtain more structural information to 
support our model for the tetramer.  
We followed the same idea as in CIU, gradually activating the tetrameric complex by increasing 
skimmer I voltage, and obtaining ECD fragmentation ions to locate unfolding regions that can’t 
be identified in CIU and IM.35, 39, 40 We submitted the entire narrow charge state distribution of 
the tetramer to ECD because the charge state envelope of the tetramer from 20+ to 25+, centered 
at m/z = 6000, is at the upper isolation limit of the instrument39 (see Figure 7.9A for ECD spectra 
at varying skimmer I voltages for apoE3). ECD fragment ions are below m/z = 2000 whereas a 
series of charge-reduced precursor ions fall into high m/z region. The densities of fragment ions 
below m/z = 2000 are increased as skimmer I potential increases from 30 V to 160 V. 
Interestingly, another tetrameric complex with slightly lower mass appears when skimmer I 
voltage is increased to 160 V (Figure 7.10). This new tetramer arises by the loss of C-terminal 
tail 293–299 from the original tetramer because the global mass difference between two 
tetramers is approximately 760 Da, and we see an abundant y7 ion of m/z 765.3473. 
Consequently, the second tetramer, when submitted to ECD, produces a series of z ions that are 
765.35 Da less than the corresponding z ions from original tetramer. Assignment of z ions from 
the second tetramer is not included in the text unless otherwise discussed. 
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Figure 64 7.9: ECD o f apoE 3WT 
Figure 7.9 (A) ECD spectra of apoE3WT tetramer at different in-source (IS) pre-activation 
voltages of 30, 60, 80, 120, and 160 V. (B) Assignment of ECD fragment ions in the N-terminal 
domain (NT; upper panel) and the C-terminal domain (CT; bottom panel). 
 
The ECD fragment ions that we identified, based on their accurate mass, show that the C- and N-
termini have different fragmentation patterns (Figure 7.9B). Fragment ions from the C-terminus 
are observed starting at the minimum activation energy required for decent signal intensities of 
the parent ions. At low activation voltages (i.e., 30 V and 60 V), z ions form containing residues 
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275–299, strongly suggest that this region is highly flexible.14 When a pre-activation voltage 
higher than 80 V is applied, fragmentation occurrs deeper along the backbone from the C-
terminus until residue 221. The new tetramer, which is formed by a loss of the C-terminal tail 
293–299 from the original tetramer, produces z ions even deeper into the hinge region to residue 
192, suggesting more unfolding of this new tetramer. We saw no c ions from the N-terminus 
until the pre-activation voltage increases to 120 V. There are fewer c ions and their relative 
abundances are much lower compared to the z ions arising from the C-terminus. We also found 
this ECD fragmentation pattern for the apoE2 and apoE4 tetramer. The overall trend is very 
similar among three isoforms except we found a few more z ions from the C-terminus of apoE4 
at low pre-activation voltages (Figure 7.11). Our gas-phase unfolding data that most ECD 
fragmentation ions are from the C-terminal domain correspond to the solution-phase unfolding 
results47. The two domains are independently unfolded in solution; the four-helix-bundle N-
terminal domain unfolds at a much higher denaturant concentration than the C-terminal 
domain.47 
Several studies of model systems show that ECD fragmentation correlates well with X-ray 
structural B-factors.35, 39 Li at al.40 reported that ECD fragmentation originates not only from 
flexible regions but also from surface-exposed regions. We propose to utilize ECD to validate 
the coarse-grained model of the tetramer. Our observations that the highly flexible C-terminal 
tail (293–299) fragments upon applying low to medium pre-activation voltages (30 V – 80 V) 
whereas no fragmentation occurs at the highly structured and stable N-terminal domain is 
consistent with our proposed correlation between ECD fragmentation and B-factors.   
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Figure 65 7.10: Na tive ESI spectrum o f apoE 3WT tetramer befo re ECD a t in-source (IS) 160 V 
Figure 7.10 Native ESI spectrum of apoE3WT tetramer before ECD at in-source (IS) 160 V. The 
original apoE3 tetramer is labeled with red. The newly formed second tetramer is labeled with 
purple. 
 
Figure 66 7.11 E CD fragment ass ignment in the C-termina l doma in of  three WT isoforms  
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Figure 7.11 ECD fragment ions assignment in the C-terminal domain of three WT isoforms at 
different pre-activation energies. 
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mass.49 Here, the pre-activation voltage at the source region does not sufficiently energize the 
complex to eject a monomer. We suggest that one monomer subunit starts to unfold while the 
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the C-terminal domains are at the tetramer interface,2, 8, 9, 17 the arrangement in our model 
provides the opportunity for the C-terminal domain to readily interact with electrons. We found 
fewer c ions because the N-terminal domain does not extensively unfold, as also found in the 
CIU/IM experiment. In a tetrahedron arrangement, on the contrary, the C-terminal domain is 
protected somewhat by the N-terminal domain. Thus, fewer z ions would be formed owing to the 
limited access to electrons, and more c ions from the N-terminal would be expected. Thus, the 
ECD results showing that fragmentation continues deeper along the backbone from the C-
terminal than the N-terminus further confirms the proposed model of the apoE tetramer.  
Of note, we found z ions from residues 221–299 of the original tetramer and 192–299 of the 
second tetramer that had lost the C-terminus 293–299 at the highest pre-activation voltage. There 
are still regions other than 221–299 for the original tetramer and 192–299 for the new tetramer 
responsible for holding the tetrameric complex together. Although most studies suggest that the 
critical oligomerization interface is located in the C-terminus,2, 8, 9, 17  Gau et al18 found that 183–
205 in the hinge region may be also involved. Our ECD study also supports Gau’s results by 
showing that tetramer still remains intact when region 221–299 has unfolded in the gas phase.  
7.5 Conclusion 
Investigating apoE structure and self-association behavior is important for understanding its 
function in vivo. It is, however, difficult to approach this question using high resolution methods 
because of the protein is complex in solution. Only one full-length structure of apoE3MM has 
been reported thus far.14 MS-based structural proteomics,17, 18 as well as some conventional 
biophysical methods,2, 47 afford valuable yet averaged information in solution about the structure 
and biophysical properties of apoE. Native ESI coupled with IM can follow the conformation 
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and gas-phase unfolding of the monomeric and tetrameric species. The CCSs of the ground-state 
and the CIU results show that the monomer and tetramer of the three WT isoforms are 
structurally similar in the lipid-free environment, as was reported in structural proteomics 
studies17, 18.  The narrow CCS distribution of the tetramer species at the ground-state suggest that 
the tetramer is stable and less dynamic. The monomer of apoE3MM shows a similar CCS at the 
ground-state, but it has increased stability compared to that of WT, which may be attributed to 
the extensive interactions of the C and N terminal domains of the apoE3MM. The CCSs of the 
WT monomer and tetramer, and the knowledge that the C-terminal domain is involved in self-
association allows building a low resolution coarse-grained model for the tetramer with a C4 
symmetry, which may be a profitable approach for other oligomers. That the tetramer has a non-
planar arrangement is consistent with the majority of the models that we calculated. A fruitful 
approach to test the symmetry of the model (here C4), one should consider using native MS 
coupled with ECD; here we found that most fragment ions arise from the C-terminal domain. 
After increasing the collisionally activating the ions prior to the ECD step, we found that the N-
terminus starts to produce fragment ions with low abundancies Both these results indicate that 
the tetramer starts to unfold from the C-terminal domain, making the denatured C-terminus 
easily accessible to the bombarding electrons used for ECD. The C4 symmetry, not the 
tetrahedron arrangement, is in good agreement with our ECD results.  
This strategy, building low-resolution coarse-grained model from IM and seeking additional 
support from ECD, is recommended for systems in which oligomerization has hindered 
structural elucidation.  
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Mass spectrometry (MS)-based approaches serve as a bridge between high resolution structural 
biology and low resolution conventional analytical characterization. Enormous amounts of 
information for protein characterization have been obtained at high sensitivity, specificity, and 
speed. The Michael Gross group has particular interests in developing and applying MS-based 
methods to study protein–protein/ligand interaction and protein higher-order structures. We are 
taking two general approaches. First is a structural proteomics approach employing a “bottom-
up” strategy, to analyze the results of different labeling methods and enzyme digestion to 
investigate protein biophysics at peptide or residue level. Hydrogen–deuterium exchange (HDX) 
is one of those methods and is the primary method used in this thesis. A second approach is 
native MS experiment, a “top-down” strategy that introduces protein–protein/ligand complexes 
to the gas phase and interrogates them directly for stoichiometry, topology, and coarse-grained 
structural information from coupling native MS with ion mobility (IM), collision-induced 
dissociation (CID), and electron-capture dissociation (ECD). Various approaches provide 
information revealing different aspects of protein structure. It has become more important to 
utilize multiple techniques for complementary information as is shown in this thesis. 
8.1 Summary 
Chapter 1 introduces the instrumentation and methods used in the thesis. HDX is explained in 
detailed as this is the primary technique utilized. This thesis focuses on questions involved in two 
biological systems. Chapter 2, 3, and 4 study two proteins in curli biogenesis that are important 
for enteric bacteria biofilm formation. In chapter 2, we used continuous and pulsed HDX to 
understand the structure and identify oligomerization interface of CsgE. The outcomes provided 
important guidance for mutagenesis studies in developing a monomeric mutant. We also 
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developed and implemented an improved pulsed HDX platform to follow the aggregation 
behaviors of CsgA, the major curli protein, in chapter 3. We found that the first and last 
repeating units have higher aggregation propensities. After discovering that CsgA undergoes 
deamidation during storage, we systematically followed the deamidation of CsgA by CID in 
chapter 4. HDX, Thioflavin T fluorescence (ThT) assay and circular dichroism (CD) showed that 
deamidated CsgA loses its biological function. 
The protein studied in chapter 5, 6 and 7 is apolipoprotein E (apoE) that plays an important role 
in Alzheimer’s disease. In chapter 5, we characterized the interaction, using multiple techniques, 
between a small molecule compound and apoE as an example of developing a small-molecule 
drug for a therapeutic target, demonstrating a template for future drug screening. Using the same 
system in chapter 6, we adapted and integrated two HDX-based techniques to obtain binding 
constants and characterize unfolding changes upon ligand binding at peptide level. This platform 
can be readily extended to other biological applications. In chapter 7, we used native MS coupled 
with IM and ECD to study the gas-phase structure of apoE oligomers. From the results, we 
developed a coarse-grained model for apoE tetrameric complex. 
8.2 Future Directions 
8.2.1 MS in Curli Biogenesis 
An immediate interest in curli system is to study the interaction between CsgA and CsgE. CsgE 
prevents CsgA aggregation in vitro and delivers CsgA in vivo. However, the interaction region 
and the mechanism remain unclear. HDX at the shortest time point (10 s under current laboratory 
setup) for CsgA, an intrinsically disordered protein (IDP), HDX has already reached plateau. 
Thus, a conventional HDX technique will likely not report conformational changes of IDP 
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proteins. Furthermore, the interaction between CsgE and CsgA may be transient. In the future, 
HDX at millisecond time scale requiring a fast mixing device, would be appropriate for this 
application. Fast photochemical oxidation of proteins (FPOP) is an alternative approach that 
provides irreversible side-chain labeling at microsecond time scale.  
MS can also be extended to other curli proteins. For example, one can follow the aggregation 
behavior of CsgA in the presence of CsgE and CsgB with the improved pulsed HDX platform 
developed in chapter 3. The interaction regions between CsgG, CsgF and CsgB are unknown. 
Both HDX and FPOP may provide valuable information. Native MS can play a great role in 
studying the stoichiometry and conformation of CsgE–CsgG–CsgF–CsgB complex or sub-
complexes. Cross-linking is another opportunity to study protein interactions within a large 
complex. 
8.2.2 MS for Lipidated ApoE and High Throughput Drug Screen  
All the studies of apoE in the thesis are in a lipid-free environment. Lipids are important 
components for apoE to achieve its biological functions. It is known that apoE alters its structure 
upon lipid binding. However, it is difficult, although possible, for HDX to study lipidated apoE 
because the labeling is reversible and time for sample handling is limited. FPOP possesses a 
great advantage here. One can perform FPOP on apoE in an environment with lipids, followed 
by appropriate sample cleanup to permit MS analysis. All the HDX-based techniques used in this 
thesis can be transformed into FPOP-based techniques by switching the labeling methods. The 
scope of FPOP-based techniques compared to those using HDX can be readily extended because 
sample handling is flexible and the labeling time scale fast. 
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Another area to continue in the collaboration for apoE studies is high throughput drug screen. 
Several fluorescence-based techniques our collaborators implemented in Chapter 5 can be used 
to narrow down compounds from a large library. Candidates of interest are then subjected to 
HDX for further characterization. A single point high throughput HDX method can be used to 
test several candidates (data not included in the thesis). This one-point HDX is fast, and appears 
sufficient to for identifying the interaction region and associated conformation changes. 
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